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CHAPTER 1 
INTRODUCTION 
1.1 Importance of Thioacids and Thioesters 
Thioacids have been known since the first example, thioacetic acid, was 
synthesized from the reaction of acetic acid with tetraphosphorous decasulfide by 
Kekule in 1854 (Scheme 1).1-2 
 
Scheme 1. First preparation of thioacetic acid. 
 
The structures of thioacids have been studied extensively using IR, UV/Vis 
and NMR spectroscopy, and molecular orbital calculations for many decades, all 
of which indicated that thioacids exist as fast tautomeric equilibrium mixtures of 
thiol (1) and thioxo (2) forms (Figure 1).3-6 
 
Figure 1. Tautomers of thioacids. 
 
In 1996, IR, UV/Vis and NMR spectroscopic observations were reported 
which suggested that the thioxo form (2) of thioacids predominates in polar 
solvents at low temperature.7 Since then, several theoretical studies of 
tautomerism in thioacids have been reported.8 Spectroscopic experiments have 
shown that thioacids exist in the thiol form (1) in nonpolar solvents and in the 
solid state.7 This change in the equilibrium position with solvent polarity can be 
2 
 
explained by the notion that the thioxo form (2) is a better hydrogen bond donor 
toward polar solvents like THF, ether, acetone, and methanol (Figure 2).7 
 
Figure 2. Hydrogen bonding of thiol and thioxo forms of thioacids in polar 
solvent. 
 
An important difference between thioacids and carboxylic acids is their 
acidity; thioacids are stronger acids than the corresponding carboxylic acids. This 
is mainly due to the larger size of sulfur relative to oxygen, which stabilizes the 
negative charge in the conjugate anion of the acid, and thereby increases the 
acidity of sulfur compounds.3,8 For example, the pKa of thioacetic acid in water at 
25 °C is 3.33,2 about 25-30 times stronger than that of acetic acid (pKa: 4.76 in 
water at 25 °C);2  therefore it can be selectively deprotonated even at acidic pH. 
Hence, a key feature of the thioacid moiety lies in its ability to act as a 
nucleophile at pH 3–6 with a unique reactivity profile,9-12 when all other 
nucleophiles present are unreactive. Accordingly, most applications of thioacids 
have been in the field of peptide chemistry where they have been employed as 
key intermediates for the synthesis of peptides and proteins. The application 
range of thioacids in amide bond formation reactions extends from fragment 
coupling13-15 to enzyme-mediated condensation,16-17 synthesis of proteins with 
backbone-engineered18-20 or non-native architectures,21-23 peptide dendrimers24 
and cyclic peptides.25 
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However, until the 1980s the study of thioacids was a comparatively 
unexplored field in organic chemistry. In contrast, thioacid derivatives such as 
thioesters, which could easily be prepared from thioacids by simple nucleophilic 
substitution, have found more applications.11,26-34 For example, Fukuyama and 
co-workers disclosed the palladium-catalyzed synthesis of ketones by the 
reaction of thioesters 3 with organozinc reagents as exemplified in Scheme 2.33 
 
Scheme 2. Palladium-catalyzed synthesis of ketone from a thioester. 
 
  Likewise, Srogel, Liebeskind and co-workers reported the palladium-
catalyzed cross-coupling of the thioesters 5 with boronic acids to give the 
corresponding ketones 6 (Scheme 3).35      
 
Scheme 3. Palladium-catalyzed cross coupling of the thioesters. 
1.1.1 Activation of Thioacids and Amide Bond Formation 
Like carboxylic acids, thioacids are also activated with common 
carbodiimides and can be use for direct amide bond forming reactions with 
amines.13 The activation of thioacids with excess silver ion in presence of N-
4 
 
hydroxysuccinimide has been used in the coupling of protected peptide 
fragments as shown in Scheme 4.36-38  
 
Scheme 4. Activation of thioacids with silver nitrate. 
1.1.2 Native Chemical Ligation 
The usefulness of thioacids greatly increased with the description of native 
chemical ligation, by Schnölzer and Kent in 1992.18 These authors came up with 
a novel strategy for the coupling of unprotected peptide fragments in aqueous 
solution. The basis for this new approach is the presence in each peptide 
fragment of a unique, mutually reactive functionality which enables a 
chemoselective reaction between the two components. This approach is called 
‘native chemical ligation’. This chemistry was initially used for a nucleophilic 
substitution reaction between an SH group of a thioacid attached to the C-
terminus of one peptide, and an alkyl bromide attached to the N-terminus of the 
other fragment, leading to the formation of a thioester at the ligation site (Scheme 
5).18 This reaction can be performed in aqueous solution, and the selectivity of 
the reaction allows the use of unprotected peptide fragments.  
 
Scheme 5. Ligation of unprotected peptidyl thioacids.  
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The major disadvantage of the initial chemical ligation approach was that 
the reaction needed an unnatural structure at the ligation site, which leads to the 
formation of a non-native peptide. A second generation of ligation chemistry, 
referred as ‘the native chemical ligation’ (NCL), was introduced in 1994 by 
Dawson et al.39 In this new methodology the unnatural alkyl bromide  was 
replaced by a cysteine residue from N-terminus of the second fragment, allowing 
the trans thioesterification with the C-terminus thioester of first peptide fragments 
in aqueous solution, with the formation of a ‘native’ amide bond at the ligation site 
(Scheme 6).39 The characteristics of the native chemical ligation methodology 
enable all the limitations of the traditional convergent approach for the synthesis 
of large peptides or proteins (i.e., poor solubility and difficulty in purifying the fully 
protected peptide fragments) to be overcome, and established it as a method for 
reproducible and practical total chemical synthesis of small-to-medium size 
peptides and proteins.40     
 
Scheme 6. Native chemical ligation of unprotected peptidyl thioesters. 
  
1.1.2.1 Native Chemical Ligation without Cysteine: Other Thioligations 
The native chemical ligation methodology has proven very useful in the 
synthesis of large peptides and proteins. However, this strategy has some 
limitations, because of the fact that a cysteine is required at the ligation site, and 
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that naturally occurring proteins do not always contain a cysteine residue in the 
right position of their sequences, making them difficult to synthesize using this 
methodology. Therefore, several modifications of the initial methods have been 
introduced to overcome this drawback. In this respect, introduction of 
homocysteine,41-42 selenocysteine,43-45 homoselenocysteine46 and histidine47 in 
the ligation site as a replacement of cysteine, have considerable potential. In the 
case of histidine, located at the N-terminus of a peptide, the imidazole side chain 
nitrogen acts as a nucleophile in the ligation reaction (Scheme 7).47 
 
 
Scheme 7. Histidine-mediated ligation of peptidyl thioacids. 
1.1.2.2 Thioligation with a Removable Auxiliary 
Another way to overcome the N-terminal cysteine residue requirement in 
the native chemical ligation methodology is to mimic the characteristic of this 
cysteine by the use of a removable auxiliary. For this purpose, Canne et al. 
replaced the N-terminal cysteine by an oxyethanethiol-substituted N-terminal 
group (Scheme 8).48 
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Scheme 8. Peptidyl thioesters ligation through Nα-(oxyethanethiol). 
 
Several groups have shown that the N-terminal cysteine can also be 
replaced by a 2-mercaptobenzylamine linker.49-51 In this case, the intramolecular 
acyl shift proceeds through a six-membered ring with the linker, which was 
subsequently removed by treatment with an acid, leading to the native peptides 
(Scheme 9).49 
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Scheme 9. Peptidyl thioesters ligation through a mercaptobenzylamine 
linker. 
A third type of auxiliary for the thioester ligation of unprotected peptide 
fragments was introduced by Kawakami and Aimoto52 and shortly after by 
Marinzi et al.53 The auxiliary attached at the N-terminus of one peptide fragment 
is based on an O-nitrobenzyl scaffold, with which the thioester present in the 
second peptide fragment can undergo trans thioesterification as shown in 
Scheme 10.52 
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Scheme 10. Ligation of peptidyl thioesters through a photoremovable 
auxiliary. 
1.1.3 Thioester and Azide Coupling: “Traceless” Staudinger Ligation 
The Staudinger reaction54 is the reaction of a phosphine with an azide to 
produce an iminophosphorane. This iminophosphorane intermediate can then be 
trapped by different electrophiles (Scheme 11).55  
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Scheme 11. Staudinger reaction. 
 
Based on the Staudinger reaction, Raines56-59 and Bertozzi60-61 
independently developed a methodology, known as the Staudinger Ligation, in 
which, the iminophosphorane intermediate was intramolecularly trapped by an 
ester leading to an amidophosphonium salt. The amidophosphonium salt is then 
hydrolyzed to produce an amide bond attached to a phosphine oxide moiety 
(Scheme 12).60 
 Scheme 12. Staudinger ligation. 
A modification of Staudinger ligation, in which an amide bond is formed 
between the two coupling partners to give a product without a triarylphosphane 
oxide moiety, appears even more attractive. Shortly after their first report, 
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Bertozzi et al.61 and Raines et al.56-58 reported a traceless Staudinger ligation, in 
which the phosphine oxide moiety is cleaved during the hydrolysis step. This 
ligation requires two important starting materials; one is a C-terminal 
phosphinothioester58 and the other is a N-terminal azide.62 In the first step of this 
Staudinger ligation, the phosphinothioester reacts with the azide to give an 
iminophosphorane, which then undergoes an intramolecular S to N acyl shift 
leading to an amidophosphonium salt. The amidophosphonium salt is then 
hydrolyzed to produce the amide product and a phosphine oxide. The high 
reactivity of the aza-ylide does not, however, permit the presence of unprotected 
side-chain functionalities and therefore the Staudinger ligation is limited to the 
coupling of fully protected peptide fragments (Scheme 13).63 
 
Scheme 13. Ligation of protected peptidyl phosphinothioester.  
1.1.4 Thioacid and Azide Coupling 
In 2003 Williams and co-workers developed a coupling strategy based on 
a fundamental mechanistic revision of the reaction of thioacids and organic 
azides.64-68 Contrary to the conventional methods for the chemical synthesis of 
amides this method does not need active esters and amines as precursors for 
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amide synthesis. Moreover the application of this methodology for the 
preparation of several classes of complex amides in nonpolar and polar solvents 
including water was reported (Scheme 14).64 
 
Scheme 14. Reaction of thioacids and azides to form amides.  
1.1.5 Coupling of Thioacids with Isocyanates and Isothiocyanates 
Although, the above chemical ligations have proven to be very useful 
methods for peptide coupling, they are not without limitations, chief among which 
are the need for a cysteine at the ligation site in NCL, and the need to prepare an 
N-terminus azide group in Staudinger ligation. In this regard, Crich and Sasaki 
have developed a new methodology based on the reaction of thioacids with more 
widely available isocyanates and isothiocyanates, which results in the formation 
of amides (Scheme 15).69 
 
Scheme 15. Reaction of thioacids with isocyanates and isothiocyanates.  
1.2 Synthesis of C-Terminal Peptidyl Thioacids and Thioesters 
Self-evidently, the synthesis of C-terminal peptidyl thioacids and thioesters 
is an area of considerable relevance to the amide bond formation reaction by the 
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native chemical ligation and its variants. For such purposes the synthesis of 
thioacids and thioesters may be approached 1) in solution and 2) on solid-
support. 
1.2.1 Synthesis of Thioacids in Solution 
1.2.1.1 Direct Thiation of Carboxylic Acids 
Direct conversion of carboxylic acids 16 into thioacids 17 using a thiating 
agent such as tetraphosphorous decasulfide in the presence of catalytic 
triphenylantimony oxide is high yielding and proceeds under mild conditions 
(Scheme 16).70 However without catalytic triphenylantimony oxide, this 
conversion is not generally an efficient way to make thioacids, and moreover it 
requires high temperature.71 More recently, Danishefsky et al. have developed a 
direct conversion of acid to thioacid under microwave irradiation of carboxylic 
acids and Lawesson’s reagent.72  
 
Scheme 16. Direct synthesis of thioacids from carboxylic acids. 
1.2.1.2 Nucleophilic Attack on Carbonyl Sulfide 
Nucleophilic carbon species such as Grignard reagents73 or stabilized 
carbanions react with carbonyl sulfide to give thioacids. For example 
deprotonation of α-fluoroalkylphosphonates 18 with lithium diisopropylamide 
followed by quenching with carbonyl sulfide gives the corresponding α-
fluoroalkanyl thioacids 19 (Scheme 17).73  
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Scheme 17. Preparation of thioacids from carbonyl sulfide. 
1.2.1.3 Synthesis of Thioacids by Pericyclic Rearrangement 
Several methods are available for preparation of thioacids from thioesters. 
One of them is a highly diastereoselective Lewis acid promoted Ireland-Claisen 
rearrangement of a thioester 20 to the corresponding thioacid 21 (Scheme 18).74  
  
Scheme 18. Synthesis of a thioacid by an Ireland-Claisen rearrangement of 
a thioester. 
1.2.1.4 Acylation with Sulfur Sources 
Direct acylation of hydrogen sulfide at high pressure with esters, acid 
halides and anhydrides has been a common method for thioacid preparation.75-76 
Acid chlorides are generally used as the acylating agents and, when reacted with 
hydrogen sulfide in pyridine followed by addition to a solution of aqueous 
potassium hydroxide saturated with hydrogen sulfide, provide the thioacids.77-78 A 
more versatile approach to the acylation of a sulfur source involves the treatment 
of acid halides 22 with N,N-dimethylthioformamide (23) to give the intermediates 
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25, which then decompose to the thioacids with regeneration of the 
thioformamide (Scheme 19).75  
 Scheme 19. Synthesis of thioacids from acid chlorides and 
dimethylthioformamide. 
1.2.1.5 Synthesis of Amino Thioacids 
Several methods have been developed for the synthesis of small C-
terminal peptidyl thioacids in the solution phase.13,16 In most of the cases the 
formation of an active ester of N-Boc protected amino acids is invoked, followed 
by nucleophilic attack on the carbonyl carbon of the active ester by hydrogen 
sulfide gas or sodium hydrogen sulfide (Scheme 20).13 
 Scheme 20. Synthesis of amino thioacids. 
However, this method has limitations which prevent it from being used 
extensively in synthesis of thioacids. Chief among these limitations is the 
formation of the symmetrical thioanhydride by the reaction of unreacted active 
ester 29 and the thioacid salt of 30.77,79 The protocol also typically  generates a 
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di-thioacid 31 by the reaction of excess hydrogen sulfide with the thioacid 30 
(Scheme 21).79 
 Scheme 21. Formaton of di-thioacid.  
In this regard, a 2nd protocol for amino thioacids synthesis was developed 
by Williams and co-workers in 2003, wherein a trimethoxybenzyl (TMB) thioester 
32 was deprotected in mild acidic conditions to obtain thioacid 33 (Scheme 22).64 
 
Scheme 22. Synthesis of thioacids through TMB-thioesters. 
 
However, due to potential difficulties in the solution-phase methodology, in 
which the product of each individual reaction step has to be isolated and purified 
before the next step, alternatives have been sought. In contrast to the solution-
phase methodology, SPPS methodology has been employed more prominently 
for the synthesis of peptidyl thioacids. In which, the growing peptide is linked to 
an insoluble support and therefore, after each reaction step, the byproducts are 
simply removed by filtration and washing. Furthermore, because of the repetitive 
nature of peptide synthesis (deprotection, washing, coupling, washing, 
deprotection,…), the use of an insoluble support in a single reaction vessel 
allows for automatization of the processes. 
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1.2.2 Synthesis of C-Terminal Peptidyl Thioacids and Thioesters on Solid 
Support 
Since Merrifield introduced SPPS,80 new synthetic methods have 
continually been reported with the aim of improving efficiency in peptide 
assembly.81 Although the vast majority of synthetic peptides are required with C-
terminal carboxylic acids or primary carboxamide end groups, many other C-
terminal modified peptides are often found in nature and have potential interest 
as therapeutic agents.82 For example, peptides in which the C-termini are 
modified to other functionalities have been extensively used as substrates and 
inhibitors for a variety of proteolytic enzymes. In addition, C-terminal modified 
peptide fragments like amides,83-84 hydrazides,85 hydroxamic acids,86 alcohols,87-
88
 aldehydes89-90 and ketones91 can be readily engaged in segment 
condensations for the assembly of larger peptides or small proteins.92-93 In a 
similar vein, an important goal in C-terminal modified peptide synthesis is the 
inclusion of peptidyl thioacids and thioesters synthesis on a solid support using 
both Fmoc and Boc chemistries.  
1.2.2.1 Synthesis of C-Terminal Peptidyl Thioacids and Thioesters on Solid 
Support using Boc Chemistry 
The lability of the carbonyl-sulfur bond of thioesters to repeated exposure 
to the nucleophilic base piperidine in standard Fmoc-SPPS protocols, led to an 
initial reliance on Boc-SPPS chemistry for the synthesis of peptidyl thioacids and 
thioesters. In this respect, solid-phase preparation of unprotected peptides with a 
thiocarboxylic acid functionality at the C-terminus was first reported by Blake et 
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al., who used a preformed benzhydryl thioester handle 4-[α-(Boc–Gly–
S)benzyl]phenylacetic acid.36-37 Subsequently, several methods have been 
developed for the preparation of a modified handle, 2-[4-
(mercapto(phenyl)methyl)phenoxy]acetic acid.15,94-95 The first amino acid is 
derivatized with this linker, and the resulting thioester 35 is finally attached to an 
aminomethyl polystyrene resin. Standard Boc-SPPS96 is then applied for 
preparation of the desired peptide sequence. Finally, cleavage of the peptide 
from the resin with HF leads to the formation of the peptidyl thioacid 38 (Scheme 
23).94  
 
Scheme 23. Peptidyl thioacid synthesis using a handle on solid support. 
 
Schwabacher and Maynard reported a strategy, wherein the target peptide 
was assembled by standard Boc chemistry on 4-nitrobenzophenone oxime 
resin.97-98 The thioacid 40 is obtained after cleavage of active O-acyl oxime 
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peptidyl ester 39 with hexamethyldisilathiane in presence of TBAF (Scheme 
24).99  
 
Scheme 24. Synthesis of peptidyl thioacid on oxime resin. 
 
Partially protected peptide S-alkyl thioesters were first prepared by Aimoto 
et al. using the 3-sulfanylpropanoic acid handle100 or its tert-butylsulfanyl 
derivative.101 These systems were coupled to a p-methylbenzhydrylamine 
(MBHA) resin (41) and Boc protocols were employed. In a similar vein, a third 
protocol for SPPS containing a C-terminal thioester by the Boc strategy was 
developed by Tam and co-workers.24,102-103 The method is based on the use of a 
MBHA resin, which is first loaded with S-trityl mercaptopropionic acid. After 
removal of the trityl-protecting group, the desired polypeptide chain is assembled 
using standard Boc strategy. Finally, the thioester 44 is obtained after cleavage 
with HF (Scheme 25).24 
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Scheme 25. Synthesis of a peptide possessing a C-terminal thioester. 
 
Recently, Yangmei et al. reported an efficient synthesis of a fully 
deprotected peptide S-benzyl thioester using a volatilizable 
mercaptomethylphenyl-functionalized silica support (45).104 The first amino acid 
is derivatized with this linker, and the target peptide was assembled by standard 
Boc chemistry. Finally, cleavage of the peptide from the resin with HF leads to 
the formation of the peptidyl thioester 48 (Scheme 26).104  However, the 
hazardous HF105-106 conditions typically required for cleavage from the resin 
following Boc-SPPS, limit the use of this chemistry.  
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Scheme 26. Synthesis of peptidyl S-benzyl thioester on silica support. 
1.2.2.2 Synthesis of C-Terminal Peptidyl Thioacids and Thioesters on Solid 
Support using Fmoc Chemistry 
Despite the instability of thioesters to the basic conditions required to 
remove the widely used Fmoc protecting group in Fmoc-SPPS methodology, 
several Fmoc chemistry-based methods have been developed. These include 
the replacement of piperidine by new cleavage cocktails of 1-methylpyrrolidine, 
hexamethylenimine, and 1-hydroxybenzotriazole for the Fmoc removal steps, but 
it has been found that these methods tend to epimerize the stereogenic center at 
the thioester position.107-108 
In 1999, Barany et al. was the first to report the synthesis of peptidyl 
thioesters following Fmoc-SPPS with BAL strategy, where the growing peptide is 
anchored through backbone nitrogen instead of through a terminal Cα-carboxyl 
group.109-111 In the BAL strategy, an acid labile 4-[formyl-3,5-
dimethoxyphenoxy]butyric acid-based handle (49) was linked with an amino-
functionalized PEG-resin. This was followed by on-resin reductive amination with 
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an allyl ester of amino acid hydrochloride salt and the target peptide was 
assembled by standard Fmoc chemistry on this support. Then selective removal 
of the C-terminal allyl ester followed by coupling of amino acid thioester leads to 
the backbone amide anchored C-terminal peptidyl  thioester 52, which was 
cleaved by TFA to obtain the thioester 53 (Scheme 27).109 
 
Scheme 27. Preparation of unprotected peptidyl thioesters using backbone 
amide linker approach. 
Although this approach was successful in many cases, its scope is 
somewhat limited by the need for special precautions required when coupling the 
second amino acid to prevent diketopiperazine formation. However, the major 
drawback to this method is the need for careful control in the activation of 
backbone peptide carboxylic acid to avoid epimerization on introduction of the 
thioester to the C-terminal end of the peptide chain.112-113 To circumvent these 
problems, numerous methods have been developed using Fmoc chemistry 
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wherein, after completion of the peptide synthesis, the linker to the resin is 
activated and it permits the displacement by a thiol or thiolate resulting in the 
liberation of peptidyl thioesters. In this regard, Ingenito et al.114 developed the 
use of an acylsulfonamide ‘safety-catch linker’ 54 for SPPS containing a C-
terminal thioester by the Fmoc strategy. This linker, which is stable to both 
strongly basic and acidic conditions, was first introduced by Kenner et al.115 and 
later modified by Backes and Ellman.116 The peptide is assembled using the 
standard Fmoc protocol to afford solid-phase bound peptides of such as 55. After 
the final peptide coupling, the resin is activated for cleavage by treatment with 
diazomethane to give an N,N-acylmethylsulfonamide 56, or by treatment with 
iodoacetonitrile to give an N,N-acylcyanomethylsulfonamide 57. The peptide is 
then released from the activated resin by nucleophilic displacement involving a 
thiol group to yield 58 (Scheme 28).116  
 
Scheme 28. Synthesis of a peptidyl thioester on ‘Safety-Catch’ linker. 
 
Sewing and Hilvert reported a second useful strategy,117-118 in which the 
target peptide is assembled by standard Fmoc chemistry on a 4-hydroxymethyl- 
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phenylacetamidomethane (PAM) or 4-hydroxymethylbenzoic acid (HMBA) resin, 
and the cleavage was performed by activation of the ester linkage with AlMe2Cl 
in the presence of a large excess of a nucleophilic thiol to yield peptide thioester 
60 (Scheme 29).118  
 
Scheme 29. Formation of a C-terminal peptidyl thioester by 
dimethylaluminum mediated cleavage. 
In this method, Sewing and Hilvert observed that treatment with a large 
excess of oxophilic reagent favored formation of trithioortho esters and ketene 
dithioacetals, which on acidic workup yielded peptidyl thioesters, with the risk of 
racemization of C-terminal amino acid. However, the need to expose the whole 
assembled peptide to harsh reagents caused side-reactions to varying degrees, 
including conversion of side-chain ester groups to their thioesters and formation 
of aspartimide. In this regard, Albericio and Jensen et al. reported a modification 
of the BAL approach to the synthesis of peptidyl thioesters, where they linked a 
masked thioester i.e., trithioortho esters with 4-[formyl-3,5-
dimethoxyphenoxy]butyric acid (49) handle and assembled the peptide using 
Fmoc chemistry (Scheme 30).119 Although the concept of the masked thioester in 
this strategy can solve the problem of formation of diketopiperazine, its practical 
utility at the present is restricted mainly to the preparation of glycine thioester 
peptides. 
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Scheme 30. Synthesis of peptidiyl thioesters by masking of thioesters. 
A third protocol for the synthesis of thioesters along with Fmoc-SPPS and 
activation of linker was reported by Camarero et al.120 using an aryl hydrazine 
support, which is totally stable to the conditions of Fmoc- and Boc-SPPS and 
which yields a peptide hydrazide resin. At the end of the synthesis, the fully 
protected peptide resin is activated by oxidation with N-bromosuccinimide to 
peptide diazene 64. The reactive acyl diazene is then cleaved with an α-amino 
acid S-alkyl thioester followed by treatment with TFA to give the peptidyl 
thioesters 65 (Scheme 31).120 
 
Scheme 31. Synthesis of petidyl thioesters using an aryl hydrazine support. 
 
Another elegant way to synthesize petidyl thioesters based on activation 
of linker, by formation of active C-terminal aromatic N-acylurea functionality, was 
reported by Dawson and co-workers.121 The linker attached with the C-terminal 
carboxylic group is 3,4 diamino benzoic acid, which was first coupled with PEG 
amine, and the peptide was synthesized following Fmoc chemistry to obtain resin 
bound peptide 66. After which, 66 was efficiently transformed into an aromatic N-
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acylurea moiety 68, followed by deprotection and thiolysis to yield peptidyl 
thioesters 69 (Scheme 32).121  
 
Scheme 32. Synthesis of peptidiyl thioesters through N-acylurea. 
Although methods based on the activation of a linker followed by thiolysis 
leading to the synthesis of peptidyl thioesters have had noticeable success, they 
also have disadvantages, most pertinently the risk of epimerization on 
introduction of the thioester to the active C-terminal end of the peptide chain, and 
the need for additional steps after completion of synthesis of peptide chain on the 
linker. In this regard, Botti et al.,122 and Danishefsky et al.123 individually 
developed a novel methodology based on the in situ O to S acyl shift, which 
leads to the formation of a thioesters 72 (Scheme 33).122 More recently Muir et al. 
synthesized a number of naturally occurring cyclic peptidyl thioesters i.e., 
peptidyl thiolactones following the O to S acyl shift protocol.124  
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Scheme 33. In situ formation of thioesters through O to S acyl shift and 
native chemical ligation. 
A second protocol for the direct synthesis of peptidyl thioesters along with 
Fmoc-SPPS is based on the in situ N to S acyl shift reaction.125-130 The 
methodology was first reported by Aimoto et al., where 4,5-dimethoxy-2-
mercaptobenzyl protecting group mediated peptidyl thioester 77 was synthesized 
via an N to S acyl shift as shown in scheme 34.125  
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Scheme 34. Formation of thioesters through N to S acyl shift. 
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More recently Kawakami and Aimoto reported a peptide containing a 
cysteinyl prolyl ester (CPE) moiety at the C-terminus is spontaneously 
transformed into a diketopiperazine thioester 79 via an intramolecular N to S acyl 
shift reaction, followed by diketopiperazine formation.130 Moreover, due to the 
autoactivating function of the CPE peptide can be ligated with a Cys-peptide in a 
one-pot procedure and the peptide diketopiperazine thioester can also be 
transformed into a peptide thioesters 81 by intermolecular thiol–thioester 
exchange with external thiols (Scheme 35).130 
 
Scheme 35. Thioester formation and ligation of CPE peptide via N to S acyl 
shift. 
1.3 Toward the Stereochemical Elucidation and Synthesis of Virgineone  
The pyrrolidin-2,4-dione ring system carrying a 3-acyl substituent (tetramic 
acid) 82 is a key structural unit in many natural products (Figure 3).131-132 The 
spectrum of biological activity displayed by these natural products is remarkable 
in its diversity; ranging from potent antibiotic, antiviral and antifungal properties, 
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cytotoxicity and mycotoxicity as well as the inhibition of tumor growth.133-137 In 
addition, certain members of this class are responsible for the pigmentation of 
certain sponges and molds.131 Self-evidently, the synthesis of this class of natural 
products has been and continues to be an area of considerable interest to 
synthetic organic chemists.132  
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Figure 3. Tetramic acid skeleton. 
 
A novel member of this group of natural products, a glycosylated tetramic 
acid, virgineone (83), was isolated and characterized by Singh et al. in 2009 from 
saprotrophic Lachnum virgineum (Figure 4).138 Virgineone was identified in a 
number of Lachnum strains collected from diverse geographies and habitats, and 
displays a broad-spectrum of antifungal activity against Candida spp. and 
Aspergillus fumigatus.138 Structurally related compounds include militarinone C 
(84) isolated from the fungus Cordyceps militaris,139 epicoccamide A (85) from 
jellyfish-derived strains of Epicoccum purpurascens,140 and epicoccamide D (86) 
from an Epicoccum sp. associated with the wood-decay fungus Pholiota 
squarrosa (Figure 4).141 
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Figure 4. Virgineone and structurally related natural products. 
 
In addition to a tyrosine derived acyl-tetramic acid terminus, virgineone 
contains a central C-22 oxygenated chain attached at its terminus to β-
mannopyranoside. Unfortunately, other than the β-configuration of the 
mannoside unit, neither the absolute nor the relative configuration of virgineone 
was established by the original investigators, making it an ideal target for total 
synthesis.  The synthesis of virgineone can be considered to revolve around two 
key steps: 1) the formation of tetramic acid moiety, and 2) the stereoselective β-
mannosylation.  In this regard a succinct overview of the currently optimal 
methods for the synthesis of these two units is given. 
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1.3.1 Synthesis of Tetramic Acids: Overview 
In 1914, Gabriel was the first to synthesize a tetramic acid derivative 88 by 
cyclization of phthalimidomalonate derivative 87 with concentrated sulfuric acid 
(Scheme 36).142-143 
 
Scheme 36. First synthesis of tetramic acid. 
Subsequently and especially during the last few decades tremendous 
advances in the synthesis of chiral tetramic acids have been reported.144-146 In 
most cases, the synthesis is based on the use of amino acid derived precursors 
whose stereochemical integrity remains more or less conserved in the structure 
of products. In this context, the most appreciated studies on the synthesis of 
such optically active compounds have been reported by Ley et al., where a 
series of enantiomerically pure tetramic acids were prepared by the cyclization of 
β-keto amides 89 with TBAF or KOtBu as base (Scheme 37).147 
 
Scheme 37. Synthesis of enantiomerically pure tetramic acids. 
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More recently Schobert et al. reported a multistep process for the 
synthesis of enantiomerically pure tetramic acids.148-149 The method is based on 
the high temperature Wittig type reaction of excess 
(triphenylphosphoranylidene)ketene  with α-amino acid benzyl esters to obtain 
tetramates 91. Hydrogenolysis of 91, followed by C-acylation with an excess acyl 
chloride gave the tetramic acid 92 (Scheme 38).149  
 
Scheme 38. Synthesis of tetramic acids by Wittig type reaction. 
1.3.2 Stereoselective β-Mannosylations: Overview150 
Due to a formidable combination of steric and stereoelectronic factors, the 
formation of the equatorial β-mannoside bond has long been considered one of 
the most challenging linkages to prepare in the field of carbohydrate 
synthesis.151-152  
In this regard, as developed and demonstrated by Crich et al., the use of 
4,6-O-benzylidene protected mannosyl donors bearing ether-type protecting 
groups on O-2 and O-3, is well-proven to be the most efficient general approach 
for the construction of β-mannosides with high yield and excellent 
stereoselectivity. Crich and Sun initially demonstrated this chemistry with 
mannosyl sulfoxide donors,153 wherein the donor  was activated with Tf2O and 
the so-generated covalently bound α-mannosyl triflate was subjected to 
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nucleophilic displacement by the glycosyl acceptor to give the β-mannoside.153 
Subsequently, Crich and Smith demonstrated the use of thiomannoside donors 
to generate α-mannosyl triflates with the help of an electrophilic promoter 
combination of BSP/Tf2O154 in presence of a non-participating hindered base, 
TTBP155 (Scheme 39).150 This methodology is highly appreciated and has been 
extended to the stereocontrolled synthesis of a number of complex β-mannoside-
containing oligosaccharides by numerous groups worldwide.150  
 
Scheme 39. 4,6-O-Benzylidene directed β-mannosylations. 
1.4 Goals of This Thesis 
The work described in this dissertation was undertaken with two different 
goals in mind. Firstly, the development of the chemistry of thioacids with 
particular emphasis on applications in peptide chemistry was envisaged.  Thus, 
as described in Chapter 2, investigations were conducted towards the 
development of methodologies for the synthesis of thioacids, and their coupling 
with sulfonamides to synthesize peptide bonds, while Chapter 3 deals with the 
synthesis of peptidyl thioacids on a solid-support. Continuing this theme, Chapter 
4 describes the in situ generation of thioacids by the regioselective ring opening 
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of β-thiolactones and the application of this chemistry to the formation of amide 
bonds.  A second goal was the exploration of methods toward the synthesis of 
virgineone and the establishment of its relative and absolute configuration.  Work 
directed toward this end is presented in Chapter 5.   
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CHAPTER 2 
SYNTHESIS OF AMINO THIOACIDS: APPLICATIONS TO THE FORMATION 
OF AMIDE BONDS AND SYNTHESIS OF PEPTIDES BY THEIR REACTION 
WITH 2,4-DINITROBENZENESULFONAMIDES  
2.1 Background and Significance 
The amide function is a common feature in both small and complex 
synthetic or natural molecules. For example, peptides and proteins are 
heteropolymers composed of amino acid residues linked by amide bonds 
between the carboxyl group of one amino acid residue and the α-amino group of 
the next one, and proteins play a crucial role in virtually all biological processes 
such as enzymatic catalysis,156 transport and storage, immune protection157-158 
and mechanical support.159 Understanding the mechanisms and principles 
governing the structural and functional properties of bioactive proteins is an 
important objective in biological and medical research. The first requirement for 
the study of proteins is to assess their ease of availability in terms of purity and 
quantity. There are three main routes to consider: (i) native protein isolation,160-
162
 (ii) recombinant techniques for the expression of proteins in 
microorganisms,163-164 and (iii) chemical synthesis.165-166 Each of these methods 
has its advantages and disadvantages, but only chemical peptide synthesis 
permits the production of large quantities of pure peptides.  
As discussed in section 1.1, a number of elegant approaches have been 
investigated to meet the challenges present in the synthesis of peptides and 
proteins, however, these are not without limitations. In this context, the 
development of a new method for amide and peptide bond formation is 
envisaged in this chapter. 
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2.2 Amide Bond Formation by the Tomkinson Reaction  
As demonstrated by Fukuyama,167-168 the 2-nitro- and 2,4-
dinitrobenzenesulfonamides function as excellent protecting groups for amines 
and enable their alkylation on nitrogen under mild reaction conditions, because of 
acidity of their N-H bond. The sulfonamides are also deprotected under very mild 
conditions by nucleophilic aromatic substitution with a thiol or amine (Scheme 
40).167  
  
Scheme 40. Formation of sulfonamides and synthesis of secondary amines. 
However, as reported by Tomkinson and co-workers,169-170 when the 
nucleophilic thiol is replaced by a simple organic thioacid as in Scheme 35, the 
product is the amide (Scheme 41). 
 
Scheme 41. Formation of an amide bond by Tomkinson's reaction. 
Accordingly, when the simple organic thioacid is replaced by an amino 
thioacid as in Scheme 41, the product is a peptide. Therefore, an amino acid 
bearing a C-terminal thioacid group is the key starting material in the synthesis of 
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peptide bond by the Tomkinson reaction. As discussed in the introduction 
(section 1.2.1.5), several methods have been developed for the preparation of 
thioacids in solution, however, a general or largely accepted method has yet to 
be accomplished. 
2.3 A Process for the Synthesis of Amino Thioacids 
As demonstrated by Giralt et al.171-172 the 9-fluorenylmethyl (Fm) group is 
an acid stable protecting group for the side chain thiol of cysteine as a cysteine 
thioether, and can be deprotected under standard Fmoc deprotection conditions 
leaving the side chain thiol of cysteine. Bearing this fact in mind, the synthesis of 
9-fluorenylmethylthiol (FmSH) and the formation of 9-fluorenlylmethylthioester of 
N-Boc protected amino acids, was considered to have significant potential for the 
synthesis of amino thioacids in solution. 
2.3.1 Synthesis of 9-Fluorenylmethylthiol (FmSH) 
The synthesis of FmSH (107) began with the commercially available 
starting material, 9-fluorenylmethanol (104) (Scheme 42). First, 104 was 
converted to corresponding tosylate 105,173 followed by displacement  with 
potassium thioacetate to provide compound 106. However, attempted hydrolysis 
of thioacetate 106 with commonly used basic conditions, such as hydrazine,174 
methanolic ammonia,175 lithium hydroxide176 or even mild carbonate base177 in 
methanol were unsuccessful, leading to exclusive formation of the eliminated 
product 108. Subsequently, the low temperature reduction of 106 with DIBAL-
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H178 was found to achieve the desired deprotection and is the method of choice 
to afford FmSH (Scheme 42). 
  
Scheme 42. Synthesis of FmSH. 
2.3.2 Synthesis of 9-Fluorenylmethylthioesters of N-tert-Butoxycarbonyl-α-
amino Acids  
Several N-tert-butoxycarbonyl-α-amino acids were coupled with FmSH 
under standard carbodiimide conditions to give the thioesters in good yield 
(Scheme 43). The thioesters obtained by the coupling, were purified by column 
chromatography over silica and were found to be stable at room temperature.   
 
 
Scheme 43. Synthesis of various Fm thioesters. 
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The Fm group is compatible with Boc deprotection conditions, but was 
selectively cleaved by piperidine in DMF to afford the N-Boc protected amino 
thioacid from the corresponding thioester in good yield. These thioacids were 
taken on to the coupling reaction without any purification (Scheme 44). 
 
Scheme 44. Deprotection of 9-fluorenylmethylthioester. 
N-Benzyloxycarbonyl-L-alanyl-L-phenylalanine 9-fluorenylmethyl thioester 
(116) was synthesized following the PyBOP coupling method, recommended by 
Kajihara and coworkers179 from the corresponding dipeptide 115, to suppress 
any racemization of 115 (Scheme 45).  
 
Scheme 45. Synthesis of a thioester under the Kajihara conditions. 
The analytical RP-HPLC trace of thioester 116 is shown in Figure 5. Only 
a single peak with retention time of 38.54 min was seen in the trace with a 
molecular weight corresponding to that of the thioester, which argues strongly 
against the possibility of racemization of 115 during thioesterification.  
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5 - 50% acetonitrile in water over 60 min with a flow rate of 1.5 mL/min and 215 
nm UV detection, retention time = 38.54 min. 
 
Figure 5. RP-HPLC trace of thioester 116. 
2.4 Synthesis of N-[(2,4-Dinitrobenzene)sulfonyl]-α-amino Acid Methyl 
Esters 
Following the literature,167 several N-[(2,4-dinitrobenzene)sulfonyl]-α-
amino acid methyl esters were prepared from the reaction of the corresponding 
hydrochloride salts of α-amino acid methyl esters and 2,4-dinitrobenzenesulfonyl 
chloride in presence of pyridine (Scheme 46). N-[(2,4-Dinitrobenzene)sulfonyl]-
glycyl-glycine methyl ester (123) was prepared from the corresponding water 
soluble dipeptide in H2O/THF solvent system using a carbonate base. 
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Scheme 46. Synthesis of sulfonamides. 
2.5 Coupling between Thioacids and Sulfonamides: Synthesis of 
Dipeptides 
Treatment of the 9-fluorenylmethyl thioesters with piperidine in DMF at 
room temperature gave the corresponding thioacids, which were coupled to the 
sulfonamides in the presence of cesium carbonate, at room temperature, 
resulting in the formation of dipeptides in good yield (Table 1).  
Table 1.Synthesis of Dipeptides from Thioesters and Sulfonamides. 
 
 
 
 
Fm Thioester
1) piperidine,
DMF
2) sulfonamide,
DMF, Cs2CO3, 1 h.
Peptide
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Entry Thioester Sulfonamide Peptide Yield 
(%) 
 
1 
 
 
 
 
 
81 
 
 
2 
 
 
 
 
82 
  
 
3 
 
 
ArO2SHN
NH
O
OMe
121
 
BocHN
O
H
N
O
OMe
126
NH
 
 
 
82 
 
4 
 
 
 
 
78 
 
 
5 
 
 
ArO2SHN
NH
O
OMe
121
 
O
H
N
O
OMe
128
NH
N
Boc
 
 
 
77 
 
6 
 
 
 
 
75 
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79 
 
8 
 
 
 
 
82 
 
 
9 
 
 ArO2SHN
NH
O
OMe
121
 
N
H
NH
O
OMe
O
BocHN
132
 
 
 
80 
 
10 
 
 
 
 
80 
 
11 
 
 
 
 
82 
 
a,b12 
 
 
 
 
51 
a
 Reaction conducted in methanol as solvent. b 20% of 57 was recovered after the reaction. 
  
All reactions in Table 1 were conducted with 1.2:1 ratios of the thioacid 
and the sulfonamide at ambient temperature. In particular, attention is drawn to 
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entries 1 and 2 of Table 1 in which diastereomeric products were obtained, 
enabling the possibility of racemization in the course of thioester deprotection or 
in the coupling process to be ruled out, by a qualitative comparison of the 500 
MHz 1H NMR spectra of both diastereomers as shown in Figure 6. A careful 
review of the proton NMR spectra of both isomers indicates, each spectrum 
corresponds to a single diasteromer. The characteristic chemical shifts of the α 
and β protons of the phenylalanine unit in the diastereomeric dipeptides 124 and 
125, which identify the two diastereomers, are furnished in Table 2 to facilitate 
comparison. The obtention of the 124 and 125 as single diastereomers also 
enables it to be stated with confidence that the Fm thioesters themselves were 
initially formed without racemization. 
 
 
5.0 4.5 4.0 3.5 3.0 PPM 
BocHN
O
H
N
O
OMe
Ph
124
α
β
β 
 α 
5.0 4.5 4.0 3.5 3.0 PPM 
BocHN
O
H
N
O
OMe
Ph
125
α
β
β 
α 
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Figure 6. 1H spectra of dipeptides 124 and 125 in CDCl3. 
 
Table 2. Selected 1H Chemical Shifts (δ in ppm) and Coupling Constants (J) 
of Dipeptides 124 and 125. 
Dipeptide δ of α-proton 
(multiplicity, J, proton counts) 
δ of β- proton 
(multiplicity, J, proton counts) 
124 4.87-4.86 (m, 1H) 3.12-3.06 (m, 2H) 
125 4.91-4.87 (m, 1H) 3.14-3.10 (dd, J = 5.5, 13.7 Hz, 1H) 
3.08-3.04 (dd, J = 5.5, 13.7 Hz, 1H) 
 
The examples employing proline or aminoisobutyric acid derivatives 
(Table 1, entries 4-7 and 9-11) are particularly interesting. A successful synthesis 
of the corresponding dipeptides indicates that the protocol is equally applicable to 
coupling of hindered amino acids, whichever side of the nascent peptide bond 
they occupy.  
In particular, comparison of entries 1 and 12 in Table 1 indicates that the 
coupling reaction is compatible with the presence of alcohols, and that methanol 
may even be employed as solvent. However, a slight loss of yield was recorded, 
which was due to incompletion of coupling between thioacids and sulfonamides 
in methanol. In a polar protic solvent like methanol, the decreased acidity of 
thioacids and the increased solvation of thiocarboxylates, results in a slower 
reaction.180-181 
Accordingly, when a standard reaction of thioacid obtained from 109 and 
the sulfonamide 117 was conducted in the presence of Boc-L-Asp-α-OBn, a 
comparable yield of the desired dipeptide 124 was recorded but no coupling was 
observed to the spectator acid as shown in Scheme 47. The absence of side-
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chain aspartic acid derivatized amide 131 in the coupling indicates the carboxylic 
acid compatibility of the reaction.  
 
Scheme 47. Coupling of thioacid and sulfonamide in presence of a 
carboxylic acid.  
Interestingly, coupling of amino thioacids with the sulfonamide of 
tryptophan containing unprotected indole amine gave only the desired dipeptides 
in good yield (Table 1, entries 3, 5 and 9); no indole amine functionalized 
products were observed. However, the inclusion of N-α-Cbz-L-Lys-OBn in the 
reaction mixture resulted in some loss of yield accompanied by some amidation 
of the free side chain amine group (Scheme 48).  
 
Scheme 48. Involvement of free amine in a thioacid and sulfonamide 
coupling. 
The interference of unprotected alkyl amines in the peptide bond forming 
reactions is common to most such reactions. In this case it suggests that the 
reaction proceeds, at least in part, by decomposition of the intermediate 
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Meisenheimer complex 137 to a 2,4-dinitrophenyl thioester 138 that 
subsequently captures the nucleophilic amine in an intermolecular fashion 
(Scheme 49, path b).  
 Scheme 49. Mechanism of Tomkinson reaction. 
Finally, this methodology was also applied to the synthesis of model 
tetrapeptides (Table 3) by the segment coupling of two dipeptides with moderate 
isolated yield. The tetrapeptides obtained by the coupling, are sparingly soluble 
in common organic solvents like, chloroform, methanol or ethyl acetate, resulting 
in some loss of products during column chromatographic purification. 
Table 3. Synthesis of Tetrapeptides from Thioesters and Sulfonamides. 
Thioester Sulfonamide Peptide (% Yield) 
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The analytical RP-HPLC trace of the tetrapeptide 142 is shown in Figure 
7. In the HPLC trace, a single symmetrical retention peak at 24.22 min 
corresponding to the desired tetrapeptide was observed, which argues against 
the possibility of racemization of 116 during piperidine deprotection or segment 
coupling of two dipeptides.  
 
0 - 50% acetonitrile in water over 60 min with a flow rate of 1.5 mL/min and 215 
nm UV detection, retention time = 24.22 min. 
 
Figure 7. RP-HPLC trace of tetrapeptide 142. 
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2.6 Conclusions 
The above results demonstrate that the methodology based on the 
reaction of thioacids with readily available 2,4-dinitrobenzenesulfonamides is 
suitable for the formation of peptide bonds. Unlike native chemical ligation and its 
variants, this methodology is not limited to the use of any particular amino acid, 
and importantly is epimerization free. The precursors are easy to prepare, and 
the coupling reaction takes place under mild conditions at room temperature and 
is compatible with typical amino acid protecting groups.  
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CHAPTER 3 
SOLID-PHASE SYNTHESIS OF PEPTIDYL THIOACIDS EMPLOYING A 9-
FLUORENYLMETHYLTHIOL-LINKED RESIN IN CONJUNCTION WITH Boc 
CHEMISTRY 
3.1 Background and Significance 
As discussed in Chapter One, over the years several useful and elegant 
strategies have been developed for the synthesis of C-terminal peptidyl thioacids 
and thioesters by SPPS. Despite these notable advances, the synthesis of 
peptidyl thioacids remains significantly more challenging than the synthesis of the 
corresponding peptidyl acids or amides. In this regard, the development of an 
appropriate linker and a general method for solid-phase peptidyl α-thioacids and 
thioesters synthesis was undertaken and forms the basis of this chapter. 
 In a new approach to the synthesis of thioacids, as presented in section 
2.2.2, the FmSH method was introduced to make 9-fluorenylmethyl thioesters, 
from which thioacids are liberated by simple treatment with piperidine, i.e., under 
the conditions usually employed for the cleavage of Fmoc groups in Fmoc-SPPS 
as shown in Scheme 44.  These results prompted the design of a linker based on 
the 9-fluorenylmethyl thioester, N-[9-(tritylthiomethyl)-9H-fluoren-2-yl]succinamic 
acid (147), which can be attached to an amino functional resin and a peptide 
sequence constructed on it. 
3.2 Synthesis of N-[9-(Tritylthiomethyl)-9H-fluoren-2-yl]succinamic acid 
(147) 
The mercapto functionalized linker, N-[9-(tritylthiomethyl)-9H-fluoren-2-
yl]succinamic acid (147), was synthesized starting from commercially available 
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9H-fluoren-2-amine as shown in Scheme 50. The synthesis began with the 
conversion of 9H-fluoren-2-amine to corresponding hydroxyl functional 
compound 143 following a known literature182 procedure, which involved 
formylation of 9H-fluorenyl amine derivative by treatment with NaH and ethyl 
formate, followed by reduction of the resulting aldehyde. Tosylation of the 
hydroxyl functionality of compound 143 using tosyl chloride and pyridine provided 
the tosylate 144, from which the amine 145 was liberated by treatment with 
trifluoroacetic acid.  Then the succinamic acid 146 was obtained by nucleophilic 
ring opening of succinic anhydride by the free amine group of 145. Finally, the 
nucleophilic displacement of tosylate group from compound 146 by 
tritylmercaptan in presence of Hunig’s base led to the protected linker 147 in 
excellent yield (Scheme 50).  
 
Scheme 50. Synthesis of N-[9-(tritylthiomethyl)-9H-fluoren-2-yl]succinamic 
acid. 
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Treatment of linker 147 with DIC and HOBt in DMF gave an activated 
intermediate, which was allowed to react with 1% divinylbenzene cross linked 
aminomethylpolystyrene resin.  After washing with DMF, the trityl group was 
removed by treatment with TFA to yield the resin-bound 9-fluorenylmethylthiol 
derivative 148 as shown in Scheme 51. The attachment of linker 147 to the 
aminomethylpolystyrene resin was also accomplished in a satisfactory manner 
with other commonly used activating reagents such as HBTU,183-186 with the aid 
of Hunig’s base.   
 
Scheme 51. Preparation of a mercapto functionalized resin. 
3.3 Amino Acid Side-Chain Functional Group Protection and Orthogonal 
Protection Strategies 
More than half of the amino acids commonly encountered in proteins have 
side chains that contain reactive functional groups. In solid-phase synthesis it is 
necessary for all of these potentially reactive groups to be masked because of 
rather harsh conditions employed and the need to achieve the highest level of 
efficiency in all chemical reactions.  
The concept of orthogonal protection was defined by Baranay and 
Merrifield in 1977 as “a set of completely independent classes of protection 
groups, such that each class can be removed in any order and in the presence of 
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all other classes”.187-188 Due to the multifunctional nature of amino acids, 
orthogonal protecting group manipulations are widely employed in peptide 
chemistry and the orthogonality of protecting groups is a key issue in the 
planning and experimental execution of any given peptide synthesis. For 
example, the most commonly used Fmoc-SPPS approach based on an 
orthogonal protecting group strategy, known as Fmoc/t-Butyl, involves the use of 
base-labile Nα-Fmoc group and acid-labile side chain protecting groups. In 
contrast, the most commonly used Boc-SPPS technique, i.e., the Boc/Benzyl 
strategy, uses the acid-labile Nα-Boc group for protection of the α-amino group, 
which is removed selectively by the treatment with TFA, and the benzyl type side 
chain protecting groups, with cleavage from the resin by treatment with 
hazardous HF.  
As discussed earlier in the Chapter, the linker 147 for the synthesis of 
peptidyl thioacids on solid support is labile to base, which permits the synthesis 
employing Boc-SPPS strategy. In this context, the manipulations of protecting 
groups of amino acids side chain functionalities were considered. Accordingly, 
the protecting groups were selected based on their orthogonality to the Boc-
SPPS and the groups can be deprotected during the final cleavage of peptidyl 
thioacids from the linker. For example, side-chain alcohols and amines were 
protected as Fmoc- carbonates and carbamates respectively, where as acids 
and thiols were protected as Fm- esters and thioethers respectively. In addition, 
a third orthogonal side-chain protecting strategy, i.e. Alloc/allyl was also 
employed with Boc chemistry. This protection strategy was extensively used in 
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synthesis of cyclic peptides in conjunction with Fmoc/t-Butyl methodology,189-192 
and the protecting groups were selectively removed using a palladium(0) catalyst 
in presence of a nucleophilic scavenger.190,193 In this regard, the preparation of a 
series of suitably side-chain protected amino acids was then undertaken. 
3.3.1 Preparation of O-Fmoc Protected Serine, Threonine and Tyrosine 
Derivatives  
Although the protected derivatives are the safest way to incorporate serine 
and threonine into the peptide sequence, these amino acids can also be used 
with the free hydroxyl functionality.194-195 But unprotected hydroxyl functionalities 
of serine and threonine can undergo side reactions such as dehydration or O-
acylation followed by O to N acyl migration.196-197 However, protection is more 
necessary in case of serine and tyrosine in SPPS. In case of serine, the primary 
alcohol of which is more prone to acylation than the secondary alcohols of 
threonine, and the high nucleophilicity of unprotected tyrosine can lead to 
acylation of the phenol group with excess acylating agents used in SPPS. In 
addition, the electron-rich aromatic ring can undergo alkylation at the ortho 
position of the unprotected tyrosine aromatic ring. In this respect, the Fmoc 
group, which is orthogonal to Boc chemistry, was selected as the choice of 
protecting group for hydroxyl functionality.  
Thus, Nα-Boc-L-serine and the analogous L-threonine and L-tyrosine 
derivatives were converted to their allyl esters by the reaction of allyl bromide in 
presence of potassium carbonate and then to the 9-fluorenylmethyl carbonates 
with Fmoc chloride and pyridine.  Subsequently, the removal of the allyl groups 
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was carried out with a combination of palladium(II) acetate, triphenylphosphine 
and phenylsilane (Scheme 52).  
 
Scheme 52. Preparation of O-Fmoc protected hydroxyl amino acids. 
3.3.2 Preparation of Aspartic and Glutamic Acid Derivatives  
The side chain carboxylic groups of aspartic acid and glutamic acid must 
be protected in order to prevent their activation during peptide synthesis, which 
would lead to undesired branched peptides. Furthermore, in the case of aspartic 
acid, the protecting groups used must also prevent or at least minimize the 
formation of aspartimide.198 However, the protection of the side-chain carboxylic 
acid can be achieved using several methods. The simplest one is the acid 
catalyzed esterification of the free amino acid, where protonation of the α-amino 
group makes the α-carboxylic acid less reactive, thereby allowing the selective 
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protection of the side-chain.199-200 Copper(II) and boron chelates are also applied 
for the selective protection of the side-chain of aspartic and glutamic acids.201-203 
Accordingly, aspartic and glutamic acids were esterified by treatment with 
HCl in allyl alcohol to give the corresponding allyl ester hydrochlorides. The 
amino groups were protected as their Nα-Boc derivatives by treatment with 
(Boc)2O and triethylamine to give Nα-Boc-L-aspartic acid β-allyl ester (157) and 
Nα-Boc-L-glutamic acid γ-allyl ester (158) (Scheme 53).204 
 
Scheme 53. Preparation of mono allyl esters of aspartic and glutamic acid. 
Following a literature protocol,203 treatment of powdered L-aspartic and L-
glutamic acids with triethylborane in THF at reflux afforded the oxazaborolidinone 
derivatives. Then the side chain carboxylic acid groups were esterified by the 
activation with DCC and DMAP in the presence of 9-fluorenylmethanol, and 
finally removal of the chelates with gaseous hydrogen chloride gave the mono 
esters 159 and 160.  These HCl salts were then converted to the Nα-Boc 
derivatives by the treatment with (Boc)2O in aqueous sodium carbonate (Scheme 
54).203  
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Scheme 54. Preparation of mono 9-fluorenylmethyl esters of aspartic and 
glutamic acid. 
3.3.3 Preparation of an Alloc Protected Lysine Derivative 
The protection of the side chain amine group of lysine is essential in 
peptide synthesis to prevent its acylation, which would lead to the formation of 
undesired branched peptides. Like aspartic and glutamic acids, selective 
protection of lysine can be achieved by the formation of copper(II)  or boron 
complexes between the α-amino and α-carboxylate groups.203,205-206 Accordingly, 
refluxing L-lysine hydrochloride with basic copper carbonate afforded the 
copper(II) complex, which was reacted with Alloc chloride before decomplexation 
with ethylenediamine tetraacetic acid disodium salt to give Nε-Alloc-L-lysine 
(163). Reaction of 163 with (Boc)2O in aqueous sodium carbonate gave Nα-Boc-
Nε-Alloc-L-lysine (164) (Scheme 55).207-208  
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Scheme 55. Preparation of an Nε-Alloc protected lysine derivative. 
3.3.4 Preparation of a Guanidino Protected Arginine Derivative  
Owing to the nucleophilicity of the guanidino group, protection of the 
guanidino group of arginine is required to prevent deguanidination209 and δ-
lactam formation.210 Therefore in principle, protection of all the nitrogens of the 
guanidino group is required to fully mask its nucleophilicity. However, mono- and 
diprotection are easier to achieve and are usually sufficient to minimize side 
reactions if bulky and electron withdrawing protecting groups are used. In this 
regard, a guanidine protected arginine derivative 166 was synthesized following 
a literature protocol (Scheme 56).211 The synthesis began with the generation of 
arginine silyl ester by the treatment of commercially available Nα-Boc-L-arginine 
(165) and chlorotrimethylsilane in presence of Hunig’s base, followed by 
installation of the Fmoc group. Finally, hydrolysis of the silyl ester by a simple 
aqueous work-up afforded the desire arginine derivative 166 (Scheme 56).211 
 
Scheme 56. Preparation of a guanidine protected arginine. 
3.3.5 Preparation of S-Fm Protected Cysteine Derivative 
Protection of the side chain of cysteine is mandatory in peptide synthesis 
to avoid acylation, alkylation, or aerial oxidation to the disulfide of the highly 
nucleophilic thiol. Cysteine thiol protection is usually carried out on free cysteine 
itself. Therefore, treatment of cysteine with 9-fluorenylmethyl tosylate (105) in 
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presence of Hunig’s base led to the thiol protected cysteine 167. Subsequently, 
protection of α-amino function of 167 with (Boc)2O in aqueous sodium carbonate 
gave Nα-Boc derivative 168 (Scheme 57).203 
 
Scheme 57. Preparation of a 9-fluorenylmethyl thioether of cysteine. 
3.3.6 Preparation of Alloc Protected Histidine  
The imidazole ring of histidine has two nucleophilic points; the pi- and τ-
nitrogens.212 Unprotected histidine is highly prone to racemization during the 
coupling and acylation during peptide synthesis.213-214 The basic and nucleophilic 
pi-nitrogen is involved in racemization and can be masked in two ways: (i) direct 
protection and (ii) τ-nitrogen protection with bulky or electron-withdrawing 
protecting groups, which reduce the basicity of the pi-nitrogen. In this respect, 
both α-amino and τ-nitrogen were protected with the Alloc group, as it was 
intended that this Alloc protected histidine residue would be used at the N-
terminus of a target peptidyl thioacid. Accordingly, the Alloc protected histidine 
derivative 169 was synthesized by the treatment of histidine with Alloc chloride in 
ice-cold aqueous sodium hydroxide (Scheme 58).193 
 
Scheme 58. Preparation of an Alloc protected histidine. 
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3.4 Solid-Phase Synthesis of Peptidyl Thioacids on the Mercapto 
Functionalized Resin 148 
With all building blocks in hand attention was turned to manual solid-
phase synthesis of peptidyl thioacids on the mercapto functionalized resin 148 
(Scheme 59). Accordingly, the first Nα-Boc amino acid was activated with DIC 
and HOBt in DMF and the pre-activated amino acid was then allowed to react 
with resin 148 to yield the resin bound thioester derivative 170. Subsequently, the 
desired peptide chain was elongated on the resin 170 using standard Boc 
techniques,186,215 which consist of the following steps in each cycle: (i) removal of 
the Nα-Boc protecting group of the last coupled amino acid by treatment with 
TFA; (ii) neutralization of the CF3CO2- . +NH3-peptide-resin salt with Hunig’s base; 
and, (iii) coupling of the next pre-activated appropriate side-chain protected Nα-
Boc amino acid. Between each of these steps a thorough flow wash with DMF 
was carried out to remove excess reagents, and few of peptide-resin beads were 
removed to monitor the individual reaction steps by a qualitative Kaiser ninhydrin 
color test.216 In this test, a dark blue color corresponds to the free amine group 
before the coupling and changes to a light yellow after the coupling step. In 
addition, after each coupling step, formation of the desired peptidyl thioacid was 
confirmed by cleavage of a small amount (~ 5 mg) of resin using a solution of 
piperidine in DMF, followed by examination by ESI-TOF mass spectrometry.  
Finally after completion of the on-resin procedure, the resin-bound peptide was 
treated with a solution of piperidine in DMF or acetonitrile to liberate the desired 
peptidyl thioacids as shown in Scheme 59.  
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Scheme 59. Solid-phase synthesis of peptidyl thioacids. 
A number of peptidyl thioacids were synthesized in this manner as set out 
in Table 4 (Entries 1-5).  As with the preparation of the resin-bound thiol 148 
(Scheme 51), this methodology is adaptable to the use of other coupling 
reagents as evidenced by the application of a combination of HBTU and Hunig’s 
base activation of the amino acids (Table 4, entry 6).   
The thioacid 171 is a simple model tetrapeptidyl thioacid (Table 4, entry 
1), the peptidyl thioacids 172, 173, 174 and 176 are all natural sequences (Table 
4, entries 2-5). The sequences of thioacids 172 and 173 (Table 4, entries 2 and 
3) were selected from the Glucagon-like peptide-1 (GLP-1)217 and represent 
segments 7–16 and 17–26 respectively. Peptide 174 (Table 4, entry 4) 
represents the 94–101 segment of Human Secretory Phospholipase A2 
(hsPLAA2),218 and peptide 176 (Table 4, entry 5) is the 65-84 unit of Human 
Parathyroid Hormone (hPTH).219 Whatever their origins or activities, the 
sequences were selected based-on their compositions with a wide variety of 
amino acid residues in different positions of the sequences. The successful 
synthesis of all sequences indicates that the methodology is not limited to any 
particular amino acid residue of the sequence, during coupling or in final 
cleavage as shown in Table 4 (Entries 1-5). 
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Table 4. Solid-Phase Synthesis of Peptidyl Thioacids  
Entry Resin-Bound Peptide Peptidyl Thioacid  
( %Yield) 
1 
 
 
2 
 
 
3 
 
 
4  
 
 
5 
 
 
6a 
 
 
 
a
 This reaction sequence employed HBTU and Hunig’s base for the coupling reactions in place of 
DIC/HOBt. 
 
The peptidyl thioacids obtained by this methodology, were typically 
achieved with a high degree of purity as determined by either NMR or ESI-TOF 
and HPLC methods. For example, the 500 MHz 1H NMR spectrum of the crude 
tetrapeptidyl thioacid 171 as obtained on simple release from the resin, followed 
by aqueous HCl work-up, extraction with ethyl acetate and drying is presented in 
Figure 8. A careful review of the proton NMR spectrum indicates, the spectrum 
corresponds to a single peptidyl thioacid 171, which required no further 
purification. Therefore, with the exception of thioacid 171 (Table 4, entry 1), 
yields of the other thioacids (Table 4, entries 2-5) were for compounds isolated 
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and purified by RP-HPLC and were based on the substitution level of the 
aminomethyl polystyrene resin. The thioacids obtained in this manner were 
unstable and were found to decompose even at 0 °C after few weeks.  
Figure 8. 1H spectrum of thioacid 171 in CD3OD. 
 
In a similar vein the crude analytical RP-HPLC trace and ESI-TOF mass 
spectrum of the icosamer peptidyl thioacid 176, immediately after release from 
the resin and prior to purification by HPLC are presented in Figure 9. Only a 
single peak with retention time of 15.58 min is seen in this trace with a molecular 
weight corresponding to that of the thioacid 176. Accordingly, m/z = 2220 in the 
mass spectrum is corresponds to the desired thioacid 176 and a careful review of 
the spectrum indicates, the absence of any other partially formed peptidyl 
thioacids or incomplete thioacids of the same sequence. These results also 
illustrate the high degree of purity of peptidyl thioacids obtained by this method. 
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0 - 50% acetonitrile in water over 35 min with a flow rate of 1.5 mL/min and 215 
nm UV detection, retention time = 15.58 min. 
 
 
Figure 9. A) RP-HPLC trace of thioacid 176; B) ESI-TOF mass spectrum of 
thioacid 176. 
[M + H]+ 
 
[M + 2H]2+ 
[M + H + Na]2+ 
[M + 2Na]2+ 
Boc-Lys-Ser-Leu-Gly-
Glu-Ala-Asp-Lys-Ala-
Asp-Val-Asp-Val-Leu-
Thr-Lys-Ala-Lys-Ser-
Gln-SH (27), 
        m/z = 2219.1549 
B) 
A) 
64 
 
The Alloc group was cleaved from the side chain of the histidine residue in 
the course of the treatment of corresponding resin-bound peptide with piperidine 
to obtain the unprotected histidine side chain peptidyl thioacid 172 (Table 4, entry 
2). The similar deprotection of histidine side chain is known in literature,220 where 
Nα,Nτ-di-Cbz-L-histidine (177) is readily decarbobenzoxylated by nucleophilic 
reagents such as sodium methoxide and amines, yielding Nα-Cbz-L-histidine 
(178) (Scheme 60).220 The better leaving group ability of imidazole favors the 
nucleophilic deprotection of imidazole carbamate group.  
 
Scheme 60. Decarbobenzoxylation from histidine imidazole side chain. 
Particular attention is drawn to entries 4 and 5 of Table 4, where the C-
terminal amino acid is asparagine and glutamine respectively. The amino acid 
building blocks for these residues were employed with trityl protecting group for 
the side chain amide functionality. The acid labile trityl group was removed during 
first TFA deprotection of Nα-Boc and the subsequent peptide chain was 
elongated with the free side chain amide functionality of asparagine or glutamine. 
It is noteworthy that the possibility of cyclization of the free side chain amides of 
asparagine and glutamine onto the resin-bound thioester with premature release 
of peptidyl imide did not occur to any significant extent during Nα-Boc 
deprotection or in coupling steps (Scheme 61).  
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Scheme 61. Possibility of formation of peptidyl imide. 
The insignificant formation of peptidyl imides is reasoned simply from the 
calculation of yields of the isolated thioacids. For example, the combined yield of 
octamer thioacid 174 with the corresponding disulfide 175 is 72%, and is 55% for 
the icosamer thioacid 176, which requires average minimum coupling yields of 
~96% and ~97% respectively, for each coupling and Nα-Boc deprotection cycle.   
Attention is drawn to entry 4 of Table 4 in which the disulfide thioacid 175 
of the corresponding oxidative dimerization of thioacid 174 was isolated after 
global deprotection of resin-bound peptide, followed by HPLC purification. This 
oxidative dimerization is even more rapid, when the deprotection is carried out in 
alkaline medium.198,221-222  
The attempted synthesis of icosamer peptidyl thioacid 176 following the 
standard protocol was unsuccessful (Table 4, entry 5). The problem was 
encountered during the coupling of 9th amino acid in the sequence, which led 
incomplete coupling of the corresponding activated amino acid residue. Further 
efforts of the particular coupling were unproductive, which presumably is due to 
formation of secondary structure by association of the growing peptide chain, 
known as aggregation.223 This association leads to the incomplete solvation of 
the peptide-resin complex, and reduced reagent penetration, resulting in failure 
of either the acylation or deprotection or both. The tendency of aggregation 
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depends on the nature of the peptide and side chain protecting groups.224 
However, numerous modifications have been developed to avoid the aggregation 
of peptide chains on SPPS. Accordingly, several new polymer supports have 
been introduced to improve the solvation during the synthesis of peptides.225-227 
Alternatively, improved solvation has been described upon the addition of 
solvents like, NMP,228 TFE,229 hexafluoroisopropanol,230 and DMSO.231 In this 
context, in order to avoid possibility of aggregation during the synthesis of 
peptidyl thioacid 176, NMP was employed as solvent from the 9th amino acid of 
the sequence and the synthesis was completed without finding any other 
difficulties. This can be explained by the presence of polar and nonpolar 
functionalities of NMP solvent, which can interact simultaneously with polar 
amide backbone and nonpolar side chain of the resin-bound peptide, thus 
preventing aggregation by better solvation. 
Finally, the strategy of manipulation of protecting groups of side chain 
amines and hydroxyls functionalities to Fmoc- carbamates and carbonates, 
together with the protection of side chain carboxylates and thiols to Fm- esters 
and thioethers ensures the clean synthesis. In addition, the protecting groups 
were deprotected during the final cleavage of the resin-bound peptide, which 
leads to the corresponding fully unprotected peptidyl thioacid (Table 4, entries 4 
and 5). Nevertheless, the methodology is also applicable for the synthesis of 
peptidyl thioacids, in which the retention of side chain protection is required on 
cleavage from the resin. Accordingly, the side chains protected peptidyl thioacids 
were conveniently accomplished through the use of building blocks whose side 
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chain carboxylates and amines were covered with allyl esters and Alloc 
carbamates respectively (Table 4, entries 2 and 3). 
3.5 Application of Peptidyl Thioacids to the Synthesis of Thioesters and 
Sulfonamide 
As discussed in the Chapter One, the synthesis of peptidyl thioacids and 
thioesters are closely associated with each other, but the latter have found more 
applications in the synthesis of peptides through chemical ligation. Owing to 
unique reactivity of thioacids as discussed in Chapter One, unprotected peptidyl 
thioesters could easily be prepared from the corresponding thioacids by simple 
nucleophilic substitution in an aqueous buffer solution.232 In contrast, the 
unprotected side chains hydroxyl functionalities peptidyl thioacids 172 and 173 
were converted to the corresponding S-benzyl thioesters by simple alkylation 
with benzyl bromide and 2,4,6-collidine in an organic solvent (Scheme 62). The 
thioesters obtained by this method were purified by RP-HPLC and were found to 
decompose even at 0 °C.  
 
Scheme 62. Synthesis of peptidyl thioesters. 
Finally as a discussed in the introduction (section 1.1.4), thioacids were 
reacted with organic azides to form amide bonds. Accordingly, peptidyl thioacid 
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172 was subjected to reaction with an electron deficient sulfonyl azide in 
presence of 2,4,6-collidine to give corresponding peptidyl sulfonamide 181 
(Scheme 63). The acyl sulfonamide 181 was purified by RP-HPLC and was 
found to be stable at 0 °C for few weeks.  
 
Scheme 63. Formation of an acyl sulfonamide. 
3.6 Conclusions 
The above results demonstrate that this novel approach for the solid-
phase synthesis of peptidyl thioacids on a mercapto functionalized 9-
fluorenylmethyl linker in conjunction with standard Boc chemistry is a 
straightforward and efficient process. By way of protecting group manipulation of 
amino acids side chain functionalities, this chemistry provides a very convenient 
and mild means to access protected or unprotected peptidyl thioacids. 
Additionally, this new approach eliminates the use of HF, which is a very 
common deprotecting reagent in final cleavage from solid support and side chain 
functional protecting groups of the peptide in most solid-phase Boc chemistry.   
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CHAPTER 4 
SN2-TYPE NUCLEOPHILIC RING OPENING OF β-THIOLACTONES AS A 
SOURCE OF THIOACIDS: APPLICATION TO THE FORMATION OF AMIDE 
BONDS 
4.1 Background and Significance  
β-Thiolactones (2-oxothietanes) are sulfur analogues of β-lactones,233-237 
and their structural resemblance to β-lactones is reflected in some of the 
methods of preparing these compounds as well as in their chemistry. The few 
structural differences between the two series of lactones are reflected in their IR 
and 13C NMR spectra. For example, for the parent β-propiolactone the IR 
carbonyl absorption is C=O vmaxCHCl3 1845 cm-1 and the 13C NMR carbonyl C-2 
and C-4 chemical shifts are 169.4 and 59.1 ppm, respectively238-239 while those 
for β-propiothiolactone are 1776 cm-1 and 191.1 and 15.0 ppm, respectively.240-
241
 However, unlike the widely prized β-lactones, β-thiolactones have seen little 
use in synthesis. It was envisaged that one of the lesser employed features of β-
lactone chemistry, ring opening by SN2-type attack at the 4-position by a series of 
hard and soft nucleophiles (Scheme 64),242 might be extended to the β-
thiolactones, thereby providing a novel means of generation of thioacids for 
subsequent exploitation in a one pot reaction. 
 
Scheme 64. SN2-Type ring opening of a β-lactone. 
70 
 
Although the reactivity of β-thiolactones has been relatively little explored, 
it was known that one of the simplest, 3-methyl-2-oxothietane (185) reacts with 
benzylamine to give amide 186 exclusively via addition to the carbonyl carbon of 
the thiolactone (Scheme 65, eq. 1).241 In contrast, the close oxygen analog, 4-
methyl-2-oxetane (187), displays both modes of reactivity, despite the more 
highly substituted nature of its 4-position, and affords 188 via SN2 attack at 
secondary β-carbon accompanied by formation of the amide 189 (Scheme 65, 
eq. 2).243-244  
 
Scheme 65. Modes of reactivity of β-thiolactones and β-lactones toward 
benzylamine. 
Despite the regiochemistry of the reaction of benzylamine with the β-
thiolactone 185, it was considered that nucleophiles softer than amines might still 
allow access to the alternate mode of SN2-ring opening, thereby providing a 
novel entry to thioacids and possible amide bond forming reactions. 
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4.2 Preparation of Substrates 
4.2.1 Synthesis of Simple Mono-Alkyl Substituted β-Thiolactones  
In general, small ring thiolactones can be prepared by the addition of 
thioacetic acid to simple β-, γ- or δ-unsaturated acids241,245 or by reaction of ω-
halo acid chlorides with sulfur based nucleophiles such as 
benzyltriethylammonium tetrathiomolybdate, followed by ring closure.246 
Accordingly, β-thiolactones were accessed starting from 2-alkylacrylic acids. For 
this purpose acrylic acid and 2-methylacrylic acid were obtained from commercial 
sources, while 2-benzylacrylic acid was synthesized following a literature 
procedure247 starting from ethyl acetoacetate as shown in Scheme 66.  
 
Scheme 66. Synthesis of 2-benzylacrylic acid. 
Following a literature protocol,241 conjugate addition of thioacetic acid to 
the various 2-alkylacrylic acids in THF at reflux afforded the thioacetate 
derivatives. Acidic hydrolysis of these thioacetates followed by ring closure with 
isobutyl chloroformate in presence of triethylamine led to the formation of 
corresponding β-thiolactones (Scheme 67).241 While the thiolactones 185 and 
200 were isolated by Kugelrohr distillation, the thiolactone 199 was purified by 
column chromatography over silica. The low isolated yield reported for parent 
thiolactone 200 is mainly due to the volatility of this substance. All of the 
thiolactones obtained in this manner were found to be stable at room 
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temperature.  The C=O vmaxCHCl3 of 185, 199 and 200 are 1749, 1747 and 1771 
cm-1 and the 13C chemical shifts of C-2 of the thiolactones are 195.0, 194.3 and 
191.2 ppm, respectively. 
 
Scheme 67. Synthesis of simple β-thiolactones. 
4.2.2 Synthesis of a Spirocyclic β-Thiolactone 
The spirocyclic thiolactone, 2-thiaspiro[3.5]nonan-1-one (204), was 
prepared from methyl 1-(acetylthiomethyl)cyclohexanecarboxylate (203), which 
was synthesized from methyl cyclohexanecarboxylate (201), following a literature 
procedure248 as shown in Scheme 68. The synthesis started with the 
deprotonation of methyl ester 201 with LDA followed by quenching of the enolate 
with methylene iodide to give the iodo derivative 202. The nucleophilic 
displacement of iodide group from compound 202 by potassium thioacetate led 
to the thioacetate 203. Finally, the strong alkaline hydrolysis of hindered ester 
and thioacetate groups of compound 203 followed by ring closure with isobutyl 
chloroformate in presence of triethylamine afforded the desired thiolactone 204 
(Scheme 68). The spirocyclic thiolactone 204 was purified by column 
chromatography over silica and was found to be stable at room temperature. 
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Scheme 68. Synthesis of 2-thiaspiro[3.5]nonan-1-one. 
4.2.3 Synthesis of a Cysteine Derived β-Thiolactone 
L-O-(tert-Butyl) N-(2-oxothietan-3-yl) carbamate (205) was prepared from 
N-Boc-L-cysteine by cyclization with isobutyl chloroformate in presence of 
triethylamine (Scheme 69).  The thiolactone 205 was obtained as a white solid 
after purification by column chromatography over silica and was found to be 
stable at room temperature. 
 
Scheme 69. Synthesis of L-O-(tert-butyl) N-(2-oxothietan-3-yl) carbamate. 
In order to investigate the stereochemical integrity of L-O-(tert-butyl) N-(2-
oxothietan-3-yl) carbamate (205), a racemic modification of the same β-
thiolactone was synthesized from commercially available N-Boc-DL-cysteine 
following an identical cyclization protocol. The enantiomeric purity of L-isomer of 
the carbamate 205 was determined by 500 MHz NMR spectroscopy with the aid 
of a chiral shift reagent,249 tris[3-(heptafluoropropylhydroxymethylene)-(+)-
camphorato]europium(III), [Eu(hfc)3].250  
Thus, a series of 500 MHz 1H NMR spectra of the DL- and L-isomers of the 
carbamate were recorded with 0.1 equiv. increments of the Eu(hfc)3 in CDCl3, 
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leading to the plots presented in Figure 10, which clearly reveal the ability of this 
chiral shift reagent to distinguish the enantiomers of 205 and enable it to be 
stated with confidence that no racemization occurred in the ring closure. In 
particular, attention is drawn to the 1H NMR spectra b and c of Figure 10 in which 
signals of the two enantiomers of DL mixture of the carbamate are resolved. In 
contrast, under identical conditions the L-isomer of the carbamate gave 1H NMR 
spectra d and e (Figure 10), which indicates the presence of only one 
enantiomer.  
 
Figure 10. Stack plot of DL- and L-O-(tert-butyl) N-(2-oxothietan-3-yl) 
carbamate with Eu(hfc)3: a) 1H spectrum of DL-O-(tert-butyl) N-(2-
S
OBocHN
1
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oxothietan-3-yl) carbamate; b) 1H spectrum of DL-O-(tert-butyl) N-(2-
oxothietan-3-yl) carbamate with 0.7 equiv. of Eu(hfc)3 and c) with 0.8 equiv. 
of Eu(hfc)3; d) 1H spectrum of L-O-(tert-butyl) N-(2-oxothietan-3-yl) 
carbamate with 0.7 equiv. of Eu(hfc)3 and e) with 0.8 equiv. of Eu(hfc)3. 
4.3 SN2-Type Ring Opening of β-Thiolactones: Sanger or Mukaiyama 
Reagent Promoted Multicomponent Coupling                                           
With several β-thiolactones in hand attention was turned to investigation of 
a reaction sequence involving reaction with an aromatic thiolate followed by 
trapping of the intended thiocarboxylate 206 (Scheme 70). As discussed in 
section 2.5, the condensation of thioacids with 2,4-dinitrobenezensulfonamides 
goes through 2,4-dinitrophenylthioester 138 intermediates, which are formed by 
nucleophilic aromatic substitution. The liberated amines then react with the 
thioester to give the resulting amide (Scheme 49). On the basis of this 
mechanistic rationale, Crich and Sharma251 demonstrated that the sulfonamide 
could be efficiently replaced by a simple amine and Sanger’s reagent (2,4-
dinitrofluorobenzene).252-253 In this chemistry the thiocarboxylate 206 replaced 
the fluoride of the reagent by nucleophilic aromatic substitution to give the active 
thioester 207, that was then subjected to reaction with an amine, resulting overall 
in a one-pot, three-component coupling process to give amides (Scheme 70). A 
directly analogous protocol employed Mukaiyama’s reagent (2-chloro-N-
methylpyridinium iodide)254 in the place of Sanger’s reagent and involved the 
alternative intermediate thioester 208 (Scheme 70).251 
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Scheme 70. Mechanism of three component coupling of β-thiolactones. 
 
SN2-Type ring opening of simple β-thiolactones (185, 199 and 200) with a 
series of aromatic thiols as nucleophile in presence of cesium carbonate as base 
followed the anticipated course, resulting in situ generation of thioacids. 
Subsequent addition of Mukaiyama’s reagent or Sanger’s reagent and an amine, 
in the reaction mixture gave a range of 3-arylthiocarboxamides as illustrated in 
Table 5.  
Table 5. Sanger’s or Mukaiyama’s Reagents Promoted Three-Component 
Coupling of β-Thiolactones (185, 199 and 200)  
Entry Thiolactone Nucleophile Reagent for 
Amide 
Bond Formation 
Product (% Yield) 
1 
 
thiophenol 2-
phenethylamine, 
2-chloro-N-
methylpyridinium 
iodide  
 
2 
 
 
4-
chlorothiophenol 
2-
phenethylamine, 
2-chloro-N-
methylpyridinium 
iodide  
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3 
 
 
methyl 2-
mercaptobenzo
ate 
2-
phenethylamine, 
2-chloro-N-
methylpyridinium 
iodide 
 
 
4 
 
 
4-
chlorothiophenol 
piperidine, 2-
chloro-N-
methylpyridinium 
iodide 
 
 
5 
 
 
thiophenol L-PheOMe.HCl, 2-
chloro-N-
methylpyridinium 
iodide 
 
 
6 
S
O
185
 
 
4-
chlorothiophenol 
2-
phenethylamine, 
2,4-
dinitrofluorobenze
ne  
 
7 
S
O
185
 
 
4-
chlorothiophenol 
piperidine,  
2,4-
dinitrofluorobenze
ne 
 
 
8 
S
OBn
199
 
 
thiophenol 2-
phenethylamine, 
2-chloro-N-
methylpyridinium 
iodide 
 
 
9 
S
OBn
199
 
4-
chlorothiophenol 
2-
phenethylamine, 
2-chloro-N-
methylpyridinium 
iodide  
 
10 
S
OBn
199
 
 
4-
chlorothiophenol 
piperidine,  
2,4-
dinitrofluorobenze
ne 
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11 
S
OBn
199
 
 
2-
mercaptopyridin
e 
piperidine,  
2,4-
dinitrofluorobenze
ne 
 
 
 
All reactions in Table 5 were conducted under ambient temperature 
conditions by addition of the nucleophilic aromatic thiol and cesium carbonate to 
the β-thiolactone followed by capture by an electron-deficient arene and 
subsequent reaction of the resulting thioester with an amine, enabling the one-
pot formation of both secondary or tertiary 3-arylmercaptocarboxamides in a 
straightforward manner. In particular, attention is drawn to Table 5 (entries 1-11), 
where no significant difference in overall yield between the uses of Mukaiyama’s 
or Sanger’s reagent was observed.  On the other hand, minor differences were 
seen with the nature of the nucleophilic thiolate and the ultimate amine in the 
reaction mixture. For example, comparison of entries 1 and 2 of Table 5 in which 
the ring opening of thiolactone 200 with thiophenol or 4-chlorothiophenol, 
followed by addition of Mukaiyama’s reagent and 2-phenethylamine reveals the 
3-arylmercaptocarboxamides 209 and 210 to be obtained in comparable yields. 
When a weaker nucleophilic methyl 2-mercaptobenzoate was employed for the 
ring opening of 200 (Table 5, entry 3), a lower yield of corresponding amide 211 
was observed. From a comparison of entries 2 and 4 of Table 5, it is clear that 
lower yield of the final product was observed with a secondary rather than a 
primary amine.  
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Table 6. Three-Component Coupling Process with Cysteine Derived β-
Thiolactone  
Entry Thiolactone Nucleophile Reagent for Amide 
Bond Formation 
Product (% Yield) 
 
 
1 
 
 
 
 
4-
chlorothiophenol 
 
2-phenethylamine, 
2,4-
dinitrofluorobenzen
e 
 
 
 
 
2a 
 
 
 
 
4-
chlorothiophenol 
 
 
 
 
 
 
 
3a 
 
 
 
 
2-
mercaptopyridin
e 
 
 
 
 
 
 
 
4a 
 
 
 
 
 
thiophenol 
 
 
 
 
 
 
 
5a 
 
 
 
 
 
4-
chlorothiophenol 
 
 
 
 
a
 Ar = 2,4-dinitrophenyl 
The examples employing the β-thiolactone 205 (Table 6) are particularly 
interesting in so far as the products were obtained in highly enantiomerically 
enriched form when a simple amine was used as nucleophile and as single 
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diastereomers when a chiral amine was employed. In particular, attention was 
drawn to entry 5 of Table 6 in which a pure diastereomeric peptide 226 was 
obtained in 62% yield. The formation of pure 226 was confirmed by the 500 MHz 
1H NMR spectrum, which clearly indicates the single diastereomer 226 (Figure 
11).  
7 6 5 4 3 2 1 PPM
Figure 11. 1H spectrum of 226 in CDCl3. 
 
This result clearly sets this chemistry apart from the literature preparation 
of such compounds by conjugate addition to dehydroalanine derivatives when 
mixtures of DL isomers are obtained (Scheme 71).255-256 
 
Scheme 71. Formation of DL-alanine derivatives via conjugate addition. 
As expected, the final coupling using amine with Sanger’s reagent (Table 
6, entry 1) or corresponding amine sulfonamide (Table 6, entry 2) gave 
comparable yields of the final products. An especially noteworthy example is that 
involving the cysteine β-thiolactone 205 with capture by the 2,4-
81 
 
dinitrobenzenesulfonamide of L-phenylalanine methyl ester that couples the 
nucleophilic ring opening of the thiolactone, with a peptide bond forming process 
resulting in a dipeptide containing alanine derivative (Table 6, entry 5). In a 
variant on the general theme the thioacid generated from the ring opening of 
cysteine β-thiolactone 205 also was captured with an electron deficient azide, 
resulting in an N-sulfonyl amide (Scheme 72). 
 
Scheme 72. A sulfonyl azide-based three-component coupling of cysteine 
β-thiolactone. 
In this chemistry the overall reaction time generally was dependent upon 
the first step, the SN2-type ring opening of the β-thiolactones.  This is particularly 
clear from the reaction of 2-thiaspiro[3.5]nonan-1-one (204) with 4-
chlorothiophenol when no reaction was seen  at room temperature even after 24 
h unlike the other β-thiolactones which reacted in 2 h. Heating the reaction 
mixture on an oil-bath at 50 °C for 5 h or in a microwave oven at 120 °C for 30 
min resulted in complex reaction mixtures. Several attempts at the ring opening 
of β-thiolactone 204 with other aromatic thiolates were unsuccessful. Clearly, the 
highly sterically hindered neopentyl-like nature of the 4-position effectively 
prevented the SN2 mode of ring opening.  When an amine was introduced into 
the reaction mixture a product 228 was obtained in high yield but it resulted from 
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a simple ring opening by attack of the amine on the carbonyl carbon followed by 
capture of the thiolate by the coupling reagent (Scheme 73). 
 
Scheme 73. Formation an amide via carbonyl addition of an amine to 
spirocyclic β-thiolactone. 
The attempted use of alkanethiols and/or thiolates as nucleophiles in this 
chemistry was unproductive under a variety of conditions resulting only in the 
formation of complex reaction mixtures. Ring opening in methanol as solvent or 
using 2-aminobenzenethiol as nucleophile gave complex reaction mixtures, 
indicating the incompatibility of alcohol or amine functional groups with the 
thiolactone reaction. 
Finally, the possibility of replacing the thiolate nucleophile by an amine 
was investigated for the SN2-type ring opening of β-thiolactone 199 (Scheme 74), 
but it proved impossible to divert the chemistry away from attack at the β-
thiolactone carbonyl carbon as had been described previously in the literature for 
this class of nucleophiles (Scheme 65, eq. 1). 
 
Scheme 74. Nucleophilic addition at carbonyl carbon of β-thiolactone with 
an amine nucleophile. 
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From the literature242 and from the above results, the reactivity of 
nucleophiles towards ring opening of β-lactones and β-thiolactones is seen to be 
quite different, with ring opening of β-thiolactones being more strongly dependent 
on the nature of the nucleophile. The differing reactivity between the β-
thiolactones and their oxygen counterparts apparent from the literature (Scheme 
65, eq. 1) and highlighted by the contrast of Table 5 and Table 6 with Scheme 73 
and Scheme 74 is likely at least in part, due to the reduced resonance of the ring 
heteroatom with the carbonyl group and to the less strained nature of the 
thiolactone. In the case of thiolactones, due to the less efficient overlap between 
the C=O pi and sulfur 3p orbitals,8,241 the reduced resonance may make the 4-
position softer and less reactive toward harder nucleophiles (Figure 12).  
 
 
Figure 12. Reduced resonance delocalization in the thiolactones. 
4.4 Conclusions 
The above results make it obvious that the regioselective ring opening of 
β-thiolactones by aromatic thiolates is a novel way to generate in situ thioacids 
for use in amidation reactions. The precursors are easy to prepare, and the 
coupling reactions take place under mild conditions at room temperature. More 
importantly, the amino acid derived β-thiolactone has been shown to be 
compatible with conditions of the three-component coupling reaction to provide 
peptides containing unnatural alanine derivatives.  
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CHAPTER 5 
TOWARD THE STEREOCHEMICAL ELUCIDATION AND SYNTHETIC 
STUDIES OF VIRGINEONE 
5.1 Synthesis of Models: Approaches to the Assignment of Configuration  
As discussed in the introduction (section 1.3), the original investigators 
established the stereochemistry of the pyranose moiety to be that of a β-O-
mannosidic linkage but neither the absolute nor the relative configuration of the 
remaining stereogenic centers of virgineone were established (Figure 13). 
Hence, a total synthesis program was initiated towards this challenging molecule 
with the goal of defining the relative and absolute configurations at the respective 
positions of this molecule.  
 
Figure 13. Virgineone and related models. 
 
In this first instance the molecule was dissected into two portions, for each 
of which two stereoisomers were possible.  On this basis the synthesis of the four 
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model compounds, 231-234 were undertaken with a view to establishing the 
relative stereochemistry of the stereocenters at the two extremes of the global 
structure by comparison of NMR chemical shifts with the literature data.  The 
assumption was also made at this stage that the tetramic acid moiety was 
derived from L-tyrosine and that the sugar moiety was the D-enantiomer on the 
basis of the predominance of these forms in nature (Figure 13).   
5.1.1 Synthesis of Models 231 and 232 
As discussed in section 1.3.2, the models 231 and 232 were considered to 
be achievable through Crich’s protocol of β-mannosylation with 
mannopyranoside donor 243257 using 238 and 242 as glycosyl acceptors 
(Scheme 76).  Accordingly, the acceptors 238 and 242 were synthesized starting 
from commercially available (2S)-decane-1,2-diol (235). Thus, the primary 
hydroxyl group of 235 was selectively protected as the trityl-ether 236 using trityl 
chloride and Et3N in presence of catalytic DMAP. Benzylation of secondary 
hydroxyl group of 236 using benzyl bromide and sodium hydride provided 237, 
from which the acceptor 238 was obtained by treatment with trifluoroacetic acid.  
In parallel, a portion of 236 was subjected to the Mitsunobu protocol,258 the 
inverted ester 239 was obtained. Hydrolysis of the ester 239 with K2CO3 in 
methanol, followed by an identical procedure as established for the synthesis of 
acceptor 238, the enantiomeric acceptor 242 was obtained in good overall yield 
(Scheme 75). 
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Scheme 75. Synthesis of acceptors 238 and 242. 
With two acceptors in hand, attention was turned to mannosylation of 
donor 243 which was first activated with a combination of BSP/Tf2O in presence 
of TTBP, followed by addition of the respective acceptor to the reaction mixture 
to obtain the fully protected β-mannosides 244 and 245 in good yields, whose 
stereochemistry was confirmed by measurement of the anomeric 1JCH coupling 
constants.259 There was no indication of the formation of the corresponding α-
isomers in this reaction. Finally, hydrogenolysis of 244 and 245 gave the models 
231 and 232 respectively (Scheme 76). 
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Scheme 76. β-Mannosylations and completion of synthesis of models 231 
and 232.  
The 1H and 13C NMR spectra of models 231 and 232 were recorded and 
are set out in Table 7 for comparison with those of the natural product. 
Table 7. a Comparison of NMR Data of 83 and 231 / 232 
Position 
b,c,d 
∆δc (83 & 
231) 
%∆δc (83 & 
231) 
∆δH (83 & 
231) 
∆δc (83 & 
232) 
%∆δc (83 
& 232) 
∆δH (83 
& 232) 
18 -9.0 -38 -0.52 -9.0 -38 -0.52 
19-24 - - - - - - 
25 0.2 0.6 0.21 0 0 0.21 
26 0.1 0.14 0.04 -0.1 -0.14 0.06 
27 0.06 0.1 0.09, 
0.03 
0 0 0.1, 
0.01 
1” 0 0 0.05 -0.3 -0.3 0.05 
2” 0.1 0.14 0.05 0.2 0.3 0.04 
3” 0.1 0.14 0.05 0.1 0.14 0.05 
4” 0 0 0.05 0 0 0.05 
5” 0 0 0.04 0 0 0.04 
6” -0.1 -0.02 0.06 
0.05 
0 0 0.05 
0.05 
 
a All NMR were recorded in DMSO-d6 using 500 MHz NMR spectrometry. b For ease of 
comparison a numbering scheme corresponding to that of the natural product is used for 
compounds in this Table. c Assignments are made on the basis of DEPT, HMQC, HMBC 
experiments. d %∆δc = (δc of model - δc of natural isolate)/ (δc of natural isolate) × 100. 
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Figure 14. Plot of carbon numbers and %∆δc [%∆δc = (δc of model - δc of 
natural isolate)/ (δc of natural isolate) × 100]. A) %∆δc of model 231 and B) 
%∆δc of model 232. 
Unfortunately, from Table 7 and Figure 14, it is clear that the chemical 
shift differences between the two models and the natural product are insufficient 
to permit conclusion to be drawn about the configuration at C-26. However, the 
excellent agreement of the NMR values in the sugar moiety of 83 with both 
models indicates that the sugar is indeed a β-mannoside.  
5.1.2 Synthesis of Models 233 and 234 
The synthetic strategy for the models 233 and 234 was based on a 
retrosynthetic approach involving two main fragments, namely the amino ester 
246 and a β-keto thioester fragment 247 (Scheme 77). Fragment 246 was readily 
available from O-benzyl-L-tyrosine methyl ester, while the fragment 247 could be 
obtained from 2-methyldecanoic acid following a literature protocol.260  
89 
 
 
Scheme 77. Retrosynthetic analysis of models 233 and 234. 
In this regard, the synthesis of amino ester 246 was readily achieved by 
the reductive N-alkylation of commercially available O-benzyl-L-tyrosine methyl 
ester. Thus, the amino ester was treated with 4-methoxybenzaldehyde in 
presence of acetic acid, followed by addition of NaBH4 to give N-PMB-L-tyrosine 
derivative 246 (Scheme 78). 
 
Scheme 78. Synthesis of N-(4-methoxybenzyl)-O-benzyl-L-tyrosine methyl 
ester 
To access acids 253 and 254, first (4R)- and (4S)-4-isopropyloxazolidin-2-
one261 were acylated with decanoyl chloride to give the corresponding imides 249 
and 250. Enolization of respective imides with NaHMDS and methylation of the 
derived enolate following the literature protocol262 provided a mixture of 
diastereomers (dr = 9:1). Chromatographic purification of these mixtures afforded 
pure diastereomers 251 and 252 in good yield. Alkaline hydrolysis of 251 and 
252 in the presence of H2O2 gave the corresponding acids 253 and 254 (Scheme 
79). 
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Scheme 79. Synthesis of (2R)- and (2S)-2-methyldecanoic acid. 
Having both enantiomers of the acid and L-tyrosine methyl ester derivative 
246 in hand, the preparation of the tert-butyl thioester fragments 255 and 256 
were carried out following a literature protocol.260 Accordingly, the activation of 
the acids with CDI followed by addition of magnesium enolate of 3-(tert-
butylthio)-3-oxopropanoic acid was provided the thioesters 255 and 256. 
Aminolysis147 of the thioester 255 with L-tyrosine amine 246 mediated by silver 
trifluoroacetate afforded the β-keto amide 257. Finally, the fully protected tetramic 
acid derivative 258 was obtained by the Dieckmann cyclization of 257 with 
KOtBu over 30 min (Scheme 80).  
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Scheme 80. Synthesis of protected tetramic acid. 
The attempted hydrogenolysis of 258 over Pd/C or Pd(OH)2/C as catalyst 
was unsuccessful and resulted only in a complex reaction mixture within 1 h of 
shaking under 50 psi of hydrogen. Similarly, various other attempts at benzyl and 
amide N-PMB group removal from 258 using CAN,263-264 anhydrous FeCl3265 or 
anhydrous AlCl3266 were unproductive and afforded only complex reaction 
mixtures. In addition, the treatment of 258 with 50% aqueous HBr or 33% HBr in 
acetic acid, resulted in no cleavage of the benzyl or PMB groups.  
Attention, therefore, was turned to the synthesis of the tetramic acid 
moiety by simple modifications of the reaction sequences, in which the benzyl 
group was successfully deprotected from the β-keto amide 257 before the 
Dieckmann cyclization. Subsequently, the treatment of benzyl-free β-keto amide 
with KOtBu gave the tetramic acid 259 in 92% yield (Scheme 81). 
 
Scheme 81. Cyclization of a phenolic β-keto amide. 
In addition to modification of the reaction sequences, the N-PMB group 
was replaced by the more acid labile N-TMB group from the N-TMB amino ester 
260, whose synthesis was readily achieved by the condensation of a methanolic 
solution of O-benzyl-L-tyrosine methyl ester hydrochloride with 1,3,5-
trimethoxybenzene and paraformaldehyde (Scheme 82). 
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Scheme 82. Synthesis of N-(2,4,6-trimethoxybenzyl)-O-benzyl-L-tyrosine 
methyl ester. 
Finally, combining the chemistry of Schemes 80 and 81, the N-TMB 
derived tetramic acids 263 and 264 were obtained in excellent yields.  
Subsequently, removal of the TMB was achieved by the treatment with 
trifluoroacetic acid in presence of anisole, and purification by column 
chromatography of the crude reaction mixture over silica gel afforded the models 
233 and 234 as light yellow foams, which were found to be stable at room 
temperature (Scheme 83). 
 
Scheme 83. Completion of the synthesis of model tetramic acids.  
The 1H and 13C chemical shifts of natural product 83 along with those of 
233 and 234 are summarized in Table 8 for comparison. In addition, Table 9 
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furnishes the comparisons of the spectral data of models 233 and 234 with that 
of the aglycone 265.138  
Table 8. a Comparisons of NMR Data of 83 and 233 / 234 
Position 
b,c,d 
∆δc (83 
& 233)
 
%∆δc (83 
& 233)
 
∆δH (83 & 
233)
 
∆δc (83 & 
234)
 
%∆δc (83 
& 234)
 
  ∆δH (83  
& 234)
 
1 - - 1.62 - - 1.6 
2 1.6 2.6 0.52 1.7 2.8 0.53 
3 -1.9 -1.0 - -1.6 -0.8 - 
4 0.7 0.7 - 0.7 0.7 - 
5 -1.7 -1.0 - -1.6 -0.9 - 
6 -3.0 -1.5 - -2.9 -1.5 - 
7 -2.9 -7.5 -0.2 -2.6 -6.8 -0.22 
8 0 0 0.02, 
0.30 
0.5 1.5 0.07, 
0.32 
9-15 - - - - - - 
28 -1.1 -6.2 0.23 0.6 3.4 0.16 
1’ -1.4 -3.8 0.24 
0.10 
-1.1 -3.0 - 
2’ -2.2 -1.7 - -2.1 -1.6 - 
3’/7’ 0.2 0.1 -0.01 0.3 0.23 -0.01 
4’/6’ 0.1 0.1 0.05 0.2 0.2 0.07 
5’ 0.4 0.3 - 0.5 0.3 - 
5’-OH - - -0.77 - - -0.75 
 
a All NMR were recorded in DMSO-d6 using 500 MHz NMR spectrometry. b For ease of 
comparison a numbering scheme corresponding to that of the natural product is used for 
compounds in this Table. c Assignments are made on the basis of DEPT, HMQC, HMBC 
experiments. d %∆δc = (δc of model - δc of natural isolate)/ (δc of natural isolate) × 100. 
 
 
Table 9.a Comparisons of NMR Data of 265 and 233 / 234 
Position 
b,c,d
 
∆δc (265 
& 233)
 
%∆δc (265 
& 233)
 
∆δH (265 
& 233)
 
∆δc (265 
& 234)
 
%∆δc (265 
& 234)
 
∆δH (265 
& 234)
 
1 - - - - - - 
2 0.3 0.5 0.05 0.4 0.6 0.06 
3 0 0 - 0.3 0.2 - 
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4 -0.1 -0.1 - -0.1 -0.1 - 
5 -0.1 -0.05 - 0 0 - 
6 0 0 - 0.1 0.05 - 
7 -0.3 -0.8 0.03 0 0 -0.01 
8 0 0 -0.02 
-0.05 
-0.5 1.5 0.09, 
-0.02 
9-15 - - - - - - 
28 -0.5 -3.0 0.01 0 0 0.05 
1’ -0.4 -1.1 - -0.1 -0.3 0.26 
2’ -0.2 -0.2 - 0 0 - 
3’/7’ 0 0 -0.06 0.1 0.1 -0.04 
4’/6’ 0 0 -0.04 0.1 0.1 -0.02 
5’ 0 0 - 0.1 0.75 - 
5’-OH - - - - -  
 
a All NMR were recorded in DMSO-d6 using 500 MHz NMR spectrometry. b For ease of 
comparison a numbering scheme corresponding to that of the natural product is used for 
compounds in this Table. c Assignments are made on the basis of DEPT, HMQC, HMBC 
experiments. d %∆δc = (δc of model - δc of natural isolate)/ (δc of natural isolate) × 100. 
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 Figure 15. Plot of carbon numbers and %∆δc [%∆δc = (δc of model - δc of 
natural isolate)/ (δc of natural isolate) × 100]. A) %∆δc between model 233 
and virgineone (83); B) %∆δc between model 234 and virgineone (83); C) 
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%∆δc between model 233 and aglycone (265); D) %∆δc between model 232 
and aglycone (265). 
As is clear from a comparison of the data in Tables 8 and 9 and as 
reported in the litureature,138 the 1H and 13C chemical shifts of the tetramic acid 
moiety of virgineone (83) and aglycone (265) depend on the presence or 
absence of the β-mannosidic linkage at C-27. Therefore, the most appropriate 
conclusions are those from the comparison of the aglycone 265 with models 233 
and 234. Although the differences between the two models are negligible, it is 
clear from both Tables 8 and 9 and Figure 15 that, particularly at positions C-7 
and C-28, the differences are smaller in case of model 234 (C-7 = S) than the 
case of model 233 (C-7 = R), which tends to suggest that the aglycone 265 and 
hence virgineone itself should have the relative stereochemistry of model 234 for 
the tetramic acid portion. Nevertheless, and in view of the uncertainty regarding 
the stereochemistry at C-7, it was concluded that the complete synthesis of four 
stereoisomers of virgineone itself was necessary in order to come to any firm 
conclusions about the relative and absolute stereochemistry of this intriguing 
molecule.  In this regard, a plan for the total synthesis of four such isomers of 
virgineone (83), available from L-tyrosine was devised that takes advantage of 
the lessons learnt in the course of the preparation of the various models.  
5.2 Retrosynthetic Analysis 
As shown in Scheme 77, the synthesis of virgineone was envisioned to 
involve aminolysis of the β-keto thioester fragment 266 with N-TMB-L-tyrosine 
derivative 260. The intermediate thioester 266 could be derived as before from 
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the acid 267. The β-mannosidic acid 267 could be obtained from acceptor 268 
via 4,6-O-benzylidine directed β-mannosylation of donor 243. The C-22 
oxygenated chain acceptor 268 could be generated by a series of three Wittig 
reactions from aldehydes 269 and 271 (Scheme 84). 
Dieckmann Cyclization
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Scheme 84. Retrosynthetic analysis of virgineone. 
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5.3 Synthesis of Precursors 
5.3.1 Synthesis of (2R)- and (2S)-Methyl 2-Methyl-9-oxononanoate  
Following the synthetic Scheme 79 as established for the synthesis of 
acids 253 and 254, the enantiomerically pure acids 276 and 277 were 
synthesized over three steps from oleanoyl chloride, and were converted to their 
methyl esters 278 and 279 by treatment with methyl iodide in presence of 
Cs2CO3.  Subsequently, ozonolysis of 278 and 279 gave the corresponding 
aldehydes 280 and 281, which were purified by column chromatography over 
silica gel (Scheme 85).  These aldehydes were found to be stable to 
polymerization if stored in the freezer at -20 °C.  
 
Scheme 85. Synthesis of (2R)- and (2S)-methyl 2-methyl-9-oxononanoate. 
5.3.2 Synthesis of Acceptors 
The synthesis of this portion of the target began with Wittig olefination of 
ylide generated from the carboxyalkyl Wittig salt 270267 and aldehyde 269268 to 
give acid 282. The stable phosphoranylidene reagent 283 was prepared by 
addition of the acid chloride of 282, prepared from 282 by the treatment with 
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oxalyl chloride, into a freshly prepared solution of ylide resulting from n-BuLi-
mediated deprotonation of methyltriphenylphosphonium bromide. Elongation of 
stable ylide 283 by a Wittig-type reaction with aldehydes 280 and 281 gave rise 
the corresponding unsaturated C-22 oxygenated chains 284 and 285 
respectively, which upon reduction followed by acid-mediated cleavage of the 
acetonide group gave the  dihydroxy esters 286 and 287 (Scheme 86). 
 
Scheme 86. Synthesis of C-22 dihydroxy esters. 
Modifying slightly the chemistry developed in Scheme 75, the primary 
hydroxyl groups of 286 and 287 were selectively silylated using TBDPS-chloride 
in presence of imidazole, and a portion of the products were subjected to the 
Mitsunobu protocol to give the inverted esters 290 and 291. Saponification of the 
nitro-esters 290 and 291 with K2CO3 in methanol then afforded 292 and 293 
(Scheme 87). 
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Scheme 87. Synthesis of glycosyl acceptors. 
The acid-mediated benzylation of the secondary hydroxyl groups of 288, 
289, 292 and 293 with benzyl 2,2,2-trichloroacetimidate and TfOH next provided 
the fully protected acceptors 294-297. Finally, the C-22 oxygenated chain 
acceptors 298-301 were accessed by exposure to PTSA (Scheme 88).   
 
Scheme 88. Completion of the acceptor synthesis. 
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5.3.3 Mannosylation and Completion of Synthesis of Isomers of Virgineone  
Adapting the method of Scheme 76, mannosylation of acceptors 298-301 
with donor 243 was conducted leading to the formation of the mannosides 302-
305. Curiously, unlike the mannosylation of the model acceptors 238 and 242 
with donor 243 which provided only the β-mannosides, the acceptors 298-301 
gave the desired β-isomers accompanied by the minor α-isomers. Nevertheless, 
subsequent chromatographic purification of the mixtures over silica gel provided 
the pure β-mannosides 302-305, whose stereochemistry was confirmed as 
before by measurement of the 1JCH coupling constants (Table 10). 
Table 10. Mannosylation of Acceptors 298-301 with Donor 243  
 
Acceptor (α/β)a β-Mannoside 
(%Yield) 
1JCH 
(in 
Hz)  
 
1/5.8 
 
160.0 
 
1/6.2 
 
158.1 
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1/6.5 
 
158.6 
 
1/5.4 
 
157.6 
a
 Determined by 1H-NMR spectroscopy on the crude reaction mixture.   
Saponification of the methyl esters 302-305 with LiOH provided the 
corresponding acids, which required no further purification. Accordingly, 
combining the chemistry of Schemes 80 and 83, the fully protected β-keto 
amides 310-313 were then synthesized from the acids by activation with CDI 
followed by the addition of magnesium enolate of 3-(tert-butylthio)-3-
oxopropanoic acid and then silver-mediated coupling to the amino acid moiety 
(Scheme 89). Removal of the benzyl and benzylidine groups was carried out by 
brief, controlled Pd(OH)2/C-mediated hydrogenolysis of  310-313, as it was found 
that hydrogenolysis over longer reaction times resulted in premature cleavage of 
the TMB group. Subsequently, Dieckmann cyclization of homogenous methanolic 
solutions of the resulting β-keto amides with KOtBu, followed by removal of the 
TMB group with trifluoroacetic acid gave four isomers of virgineone 314-317 
(Scheme 89). These substances were obtained pure as light orange foams by 
washing the final reaction mixtures with chloroform followed by decantation of the 
solvent; they were found to be stable in the freezer at -20 °C. 
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Scheme 89. Completion of the syntheses of four stereoisomers of 
virgineone. 
The 1H and 13C NMR and ESI-HRMS spectra of these compounds were in 
full agreement with the structures assigned. However, the 13C NMR spectra 
showed broadening of the carbon signals corresponding to the tetramic acid 
moieties, indicating the presence of keto-enol tautomers in the 1,3-dicarbonyl 
functionality, which is a readily understood feature of compounds of this type.269  
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With four isomers in hand, attention was turned to the comparison of their 
1H and 13C chemical shift data with that of the natural product 83 as  summarized 
in Table 11.  
Table 11.a Comparisons of NMR Data of 83 with 314 / 315 / 316 / 317 
Positi
on 
b,c,d
 
%∆δC 
(83 & 
314) 
%∆δH 
(83 & 
314) 
%∆δC 
(83 & 
315) 
%∆δH 
(83 & 
315) 
%∆δC 
(83 & 
316) 
%∆δH 
(83 & 
316) 
%∆δC 
(83 & 
317) 
%∆δH 
(83 & 
317) 
1 - 22.0 - - - - - 13.9 
2 2.6 14.9 2.1 12.6 - 6.7 3.4 3.9 
3 -1.0 - -1.0 - - - - - 
4 0.4 - 0.3 - - - - - 
5 -1.0 - -0.9 
 
- -0.7 - -0.1 - 
 
6 -1.5 - -1.4 - -1.5 - -1.5 - 
7 -7.5 -4.9 -6.2 -5.2 -4.4 -5.5 -5.2 -5.2 
8 0.3 - 
-2.0 
-0.3 - 
-3.3 
- - 
-2.7 
-0.6 - 
0.7 
9-14 
& 
18-24 
- - - - - - - - 
15/17 0 2.6 0 2.1 0 2.1 0 2.1 
16 0.3 - 0.3 - 0.3 - 0.3 - 
25 0.6 - 
3.7 
0.6 - 
4.4 
0 - 
6.7 
0 - 
5.2 
26 0.1 1.1 0.1 1.1 0.3 2.0 -0.2 1.7 
27 0 1.5, 
0.8 
0.1 1.8, 
1.1 
0.2 3.3, 
0.3 
0 3.0, 
0 
28 -5.7 29.0 -2.8 17.0 -2.3 15.9 1.1 13.4 
1’ -3.5 - -2.2 - -0.3 2.7, 
2.5 
-1.1 5.4, 
2.5 
2’ -1.6 - -2.0 - - - -1.2 - 
3’/7’ 0.2 -0.1 0.2 0.1 0 0.4 0.1 0.3 
4’/6’ 0.1 0.6 0.1 0.9 0.1 0.8 0.1 0.9 
5’ 0.3 - 0.3 - 0.1 - 0.2 - 
1” 0 0.9 0 1.2 -0.4 1.4 -0.3 1.2 
2” 0.1 1.1 0.1 1.4 0.1 1.4 0.1 1.1 
3” 0 0.9 0.1 1.2 0 1.2 0 1.2 
4” 0 1.2 0 1.8 -0.1 2.4 0 1.8 
5” 0 1.0 0 1.3 -0.1 1.7 -0.1 1.3 
6” 0 1.5, 
0.8 
0 2.0, 
1.4 
-0.2 2.0, 
1.4 
-0.1 2.3, 
0.8 
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5’-OH  -7.5  -7.3  -7.1  -7.5 
 
a All NMR were recorded in DMSO-d6 using 500 MHz NMR spectrometry. b For ease of 
comparison a numbering scheme corresponding to that of the natural product is used for 
compounds in this Table. c Assignments are made on the basis of DEPT, HMQC, HMBC 
experiments. d %∆δc = (δc of synthetic isomer - δc of natural isolate)/ (δc of natural isolate) × 100. 
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Figure 16. Plot of carbon numbers and %∆δc [%∆δc = (δc of synthetic isomer 
- δc of natural isolate)/ (δc of natural isolate) × 100]. A) %∆δc of isomer 314; 
B) %∆δc of isomer 315; C) %∆δc of isomer 316; D) %∆δc of isomer 317. 
From the Table 11 and Figure 16, it is clear that the chemical shifts of 
none of the four isomers enable a clear distinction to be made among the various 
isomers just as it is clear that none of these isomers corresponds exactly to the 
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natural isolate. In addition the specific rotation of each of the four isomers is 
distinctly different from that of the natural compound (Table 12). 
Table 12. a Specific Rotation of Synthetic Isomers of Virgineone 
Isomer 164 165 166 167 
[α]24D (c = 0.3 
in methanol) 
-54.0 -71.7 -47.3 -63.4 
a
 [α]23D (isolated virgineone) -95.7 (c = 0.3 in methanol) 
 
In spite of the general differences in the data two trends are evident.  
Thus, the chemical shifts differences of the natural product with the isomers 314 
and 315 in the sugar half of the molecule (C-26 = S) are smaller than for the 
isomers 316 and 317 (C-26 = R), which indicates that the configuration at C-26 of 
the natural isolate is likely to be S. In the tetramic acid half of the molecule, on 
the other hand the best correlation is with isomers 315 and 316.  Notably, the 
differences of chemical shifts between the isolated product and all isomers are 
quite high in tetramic acid moiety, which suggests that the teramic acid moiety is 
likely to be derived from the non-proteinogenic amino acid D-tyrosine. Tetramic 
acids derived from D-amino acids in natural products are known. For example, 
Fuligorubin A, isolated from yellow slime mould Fuligo septica (L) Wiggers, is 
derived from D-glutamic acid.270-271 D-Amino acids in general are relatively 
common in bacterial natural products and are generally synthesized post-
translationally by the bacteria from the L-isomer by means of racemase 
enzymes.272 
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5.4 Conclusions and Feature Direction to the Synthesis of Virgineone 
Although it has not been possible to assign the configuration of virgineone, 
a viable synthetic route has been developed whose applications to the 
preparation of the remaining four isomers, employing D- rather than L-tyrosine, 
should enable identification of the correct isomer.  In principle, however, the 
complete synthesis of all four remaining isomers should not be necessary as 
hydrolysis of the four isomers in hand to the aglycones 318-321, as described for 
the natural product, will provide all four possible diastereomers of the aglycone 
for comparison of their spectra data with the one from the natural isolate.  Given 
that the natural compound is likely to be derived from the D-isomers of tyrosine 
one of these four diastereomers should also give a specific rotation of equal 
magnitude but opposite sign to that of the natural aglycone, thereby further 
assisting the identification (Scheme 90).  Unfortunately time constraints do not 
enable those syntheses to be carried out in the context of this thesis.  At this 
point the synthesis of single diastereomers from D-tyrosine should confirm the 
identity of natural virgineone.  Such work is currently underway in the Crich 
laboratories.   
 
Scheme 90. Possible hydrolysis of virgineone isomers to the aglycones. 
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CHAPTER 6 
CONCLUSIONS 
 
The potential use of an acid stable 9-fluorenylmethyl (Fm) group to the 
formation of 9-fluorenylmethylthioesters followed by base-mediated cleavage of 
the Fm group in the synthesis of amino and peptidyl thioacids has been explored. 
Thioacids obtained by this methodology were employed successfully for the 
synthesis of peptides by coupling with electron deficient N-terminal 2,4-
dinitrobenzenesulfonamides in an epimerization-free process.  
Subsequent of the solution-phase synthesis of amino and peptidyl 
thioacids, a novel 9-fluorenylmethylthioester-based linker has been developed for 
the synthesis of peptidyl thioacids on a solid support employing Boc chemistry. 
The methodology was successfully applied to the synthesis of both partially 
protected and completely unprotected peptidyl thioacids, by means of 
modifications of appropriate side chain protection strategies of the amino acids.  
The utility of β-thiolactones as convenient synthons for thioacids in three 
component coupling processes was investigated. The β-thiolactones were shown 
to undergo nucleophilic ring opening in an SN2 fashion on treatment with thiolate 
nucleophiles.  The ensuing thioacids were then employed in amide bond forming 
reactions.  In particular, a cysteine-derived β-thiolactone was demonstrated to 
have the potential to serve as precursor for the synthesis of highly 
diastereomerically enriched cysteine derived dipeptide in a three component 
coupling process.  
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A synthetic route was established for the synthesis of various 
stereoisomers of the novel glycosylated tetramic acid, virgineone.  Although the 
nature isomer was not one of those synthesized, the route developed should 
permit access to all other isomers and thus the eventual resolution of this 
problem. 
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CHAPTER 7 
EXPERIMENTAL SECTION 
 
General: All solvents were dried and distilled by standard protocols. All 
reactions were conducted under an inert atmosphere of argon or nitrogen unless 
otherwise stated. All organic extracts were dried over sodium sulfate, and 
concentrated under aspirator vacuum. Chromatographic purifications were 
carried out over silica gel. All peptide thioacid syntheses were carried out on a 
0.1 mmol scale employing 1% DVB cross linked aminomethyl polystyrene resin 
(244 mg, resin loading 0.41 mmol/g) in a 10 mL manual synthesizer glass 
reaction vessel with a Teflon-lined screw cap. The peptide resin was shaken 
during the both Nα-tert-butoxycarbonyl deprotection and coupling steps.  
Unless otherwise stated optical rotations were recorded on an Autopol® III 
automatic polarimeter in CHCl3 solution and 1H and 13C spectra were recorded in 
CDCl3 solution. Melting points were measured on a Barnstead electrothermal 
(9100) instrument and are uncorrected. Elemental analysis was carried out by 
Midwest Microlabs, Indianapolis, IN. Mass spectra were recorded by the 
Research Resources Center at the University of Illinois at Chicago and Central 
Instrumentation Facility at Wayne State University. Reverse phase HPLC (RP-
HPLC) purification was performed with 215 and 254 nm UV detection, using a C-
18 analytical and preparative columns (250 × 4.6) and (250 × 21.4), respectively. 
All runs used linear gradients of A in B (A: CH3CN and B: Water).  
9-Fluorenylmethyl thioacetate (106): A solution of 9-fluorenylmethyl p-
toluenesulfonate (1.6 g, 4.6 mmol),173 potassium thioacetate (0.62 g, 5.5 mmol)  
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and 18-crown-6 (0.12 g, 0.46 mmol) in DMF (15 mL) was stirred at room 
temperature for 2 h. Then the reaction mixture was poured into ethyl acetate and 
washed with water and brine. The organic layer was dried and concentrated. 
Chromatographic purification using 4% ethyl acetate in hexane afforded 106 
(1.09 g, 94%). Mp: 72-73 °C (ethyl acetate/ hexane 9:1); 1H NMR (500 MHz) δ 
7.77-7.76 (d, J = 7.5 Hz, 2H), 7.68-7.66 (d, J  = 7.5 Hz, 2H), 7.43-7.40 (t, J = 7.3 
Hz, 2H), 7.36-7.33 (t, J  = 7.8 Hz, 2H), 4.20-4.18 (t, J  = 5.7 Hz, 1H), 3.55-3.54 
(d, J  = 6.0 Hz, 2H), 2.29 (s, 3H); 13C NMR (125 MHz) δ 195.5, 145.5, 141.1, 
127.8, 127.2, 124.7, 120.0, 46.7, 32.5, 30.7; Anal. Calcd for C16H14OS (254.35): 
C, 75.55; H, 5.55. Found: C, 75.35; H, 5.58. 
9-Fluorenylmethylthiol (107): To a stirred solution of 106 (1.0 g, 3.9 
mmol) in Et2O (40 mL), was added DIBAL-H (5.72 mL, 8.6 mmol, 1.5 M solution 
in toluene) dropwise under nitrogen at -78 °C. After the mixture was warmed up 
to 0 °C over a period of 30 min, the reaction was quenched by 2 N HCl, and the 
mixture was vigorously stirred for 10 min. The aqueous layer was extracted with 
ether, and the combined organic layers were washed with brine. The organic 
layer was dried and concentrated. Chromatographic purification using 2% ethyl 
acetate in hexane afforded 107 (0.77 g, 93%). 1H NMR (500 MHz) δ 7.80-7.77 (t, 
J  = 8.0 Hz, 2H), 7.64-7.61 (t, J  = 8.5 Hz, 2H), 7.45-7.33 (m, 4H), 4.20-4.16 (m, 
1H), 3.22-3.17 (m, 2H), 1.25-1.20 (m, 1H); 13C NMR (125 MHz) δ 145.2, 141.56, 
127.7, 127.2, 124.5, 120.1, 49.3, 28.0; ESI-HRMS Calcd for C14H12S M+ : 
212.0659. Found: 212.0650. 
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General procedure 1. Synthesis of 9-fluorenylmethyl thiolesters of N-
tert-butoxycarbonyl-α-amino acids (109-112): To a ~2.0 M solution of N-tert-
butoxycarbonyl α-amino acid, 9-fluorenylmethylthiol (1.2 equiv.) and DMAP (0.1 
equiv.) in methylene chloride, was added a solution of DCC (1.1 equiv.) in 
methylene chloride (c = 2.0 M) at 0 °C. The suspension was stirred for 1 h at 0 
°C and overnight at room temperature. The suspension was filtered to remove 
the resulting white solid which was washed with methylene chloride (10 mL) 
repeatedly. The filtrate was concentrated.  Chromatographic purification afforded 
the N-tert-butoxycarbonyl-α-amino acid 9-fluorenylmethyl thioesters. 
N-tert-Butoxycarbonyl-L-valine 9-fluorenylmethyl thiolester (109): 
Following the general procedure 1, and eluting with 7% ethyl acetate in hexane, 
109 was obtained in 99% yield. [α]23D -37.6 (c 1.0); 1H NMR (400 MHz) δ: 7.74-
7.72 (d, J = 7.2 Hz, 2H), 7.64-7.63 (d, J  = 7.2 Hz, 2H), 7.40-7.28 (m, 4H), 4.91-
4.89 (d, J = 9.2 Hz, 1H), 4.22-4.16 (m, 2H), 3.56-3.54 (d, J = 5.2, 2H), 2.15-2.05 
(m, 1H), 1.44 (s, 9H), 0.88-0.86 (d, J = 6.8 Hz, 3H), 0.68-0.66 (d, J = 6.8 Hz, 3H); 
13C NMR (100 MHz) δ: 200.7, 155.5, 145.3, 141.2, 127.7, 127.1, 124.7, 119.8, 
80.2, 65.4, 46.7, 31.9, 31.0, 28.3, 19.3, 16.7; ESI-HRMS Calcd for C24H29NO3S 
[M + Na]+ : 434.1761. Found: 434.1760. 
N-tert-Butoxycarbonyl-α-aminoisobutyryl 9-fluorenylmethyl thiolester 
(110): Following the general procedure 1, and eluting with 10% ethyl acetate in 
hexane, 110 was obtained in 82% yield. 1H NMR (500 MHz) δ 7.74-7.73 (d, J = 
6.5 Hz, 2H), 7.68-7.67 (d, J = 6.0 Hz, 2H), 7.38-7.30 (m, 4H), 5.04 (s, 1H), 4.18 
(s, 1H), 3.51 (s, 2H), 1.43 (s, 9H), 1.35 (s,  6H); 13C NMR (125 MHz) δ 203.9, 
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154.1, 145.6, 141.2, 127.6, 127.0, 124.9, 119.8, 80.0, 62.1, 47.0, 32.3, 28.4, 
25.5; ESI-HRMS Calcd for C23H27NO3S [M + Na]+ : 420.1604. Found: 420.1616. 
N-tert-Butoxycarbonyl-L-proline 9-fluorenylmethyl thiolester (111): 
Following the general procedure 1, and eluting with 15% ethyl acetate in hexane, 
111 was obtained in 97% yield as a mixture of two rotomers. [α]20D -72.9 (c 1.0); 
1H NMR (500 MHz) δ 7.73-7.71 (d, J = 8.0 Hz, 2H), 7.65-7.60 (m, 2H), 7.39-7.36 
(t, J = 7.5 Hz, 2H), 7.31-7.28 (t, J = 6.5 Hz, 2H), 4.40-4.38, 4.27-4.25 (d, J = 8.5 
Hz, 1H), 4.18-4.16 (t, J = 5.5 Hz, 1H), 3.60-3.58 (t, J = 5.0, 1H), 3.56-3.3 (m, 3H), 
2.06-2.02 (m, 1H), 1.73-1.64 (m, 3H), 1.47, 1.33 (s, 9H); 13C NMR (125 MHz) δ 
202.3, 201.7, 154.5, 153.9, 145.6, 145.4, 145.3, 145.2, 141.3, 127.7, 127.6, 
127.2, 127.1, 127.0, 125.0, 124.9, 124.7, 124.6, 119.9, 119.8, 80.4, 80.2, 66.2, 
65.9, 47.0, 46.9, 46.5, 31.7, 31.5, 31.4, 30.6, 28.5, 28.3, 23.9, 23.1; ESI-HRMS 
Calcd for C24H27NO3S [M + Na]+ : 432.1604. Found: 432.1601. 
α-Benzyl-N-tert-butoxycarbonyl-L-β-aspartyl 9-fluorenylmethyl 
thiolester (112):  Following the general procedure 1, and eluting with 15% ethyl 
acetate in hexane, 112 was obtained in 97% yield. [α]20D +11.4 (c 1.0); 1H NMR 
(500 MHz) δ 7.76-7.75 (d, J  = 7.5 Hz, 2H), 7.63-7.62 (d, J = 7.0 Hz, 2H), 7.42-
7.39 (m, 4H), 7.35-7.32 (m, 5H), 5.43-5.41 (d, J = 8.0 Hz, 1H), 5.15 (s, 2H), 4.58-
4.57 (d, J = 4.0, 1H), 4.12 (s, 1H), 3.52–3.50 (d, J = 5.5 Hz, 2H), 3.22–3.18 (dd, J 
= 4.5, 16.5 Hz, 1H), 3.08–3.03 (dd, J = 4.0, 16.5 Hz, 1H), 1.47 (s, 1H); 13C NMR 
(125 MHz) δ 196.5, 170.7, 155.3, 145.3, 145.2, 141.1, 135.3, 128.6, 128.5, 
128.4, 127.9, 127.2, 124.8, 124.7, 120.0, 80.2, 67.5, 50.5, 46.6, 45.4, 32.4, 28.4; 
ESI-HRMS Calcd for C30H31NO5S [M + Na]+ : 540.1816. Found: 540.1812. 
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N-Benzyloxycarbonyl-L-alanyl-L-phenylalanine 9-fluorenylmethyl 
thioester (116): To a solution of N-benzyloxycarbonyl-L-alanyl-L-phenylalanine 
(0.228 g, 0.615 mmol) in DMF (10 mL), was added 4Å molecular sieves (0.35 g) 
and 9-fluorenylmethylthiol (0.18 g, 0.8 mmol), and the mixture was stirred at -20 
°C. After 15 min., PyBOP (0.8 g, 1.54 mmol) and DIEA (0.27 mL, 1.54 mmol) 
were added and the reaction mixture was stirred at -20 °C for 4h, before it was 
filtered, quenched with saturated solution of NH4Cl and diluted with methylene 
chloride. The organic layer was washed with water and brine, dried and 
concentrated. Chromatographic purification using 30% ethyl acetate in hexane 
afforded 116 (0.28 g, 81%). [α]22D -64.0 (c 1.0); 1H NMR (500 MHz) δ 7.76-7.74 
(d, J = 7.5 Hz, 2H), 7.61-7.58 (t, J = 7.3 Hz, 2H), 7.41-7.18 (m, 12H), 7.05-7.04 
(d, J = 6 Hz, 2H), 6.61–6.59 (d, J = 6 Hz, 1H), 5.31–5.30 (d, J = 5.5 Hz, 1H), 
5.12–5.02 (m, 2H), 4.91-4.86 (q, J  = 7.5 Hz, 1H), 4.22–4.21 (m, 1H), 4.16–4.14 
(t, J = 5.5 Hz, 1H), 3.56–3.46 (m, 2H), 3.05–3.02 (dd, J = 5.5, 14.0 Hz, 1H), 
2.90–2.86 (t, J = 10.3 Hz, 1H), 1.30–1.29 (d, J = 5.5 Hz, 3H); 13C NMR (125 MHz) 
δ 199.1, 171.9, 155.9, 145.2, 141.1, 136.1, 135.4, 129.2, 128.6, 128.5, 128.2, 
128.0,  127.8, 127.1, 124.7, 119.9, 67.1, 59.8, 50.3, 46.6, 38.1, 32.4, 18.0; ESI-
HRMS Calcd for C34H32N2O4S [M + Na]+ : 587.1975. Found: 587.1973. 
General procedure 2. Synthesis of amino thioacids: A solution of N-
tert-butoxycarbonyl-α-amino acid 9-fluorenylmethyl thioester in 40% piperidine in 
DMF (c = 0.1 M) was stirred for 1.5h. Then the reaction mixture was 
concentrated. The concentrate was diluted with ethyl acetate and washed with 1 
114 
 
M HCl solution, water and brine. The organic layer was dried and concentrated. 
The crude thioacid was taken further without purification. 
General procedure 3. Synthesis of N-[(2,4-dinitrophenyl)sulfonyl]-α-
amino acid methyl esters (117-122): To a ~2 M solution of α-amino acid methyl 
ester hydrochloride and 2,4-dinitrophenylsulfonyl chloride (1.2 equiv.) in 
methylene chloride was added a solution of pyridine (4 equiv.) in methylene 
chloride (c = 4.0 M) at 0 °C. The reaction mixture was stirred at 0 °C for 1h and 
4h at room temperature. Then the organic layer was washed with 1M HCl, water, 
brine, dried and concentrated. Chromatographic purification afforded the N-[(2,4-
dinitrophenyl)sulfonyl]-α-amino acid methyl esters. 
N-[(2,4-Dinitrophenyl)sulfonyl]–L-phenylalanine methyl ester (117):167 
Following the general procedure 3, and eluting with 20% ethyl acetate in hexane, 
117 was obtained in 70% yield. Mp: 117-118 °C (ethyl acetate/ hexane 9:1); 
[α]23D -38.2 (c 0.1); 1H NMR (500 MHz) δ 8.61–8.60 (d, J = 2.0 Hz, 1H), 8.40–8.38 
(dd, J = 2, 8.5 Hz, 1H), 8.05–8.04 (d, J = 8.5 Hz, 1H), 7.19–7.08 (m, 5H), 6.06 (s, 
1H), 4.53–4.51 (dd, J = 5.0, 7.5 Hz, 1H), 3.66 (s, 3H), 3.23–3.19 (dd, J = 4.5, 
14.0 Hz, 1H), 3.07–3.02 (dd, J = 8.0, 14 Hz, 1H); 13C NMR (125 MHz) δ 170.8, 
149.5, 147.4, 139.6, 134.8, 131.8, 129.3, 128.8, 127.5, 127.2, 120.8, 58.3, 52.9, 
38.9. 
N-[(2,4-Dinitrophenyl)sulfonyl]–D-phenylalanine methyl ester (118):273  
Following the general procedure 3, and eluting with 20% ethyl acetate in hexane, 
118 was obtained in 74% yield. Mp: 119-120 °C (ethyl acetate/ hexane 9:1); 
[α]23D +38.6 (c 1.0); 1H NMR (500 MHz) δ 8.60–8.59 (d, J = 2.5 Hz, 1H), 8.39–
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8.37 (dd, J = 2.5, 8.5 Hz, 1H), 8.05–8.03 (d, J = 8.5 Hz, 1H), 7.18–7.08 (m, 5H), 
6.08 (s, 1H), 4.52 (s, 1H), 3.66 (s, 3H), 3.23–3.19 (dd, J = 4.5, 14.0 Hz, 1H), 
3.06–3.02 (dd, J = 8.0, 14 Hz, 1H); 13C NMR (125 MHz) δ 170.8, 149.5, 147.4, 
139.6, 134.9, 131.8, 129.3, 128.8, 127.5, 127.2, 120.8, 58.3, 52.9, 38.9. 
N-[(2,4-Dinitrophenyl)sulfonyl]–L-proline methyl ester (119): Following 
the general procedure 3, and eluting with 25% ethyl acetate in hexane, 119 was 
obtained in 71% yield. [α]23D -69.1 (c 1.0); 1H NMR (500 MHz) δ 8.51–8.46 (m, 
2H), 8.33–8.31 (d, J = 8.5 Hz, 1H), 4.64–4.62 (m, 1H), 3.68 (s, 3H), 3.65–3.64 (d, 
J = 6.0 Hz, 1H), 2.36-2.29 (m, 1H), 2.12–2.01 (m, 3H); 13C NMR (125 MHz) δ 
171.9, 149.6, 148.1, 138.5, 132.7, 126.0, 119.5, 61.3, 52.6, 49.0, 31.0, 24.5; ESI-
HRMS Calcd for C12H13N3O8S [M + Na]+ : 382.0316. Found: 382.0312. 
N-[(2,4-Dinitrophenyl)sulfonyl]-α-aminoisobutyrate methyl ester 
(120): Following the general procedure 3, and eluting with 25% ethyl acetate in 
hexane, 120 was obtained in 63% yield. Mp: 149-150 °C (ethyl acetate/ hexane = 
9:1); 1H NMR (500 MHz) δ 8.71–8.70 (d, J =  2 Hz, 1H), 8.56–8.54 (dd, J = 2.0, 
8.5 Hz, 1H), 6.18 (s, 1H), 3.69 (s, 1H), 1.60 (s, 1H); 13C NMR (125 MHz) δ 173.7, 
149.5, 147.8, 141.6, 132.0, 127.2, 120.8, 61.0, 53.2, 26.7; Anal. Calcd for 
C11H13N3O8S (374.30): C, 38.04; H, 3.77; N, 12.10. Found: C, 38.16; H, 3.77; N, 
11.97. 
N-[(2,4-Dinitrophenyl)sulfonyl]–L-tryptophan methyl ester (121):274 
Following the general procedure 3, and eluting with 30% acetone in hexane, 121 
was obtained in 65% yield. Mp: 236-237 °C; literature274 Mp: 232-234 °C. 
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N-[(2,4-Dinitrophenyl)sulfonyl]–glycyl-L-proline methyl ester (122):  
Following the general procedure 3, and eluting with 3% MeOH in CH2Cl2, 122 
was obtained in 58% yield as a mixture of two rotomers. [α]22D -21.5 (c 1.0); 1H 
NMR (500 MHz) δ 8.67–8.66 (d, J = 2.0 Hz, 1H), 8.52–8.50 (dd, J = 2.0, 8.5 Hz, 
1H), 8.27–8.25 (d, J = 8.5 Hz, 1H), 6.52 (s, 1H), 4.36–4.29 (m, 1H), 4.17–4.12 
(dd, J = 6.0, 17.5 Hz, 1H), 4.02–3.98, 3.94–3.90 (dd, J = 2.5 Hz, 17.5 Hz, 1H), 
3.80, 3.58 (s, 3H), 3.45–3.37 (m, 1H), 2.26–2.23, 2.18–2.10 (m, 1H), 2.06–1.88 
(m, 4H); 13C NMR (125 MHz) δ 171.7, 166.0, 165.5, 150.0, 147.8, 139.4, 139.2, 
132.3, 127.3, 127.0, 120.8, 58.9, 58.5, 53.1, 52.2, 46.8, 46.0, 45.6, 45.5, 31.2, 
28.9, 24.6, 22.1; ESI-HRMS Calcd for C14H16N4O9S [M + H]+ : 417.0711. Found: 
417.0709.  
N-[(2,4-Dinitrophenyl)sulfonyl]–glycyl-glycine methyl ester (123).  To 
a stirred solution of glycyl-glycine methyl ester hydrochloride (0.15 g, 0.8 mmol) 
and NaHCO3 (0.27 g, 3.2 mmol) in THF/ H2O (1:1, 5mL), was added a solution of 
2,4-dinitrophenylsulfonyl chloride (0.21 g, 0.8 mmol) in THF (2 mL) at 0 °C. The 
reaction mixture was stirred at 0 °C for 30 min. and 2h at room temperature. 
Then the reaction was poured into 50 mL ethyl acetate and washed with 1M HCl 
solution, water and brine. The organic layer was dried and concentrated. 
Chromatographic purification using 4% MeOH in CH2Cl2 afforded 123 (0.16 g, 
52%). Mp: 167-168 °C (acetone/ hexane = 2:1); 1H NMR (400 MHz, DMSO – d6) 
δ  8.85–8.84 (d, J = 2.4 Hz, 1H), 8.76 (s, 1H), 8.61–8.58 (dd, J = 2.4, 8.4 Hz, 1H), 
8.44-8.41 (t, J = 6.0 Hz, 1H), 8.26–8.23 (d, J = 8.4 Hz, 1H), 3.79–3.77 (d, J = 6.0 
Hz, 2H), 3.75 (s, 2H), 3.58 (s, 3H); 13C NMR (100 MHz, DMSO – d6) δ 170.4, 
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168.5, 148.3, 135.8, 130.7, 130.3, 123.7, 116.2, 52.2, 46.0, 41.1; Anal. Calcd for 
C11H12N4O9S (376.30): C, 35.11; H, 3.21; N, 14.89. Found: C, 35.09; H, 3.23; N, 
14.66. 
General procedure 4. Synthesis of di- and tetra peptides: To a stirred 
solution of N-tert-butoxycarbonyl-α-amino thioacid (1.2 equiv.) in DMF (c = 0.5 M) 
under nitrogen was added Cs2CO3 (1.5 equiv.). After the solution was stirred for 
10 min. at room temperature, a solution of N-[(2,4-dinitrophenyl)sulfonyl]-α-amino 
acid methyl ester (1 equiv) in DMF (c = 0.5 M) was added to the above solution 
and stirring was continued for 1h. Then the reaction mixture was poured into 
ethyl acetate (50 mL) and washed with an ice cold 1M NaOH solution, water, and 
brine. The organic layer was dried and concentrated. Chromatographic 
purification afforded the di- and tetra peptides. 
N-tert-Butoxycarbonyl-L-valyl-L-phenylalanine methyl ester (124):275 
Following the general procedure 4, and eluting with 20% ethyl acetate in hexane, 
124 was obtained in 81% yield. Mp: 100-101 °C; literature275 Mp: 101 °C. 
N-tert-Butoxycarbonyl-L-valyl-D-phenylalanine methyl ester (125): 
Following the general procedure 4, and eluting with 22% ethyl acetate in hexane, 
125 was obtained in 82% yield. Mp: 104-105 °C (ethanol/ water = 2:1); [α]23D 37.8 
(c 1.0); 1H NMR (400 MHz) δ 7.30–7.17 (m, 3H), 7.12–7.10 (d, J = 6.8 Hz, 2H), 
6.41-6.38 (d, J = 8.4 Hz, 1H), 4.95–4.87 (m, 2H), 3.98–3.95 (m, 1H), 3.71 (s, 3H), 
3.15–3.05 (m, 2H), 2.16–2.08 (m, 1H), 1.43 (s, 9H), 0.88–0.87 (d, J = 7.2 Hz, 
3H), 0.81–0.79 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz) δ 171.8, 171.3, 155.8, 
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135.8, 129.2, 128.7, 127.2, 79.9, 59.6, 53.0, 52.3, 38.0, 30.7, 28.3, 19.3, 17.2; 
ESI-HRMS Calcd for C20H30N2O5 [M + H]+ : 379.2227. Found: 379.2225. 
N-tert-Butoxycarbonyl-L-valyl-L-tryptophan methyl ester (126):276 
Following the general procedure 4, and eluting with 45% ethyl acetate in hexane, 
126 was obtained in 82% yield. Mp: 137-138 °C; literature276 Mp: 136-138 °C. 
N-tert-Butoxycarbonyl-L-prolyl-L-proline methyl ester (127):277 
Following the general procedure 4, and eluting with 65% ethyl acetate in hexane, 
127 was obtained in 78% yield, whose spectral data corresponded with the 
literature values.277    
N-tert-Butoxycarbonyl-L-prolyl-L-tryptophan methyl ester (128):278 
Following the general procedure 4, and eluting with 60% ethyl acetate in hexane, 
128 was obtained in 77% yield. Mp: 73-74 °C; literature278 Mp: 72-74 °C.   
α-Benzyl-N-tert-butoxycarbonyl-L-β-aspartyl-L-proline methyl ester 
(129): Following the general procedure 4, and eluting with 60% ethyl acetate in 
hexane, 129 was obtained in 75% yield as a mixture of two rotomers. [α]19D -29.2 
(c 1.0); 1H NMR (400 MHz) δ 7.34–7.27 (m, 5H), 5.93–5.90 (d, J = 9.6 Hz, 1H), 
5.22–5.07 (m, 2H), 4.63–4.59 (m, 1H), 4.43–4.40 (dd, J = 2.8, 8.2 Hz, 1H), 3.71, 
3.66 (2s, 3H), 3.60–3.53 (m, 1H), 3.44–3.38 (m, 1H), 3.14–3.09 (dd, J = 4.4, 17.0 
Hz, 1H), 2.77–2.72 (dd, J = 4.2 Hz, 16.6 Hz, 1H), 2.14–1.87 (m, 4H), 1.41 (s, 
9H); 13C NMR (100 MHz) δ 172.4, 171.5, 169.3, 155.9, 135.7, 128.4, 128.1, 
128.0, 79.7, 67.2, 67.0, 59.3, 58.5, 52.5, 52.2, 50.2, 47.0, 46.3, 36.7, 36.3, 31.3, 
29.2, 28.3, 24.6, 22.5; ESI-HRMS Calcd for C22H30N2O7 [M + Na]+ : 457.1945. 
Found: 457.1939. 
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α-Benzyl-N-tert-butoxycarbonyl-L-β-aspartyl-α-aminoisobutyrate 
methyl ester (130): Following the general procedure 4, and eluting with 45% 
ethyl acetate in hexane, 130 was obtained in 79% yield.  [α]22D +7.1 (c 1.0); 1H 
NMR (500 MHz) δ 7.33-7.29 (m, 5H), 6.36 (s, 1H), 5.80–5.79 (d, J = 8.0 Hz, 1H), 
5.19–5.12 (q, J = 12.5 Hz, 2H), 4.53 (s, 1H), 3.69 (s, 3H), 2.88–2.84 (dd, J = 4.0, 
15.0 Hz, 1H), 2.70–2.66 (dd, J = 4.0, 15.0 Hz, 1H), 1.47 (s, 3H), 1.46 (s, 3H), 
1.41 (s, 9H);  13C NMR (125 MHz) δ 174.7, 171.2, 169.2, 155.7, 135.5, 128.5, 
128.2, 128.1, 79.9, 67.2, 56.6, 52.6, 50.6, 38.0, 28.3, 24.7, 24.6; ESI-HRMS 
Calcd for C21H30N2O7 [M + Na]+ : 445.1945. Found: 445.1941. 
α-Benzyl-N-tert-butoxycarbonyl-L-β-aspartyl-L-phenylalanine methyl 
ester (131): Following the general procedure 4, and eluting with 40% ethyl 
acetate in hexane, 131 was obtained in 82% yield. Mp: 116-117 °C (ethanol/ 
water = 4:1); [α]20D +82.4 (c 1.0); 1H NMR (400 MHz) δ 7.35–7.23 (m, 8H), 7.03–
7.02 (d, J = 5.6 Hz, 2H), 6.02–6.00 (d, J = 7.6 Hz, 1H), 5.72–5.70 (d, J = 8.8 Hz, 
1H), 5.18 (s, 2H), 4.84–4.80 (m, 1H), 4.57–4.55 (m, 1H), 3.71 (s, 3H), 3.06–3.05 
(d, J = 5.6 Hz, 1H), 2.94-2.89 (dd, J = 4.4, 16.2 Hz, 1H), 2.73–2.68 (dd, J = 4.4, 
16.2 Hz, 1H), 1.42 (s, 9H);  13C NMR (100 MHz) δ 171.6, 171.2, 155.6, 135.6, 
135.5, 129.2, 128.6, 128.5, 128.3, 128.1, 127.2, 80.0, 67.3, 53.2, 52.3, 50.4, 
37.8, 28.3; Anal. Calcd for C26H32N2O7 (485.54): C, 64.45; H, 6.54; N, 5.78. 
Found: C, 64.33; H, 6.54; N, 5.87. 
N-tert-Butoxycarbonyl-α-aminoisobutyryl-L-tryptophan methyl ester 
(132): Following the general procedure 4, and eluting with 50% ethyl acetate in 
hexane, 132 was obtained in 80% yield.  [α]22D +37.2 (c 1.0); 1H NMR (500 MHz) 
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δ 8.43 (s, 1H), 7.55-7.53 (d, J = 8.5 Hz, 1H), 7.34–7.32 (d, J = 8.0 Hz, 1H), 7.18–
7.15 (t, J =  7.5 Hz, 1H), 7.11–7.08 (t, J = 8 Hz, 1H), 7.03 (s, 1H), 6.91 (s, 1H), 
4.99 (s, 1H), 4.90–4.87 (q, J = 5.0 Hz, 1H), 3.63 (s, 3H), 3.35–3.26 (m, 2H), 1.43, 
1.39 (2s, 15H); 13C NMR (125 MHz) δ 174.5, 172.4, 154.6, 136.1, 127.6, 123.0, 
122.1, 119.4, 118.5, 111.3, 109.9, 56.7, 53.1, 52.2, 28.3, 27.8, 25.5; ESI-HRMS 
Calcd for C21H29N3O5 [M + Na]+ : 426.1999. Found: 426.1997. 
N-tert-Butoxycarbonyl-α-aminoisobutyryl-α-aminoisobutyrate methyl 
ester (133):279 Following the general procedure 4, and eluting with 50% ethyl 
acetate in hexane, 133 was obtained in 80% yield. Mp: 88-89 °C; literature279  
Mp: 91-92 °C. 
N-tert-Butoxycarbonyl-α-aminoisobutyryl-L-phenylalanine methyl 
ester (134):280 Following the general procedure 4, and eluting with 20% ethyl 
acetate in hexane, 134 was obtained in 82% yield. Mp: 141-142 °C; [α]20D +48.9 
(c 1.0); 1H NMR (400 MHz) δ 7.27-7.20 (m, 3H), 7.12-7.10 (m, 2H), 6.86 (s, 1H), 
4.87-4.82 (m, 2H), 3.69 (s, 3H), 3.16-3.07 (m, 2H), 1.44 (s, 3H), 1.41 (s, 12H); 
13C NMR (100 MHz) δ 174.2, 171.9, 154.5, 136.1, 129.3, 128.5, 127.0, 56.7, 
53.3, 52.1, 38.1, 28.3, 25.7, 25.4. 
N-tert-Butoxycarbonyl-L-valyl-α-N-benzyloxycarbonyl-ε-L-lysine 
benzyl ester (135): To a stirred solution of N-tert-butoxycarbonyl-L-valyl thioacid 
(105 mg, 0.5 mmol) in DMF (3 mL) under nitrogen was added Cs2CO3 (189 mg, 
0.58 mmol). After the solution was stirred for 10 min. at room temperature, 
successively α-N-benzyloxycarbonyl-L-lysine benzyl ester (70 mg, 0.19 mmol) 
and a solution of N-[(2,4-dinitrophenyl)sulfonyl]- L-phenylalanine methyl ester (77 
121 
 
mg, 0.19 mmol) in DMF (3 mL) was added to the above solution and stirring was 
continued for 2h. Then the reaction mixture was poured into ethyl acetate (50 
mL) and washed with an ice cold 1M NaOH solution, water, and brine. The 
organic layer was dried and concentrated. Chromatographic purification using 
22% ethyl acetate in hexane afforded 124 (42 mg, 59%), and 50% ethyl acetate 
in hexane afforded 135 (25 mg, 23%). Characterizations data of 135: [α]22D -29.8 
(c 1.0); 1H NMR (400 MHz) δ 7.36-7.34 (m, 10H), 6.22 (s, 1H), 5.78 (s, 1H), 5.20-
5.07 (m, 4H), 4.34-4.33 (d, J = 3.2 Hz, 1H), 3.84-3.81 (t, J = 6.4 Hz, 1H), 3.29-
3.26 (m, 1H), 3.12-3.08 (m, 1H), 2.04-2.01 (m, 1H), 1.82-1.80 (m, 1H), 1.79-1.64 
(m, 1H), 1.49-1.46 (m, 1H), 1.42 (s, 9H), 1.35-1.25 (m, 4H), 0.90-0.88 (d, J = 6.8 
Hz, 3H), 0.82-0.80 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz) δ 172.5, 172.2, 156.3, 
136.4, 135.6, 128.8, 128.7, 128.6, 128.5, 128.4, 80.1, 67.3, 60.4, 54.1, 38.7, 
31.9, 30.9, 29.9, 29.2, 28.6, 22.7, 19.5, 18.1; EI-HRMS Calcd for C26H35N3O5 [M 
– Boc + H]. : 469.2577. Found: 469.2589. 
N-Benzyloxycarbonyl-L-alanyl-L-phenylalanyl-glycyl-L-proline methyl 
ester (141): Following the general procedure 4, and eluting with 4% MeOH in 
CH2Cl2, 141 was obtained in 62% yield as a mixture of two rotomers. Mp: 188-
189 °C (ethanol/ water = 9:1); [α]23D -33.8 (c 1.0, DMSO); 1H NMR (500 MHz, 
DMSO – d6) δ 8.14–8.12 (m, 1H), 7.95–7.93 (d, J = 8.5 Hz, 1H), 7.40–7.19 (m, 
10 H), 7.16–7.15 (d, J = 6.5 Hz, 1H), 5.02–4.96 (m, 2H), 4.57–4.55 (m, 1H), 
4.32–4.30 (dd, J = 4.0, 8.5 Hz, 1H), 4.04–3.97 (m, 2H), 3.89–3.85 (dd, J = 4.5, 
17.0 Hz, 1H), 3.68, 3.60 (2s, 3H), 3.57–3.49 (m, 2H), 3.06–3.02 (dd, J = 4.0, 13.8 
Hz, 1H), 2.82–2.77 (m, 1H), 2.16–2.10 (m, 1H), 1.92–1.80 (m, 3H), 1.11-1.10 (d, 
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J = 7.0 Hz, 3H);   13C NMR (125 MHz, DMSO – d6) δ 172.8, 172.7, 171.5, 171.4, 
167.5, 167.3, 156.0, 138.1, 137.4, 129.7, 129.5, 128.8, 128.6, 128.4, 128.2, 
127.7, 127.4, 126.6, 126.5, 65.9, 65.7, 58.9, 58.3, 54.0, 52.9, 52.3, 50.6, 46.7, 
46.1, 41.6, 41.4, 38.1, 31.2, 29.1, 24.9, 22.3, 18.9; Anal. Calcd for C28H34N4O7 
(538.59): C, 62.44; H, 6.36; N, 10.40. Found: C, 62.42; H, 6.43; N, 10.36. 
N-Benzyloxycarbonyl-L-alanyl-L-phenylalanyl-glycyl-glycine methyl 
ester (142): Following the general procedure 4, and eluting with 6% MeOH in 
CH2Cl2, 142 was obtained in 64% yield. Mp: 182-183 °C (ethanol/ water = 9:1); 
[α]23D -7.0 (c 1.0, DMSO); 1H NMR (500 MHz, DMSO – d6) δ 8.29 (s, 1H), 8.19 (s, 
1H), 7.99–7.97 (d, J = 7.5 Hz, 1H), 7.43–7.42 (d,  J = 7.0 Hz, 1H), 7.34– 7.30 (m, 
5H), 7.21-7.16 (m, 5H), 5.03–4.96 (m, 2H), 4.50 (s, 1H), 4.02–3.99 (t, J = 6.5 Hz, 
1H), 3.86–3.85 (d, J = 4.0 Hz, 2H), 3.80–3.68 (m, 2H), 3.61 (s, 3H), 3.05–3.03 (d, 
J = 9.5, 1H), 2.85–2.81 (m, 1H), 1.11–1.10 (d, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, DMSO – d6) δ 172.8, 171.6, 170.6, 169.6, 156.1, 138.1, 137.4, 129.7, 
128.8, 128.4, 128.2, 126.7, 65.9, 54.3, 52.1, 50.7, 42.2, 41.0, 40.9, 37.8, 18.5; 
Anal. Calcd for C25H30N4O7 (498.53): C, 60.23; H, 6.07; N, 11.24. Found: C, 
60.33; H, 6.08; N, 11.25. 
[2-(tert-Butoxycarbonylamino)-9H-fluoren-9-yl]methyl 4-
methylbenzenesulfonate (144): To a stirred solution of [2-(tert-
butoxycarbonylamino)-9H-fluoren-9-yl]methanol182 (1.8 g, 5.8 mmol) and 4-
methylbenzenesulfonyl chloride (1.65 g, 8.7 mmol) in CHCl3 (20 mL) was added 
pyridine (0.9 mL, 11.6 mmol) at 0 °C. The reaction mixture was stirred at room 
temperature for 6 h. Then the organic layer was washed with 1M HCl, water, 
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brine, dried and concentrated. Chromatographic purification using 30% ethyl 
acetate in hexane afforded 144 (2.42 g, 90%). Yellowish syrup; 1H NMR (500 
MHz) δ 7.78-7.76 (d, J = 8.0 Hz, 2H), 7.66-7.61 (dd, J = 8.5, 12.8 Hz, 2H), 7.57 
(s, 1H), 7.51-7.50 (d, J = 7.5 Hz, 1H), 7.38-7.35 (t, J = 7.0 Hz, 2H), 7.31-7.29 (d, 
J = 8 Hz, 2H), 7.25-7.22 (t, J = 7.5 Hz, 1H), 6.61 (s, 1H), 4.31-4.24 (m, 2H), 4.20-
4.17 (t, J = 7.5 Hz, 1H), 2.43 (s, 3H), 1.56 (s, 9H); 13C NMR (125 MHz) δ 153.0, 
145.1, 143.7, 142.5, 141.3, 138.0, 136.5, 133.0, 130.1, 128.3, 128.2, 126.7, 
125.3, 120.7, 119.8, 118.8, 115.6, 80.9, 72.0, 46.9, 28.6, 21.8; ESI-HRMS Calcd 
for C26H27NO5S [M + Na]+ : 488.1508. Found: 488.1486. 
(2-Amino-9H-fluoren-9-yl)methyl 4-methylbenzenesulfonate (145): To 
a stirred solution of 144 (2.4 g, 5.2 mmol) in CH2Cl2 (16 mL), was added TFA (4 
mL) dropwise at 0 °C.  The reaction mixture was stirred at same temperature for 
20 min before it was neutralized at 0 °C by saturated aqueous NaHCO3. Then 
the organic layer was washed with water, and brine, and dried and concentrated. 
Chromatographic purification using 40% ethyl acetate in hexane afforded 145 
(1.9 g, 100%). Light yellow syrup; 1H NMR (400 MHz) δ 7.78-7.76 (d, J = 8.4 Hz, 
2H), 7.57-7.55 (d, J = 7.2 Hz, 1H), 7.50-7.48 (d, J = 8.0 Hz, 1H), 7.44-7.42 (d, J = 
7.2 Hz, 1H), 7.34-7.29 (m, 3H), 7.17-7.13 (t, J = 6.4 Hz, 1H), 6.86 (s, 1H), 6.71-
6.68 (dd, J = 1.6, 8.4 Hz, 1H), 4.26-4.18 (m, 2H), 4.13-4.09 (t, J = 7.2 Hz, 1H), 
3.67 (br s, 2H), 2.41 (s, 3H); 13C NMR (100 MHz) δ 146.4, 145.1, 144.7, 142.0, 
141.7, 133.1, 132.3, 130.1, 128.2, 128.1, 125.7, 125.1, 121.1, 119.0, 115.2, 
112.2, 72.5, 46.8, 21.9; ESI-HRMS Calcd for C21H19NO3S [M + H]+ : 366.1164. 
Found: 366.1152. 
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N-[9-(Tosyloxymethyl)-9H-fluoren-2-yl]succinamic acid (146): To a 
stirred solution of 145 (1.8 g, 4.9 mmol) in THF (10 mL) was added solid succinic 
anhydride (590 mg, 5.9 mmol) portion wise over a period of 10 min at room 
temperature. The reaction mixture was stirred at room temperature for 1 h. Then 
the reaction mixture was concentrated and subjected to chromatographic 
purification using 5% methanol in dichloromethane when it afforded 146 (2.1 g, 
91%). White solid, crystallized from chloroform/hexane, Mp: 165.8-166.2 °C. 1H 
NMR (400 MHz) δ 7.65-7.63 (m, 3H), 7.55-7.51 (m, 3H), 7.37-7.7.36 (d, J = 7.2 
Hz, 1H), 7.26-7.2 (m, 4H), 7.14-7.11 (t, J = 7.2 Hz, 1H), 4.20-4.13 (m, 2H), 4.07-
4.04 (t, J  = 7.2 Hz, 1H), 2.67-2.62 (m, 4H), 2.32 (s, 3H); 13C NMR (100 MHz) δ 
175.6, 171.1, 145.3, 143.3, 142.4, 141.1, 137.7, 137.3, 132.5, 130.1, 128.2, 
128.0, 126.8, 125.1, 120.5, 120.1, 120.0, 119.8, 116.8, 72.0, 46.8, 31.7, 29.4, 
21.7; ESI-HRMS Calcd for C25H23NO6S [M + Na]+ : 488.1144. Found: 488.1120. 
N-[9-(Tritylthiomethyl)-9H-fluoren-2-yl]succinamic acid (147): To a 
stirred solution of 146 (2.0 g, 4.3 mmol) and triphenylmethanethiol (1.5 g, 5.4 
mmol) in DMF (15 mL) was added diisopropylethylamine (1.8 mL, 10.8 mmol) at 
0 °C. The reaction mixture was stirred at room temperature for 15 h, after which 
the DMF was removed under high vacuum and the crude mixture was dissolved 
in EtOAc and washed with water, and brine, and dried and concentrated. 
Chromatographic purification of the residue using 4% methanol in 
dichloromethane afforded 147 (2.23 g, 91%). Light brown solid, crystallized from 
chloroform/hexane, Mp: 84-85 °C. 1H NMR (500 MHz) δ 7.80 (br s, 1H), 7.57-
7.53 (m, 4H), 7.43-7.41 (m, 6H), 7.31-7.24 (m, 8H), 7.21-7.7.17 (m, 4H), 3.57-
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3.54 (t, J = 7.0 Hz, 1H), 2.74-2.70 (m, 3H), 2.67-2.62 (m, 3H); 13C NMR (125 
MHz) δ 177.5, 170.5, 147.2, 146.1, 144.9, 140.5, 137.5, 136.8, 130.0, 128.2, 
127.7, 127.0, 126.7, 124.9, 120.4, 119.9, 119.7, 116.9, 67.6, 47.2, 36.1, 32.0, 
29.7; ESI-HRMS Calcd for C37H31NO3S [M + Na]+ : 592.1922. Found: 592.1892. 
N-tert-Butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine allyl 
ester (149): To a stirred solution of N-tert-butoxycarbonyl-L-serine (2.0 g, 9.8 
mmol) and K2CO3 (1.35 g, 9.8 mmol) in DMF (10 mL) was added allyl bromide 
(1.2 mL, 14.7 mmol) at 0 °C. The reaction mixture was stirred at room 
temperature for 2 h, after which the DMF was removed under high vacuum and 
the crude mixture was dissolved in EtOAc and washed with water, brine and 
dried. Evaporation of the solvent, afforded crude N-tert-butoxycarbonyl-L-serine 
allyl ester, which was taken forward without purification. 
To a stirred solution of the crude N-tert-butoxycarbonyl-L-serine allyl ester 
(2.3 g, 9.8 mmol) and Fmoc-Cl (3.8 g, 14.7 mmol) in dichloromethane (10 mL) at 
0 °C was added dropwise pyridine (1.2 mL, 14.7 mmol).  After the addition was 
complete, the reaction mixture was allowed to warm room temperature and 
stirred at room temperature for 3 h. Then the reaction mixture was diluted with 
dichloromethane (20 mL) and the organic layer was washed with water, brine, 
dried and concentrated. Chromatographic purification using 10% ethyl acetate in 
hexane afforded 149 (3.9 g, 86%). Light yellow syrup; [α]23D +9.9 (c 0.75); 1H 
NMR (500 MHz) δ: 7.79-7.78 (d, J = 7.5 Hz, 2H), 7.62-7.60 (d, J = 7.5 Hz, 2H), 
7.44-7.41 (t, J = 7.5 Hz, 2H), 7.36-7.32 (dt, J = 2.5, 7.5 Hz, 2H), 5.97-5.90 (m, 
1H), 5.41-5.33 (m, 2H), 5.27-5.25 (d, J = 10.5 Hz, 1H), 4.71-4.69 (d, J = 7.0 Hz, 
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1H), 4.66-4.58 (m, 2H), 4.49-4.46 (dd, J = 3.5, 11.0 Hz, 1H), 4.42-4.41 (d, J = 8.0 
Hz, 2H), 4.28-4.25 (t, J = 7.5 Hz, 1H), 1.48 (s, 9H); 13C NMR (125 MHz) δ: 169.4, 
155.4, 155.0, 143.4, 141.5, 131.5, 128.2, 127.4, 125.4, 120.3, 119.3, 80.7, 70.5, 
67.9, 66.7, 53.3, 46.9, 28.5; ESI-HRMS Calcd for C26H29NO7 [M + Na]+ : 
490.1842. Found: 490.1824. 
N-tert-Butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine 
(150): A mixture of Pd(OAc)2 (170 mg, 0.8 mmol) and PPh3 (1.67 g, 6.4 mmol) 
was stirred in dichloromethane (10 mL) at room temperature for 5 min until a 
clear yellow solution of tetrakis(triphenylphosphine)palladium(0) was obtained. 
This solution was transferred via cannula to a stirred solution of N-tert-
butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine allyl ester (149) (3.0 g, 
6.4 mmol) and phenylsilane (1.6 mL, 12.8 mmol) in dichloromethane (20 mL) at 
room temperature and the stirring was continued at same temperature for 1.5 h. 
Then the reaction mixture was diluted with dichloromethane (20 mL) and was 
washed with water, brine, dried and concentrated. Chromatographic purification 
using 50% ethyl acetate in hexane afforded 150 (2.5 g, 91%). White solid, 
crystallized from ethyl acetate/hexane, Mp: 65-66 °C. [α]22D +19.4 (c 1.7); 1H 
NMR (500 MHz) δ: 7.77-7.75 (d, J = 7.5 Hz, 2H), 7.60-7.59 (d, J = 7.0 Hz, 2H), 
7.42-7.39 (t, J = 7.5 Hz, 2H), 7.33-7.04 (t, J = 7.0 Hz, 2H), 5.44-5.43 (d, J = 7.5 
Hz, 1H), 4.68 ( br s, 1H), 4.61-4.59 (d, J = 8.5 Hz, 1H), 4.52-4.51 (d, J = 8.5 Hz, 
1H), 4.42-4.40 (d, J = 7.5 Hz, 2H), 4.26-4.23 (t, J = 7.5 Hz, 1H), 1.47 (s, 9H); 13C 
NMR (125 MHz) δ: 173.7, 155.7, 155.0, 143.4, 141.5, 128.2, 127.4, 125.4, 120.3, 
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81.1, 70.5, 67.6, 53.2, 46.9, 28.5; ESI-HRMS Calcd for C23H25NO7 [M + Na]+ : 
450.1529. Found: 450.1526. 
N-tert-Butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-threonine 
allyl ester (151): Following the same procedure as for the synthesis of N-tert-
butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine allyl ester (149), 
compound 151 was synthesized from N-tert-butoxycarbonyl-L-threonine in 92% 
yield. Light yellow syrup; [α]23D +14.0 (c 1.0); 1H NMR (500 MHz) δ: 7.79-7.77 (d, 
J = 7.0 Hz, 2H), 7.61-7.59 (d, J = 7.5 Hz, 2H), 7.44-7.41 (t, J = 7.5 Hz, 2H), 7.36-
7.33 (tt, J = 1.5, 7.5 Hz, 2H), 5.93-5.85 (m, 1H), 5.39-5.30 (m, 3H), 5.21-5.19 (d, 
J = 10.5 Hz, 1H), 4.68-4.63 (m, 2H), 4.56-4.54 (dd, J = 2.5, 9.7 Hz, 1H), 4.43-
4.35 (m, 2H), 4.26-4.23 (t, J = 7.5 Hz, 1H), 1.50 (s, 9H), 1.42-1.41 (d, J = 6.0 Hz, 
3H); 13C NMR (125 MHz) δ: 169.8, 156.1, 154.4, 143.5, 141.5, 131.6, 128.2, 
127.4, 125.4, 120.3, 119.3, 80.6, 75.0, 70.3, 66.6, 57.4, 46.9, 28.5, 17.1; ESI-
HRMS Calcd for C27H31NO7 [M + Na]+ : 504.1998. Found: 504.1974. 
N-tert-Butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-threonine 
(152): Following the same procedure as for the synthesis of N-tert-
butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine (150), compound 152 
was synthesized from N-tert-butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-
threonine allyl ester (151), in 90% yield. White solid, crystallized from ethyl 
acetate/hexane, mp: 69-70 °C. [α]23D +19.6 (c 1.34); 1H NMR (500 MHz) δ: 7.75-
7.73 (dd, J = 3.0, 7.5 Hz, 2H), 7.58-7.55 (t, J = 8.5 Hz, 2H, 7.41-7.38 (dt, J = 3.0, 
7.5 Hz, 2H), 7.32-7.29 (t, J = 7.5 Hz, 2H), 5.36-5.33 (m, 2H), 4.50-4.48 (d, J = 8.0 
Hz, 1H), 4.39-4.34 (m, 2H), 4.22-4.19 (t, J = 7.5 Hz, 1H), 1.47 (s, 9H), 1.38-1.37 
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(d, J = 6.5 Hz); 13C NMR (125 MHz) δ: 174.4, 156.3, 154.4, 143.6, 143.4, 141.5, 
128.1, 127.4, 125.4, 120.3, 80.8, 74.9, 70.2, 57.4, 46.9, 28.5, 17.2; ESI-HRMS 
Calcd for C24H27NO7 [M + Na]+ : 464.1685. Found: 464.1688. 
N-tert-Butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-tyrosine 
allyl ester (153): Following the same procedure as for the synthesis of N-tert-
butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine allyl ester (149), 
compound 153 was synthesized from N-tert-butoxycarbonyl-L-tyrosine in 95% 
yield. Light yellow syrup; [α]23D +14.7 (c 1.5); 1H NMR (500 MHz) δ: 7.82-7.80 (d, 
J = 7.5 Hz, 2H), 7.67-7.66 (d, J = 7.5 Hz, 2H), 7.47-7.33 (t, J = 7.5 Hz, 2H), 7.38-
7.35 (t, J = 7.5 Hz, 2H), 7.20-7.18 (d, J = 8.5 Hz, 2H), 7.14-7.13 (d, J = 8.5 Hz, 
2H), 5.60-5.82 (m, 1H), 5.34-5.26 (dd, J = 14.0, 25.0 Hz, 2H), 5.04-5.03 (d, J = 
7.0 Hz, 1H), 4.63-4.62 (t, J = 3.0 Hz, 3H), 4.55-4.4.54 (d, J = 7.0 Hz, 2H), 4.36-
4.33 (t, J = 7.0 Hz, 1H), 3.18-3.14 (dd, J = 5.5, 13.5 Hz, 1H), 3.12-3.07 (dd, J = 
5.5, 13.5 Hz, 1H), 1.45 (s, 9H); 13C NMR (125 MHz) δ: 171.6, 155.3, 153.8, 
150.4, 143.4, 141.6, 134.2, 131.7, 130.7, 128.3, 127.5, 127.3, 125.4, 121.3, 
120.4, 120.3, 119.3, 80.3, 70.7, 66.3, 54.6, 47.0, 37.9, 28.6; ESI-HRMS Calcd for 
C32H33NO7 [M + Na]+ : 566.2155. Found: 566.2128. 
N-tert-Butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-tyrosine 
(154): Following the same procedure as for the synthesis of N-tert-
butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-serine (150), compound 154 
was synthesized from N-tert-butoxycarbonyl-O-(9-fluorenylmethoxycarbonyl)-L-
tyrosine allyl ester (153), in 92% yield. White solid, crystallized from ethyl 
acetate/hexane, Mp: 84-85 °C. [α]22D -9.3 (c 0.6); 1H NMR (500 MHz) δ: 7.81-7.79 
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(d, J = 7.5 Hz, 2H), 7.66-7.65 (d, J = 7.5 Hz, 2H), 7.46-7.43 (t, J = 7.5 Hz, 2H), 
7.37-7.34 (t, J = 7.5 Hz, 2H), 7.26-7.24 (d, J = 8.5 Hz, 2H), 7.14-7.12 (d, J = 8.5 
Hz, 2H), 4.77-4.76 (d, J = 7.5 Hz, 1H), 4.55-4.53 (d, J = 7.5 Hz, 2H), 4.36-4.33 (t, 
J = 7.5 Hz, 1H), 3.87 (br s, 1H), 3.69-3.67 (dd, J = 3.5, 11 Hz, 1H), 3.59-3.56 (dd, 
J = 5.0, 10.8 Hz, 1H), 1.43 (s, 9H); 13C NMR (125 MHz) δ: 173.7, 156.3, 153.9, 
150.0, 143.4, 141.6, 136.0, 130.6, 128.2, 127.5, 125.4, 121.3, 120.4, 80.1, 70.7, 
64.4, 53.9, 47.0, 28.6; ESI-HRMS Calcd for C29H29NO7 [M + Na]+ : 526.1842. 
Found: 526.1844. 
Synthesis of Boc-L-Met-L-Ala-L-Val-L-Ala-SH (171) employing 
DIC/HOBt activation method:  
(a) Derivatization of aminomethyl polystyrene resin with N-[9-
(tritylthiomethyl)-9H-fluoren-2-yl]succinamic acid (147). In a 10 mL glass reaction 
vessel, aminomethyl polystyrene resin (244 mg, 0.1 mmol) was swelled in DMF 
(2 mL) for 30 min, after which the solvent was removed by filtration. To a stirred 
solution of 147 (114 mg, 0.2 mmol) and HOBt (27 mg, 0.2 mmol) in DMF (1 mL) 
was added DIC (31 µL, 0.2 mmol) at room temperature.  The reaction mixture 
was stirred for 30 min before the activated HOBt ester of 147 was added to the 
reaction vessel with an additional DMF (1 mL) which was then shaken for 2 h 
before the resin was washed thoroughly using DMF (3 × 2 mL) and CH2Cl2 (3 × 2 
mL). 
(b) Deprotection of trityl group from derivatized aminomethyl polystyrene 
resin. To the reaction vessel containing the derivatized resin was added 
dichloromethane /TFA [v/v 1:1, 1.5 mL, with Et3SiH (65 µL, 0.4 mmol)].  After 
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shaking for 1 h the thiol derivatized resin was washed thoroughly using 
dichloromethane (3 × 2 mL) and a 5% solution of DIPEA in dichloromethane (2 × 
2 mL).  
(c) Coupling reaction. A stirred solution of Boc-Ala-OH (75 mg, 0.4 mmol) 
and HOBt (54 mg, 0.4 mmol) in DMF (1 mL) was treated with DIC (62 µL, 0.4 
mmol) and then stirred for 30 min before it was added to the thiol derivatized 
resin with additional DMF (1 mL) and the resulting mixture shaken for 3 h, after 
which the derivatized resin was washed with DMF (3 × 2 mL) and 
dichloromethane (3 × 2 mL). 
(d) TFA deprotection of Nα-Boc group. The derivatized resin was treated 
with TFA in dichloromethane (25%, 1.5 mL), and shaken for 30 min. The 
deprotection step was repeated with fresh TFA in dichloromethane (25%, 1.5 mL) 
for additional 30 min, after which the derivatized resin was washed thoroughly 
using dichloromethane (3 × 2 mL) and 5% solution of DIPEA in dichloromethane 
(2 × 2 mL).  
(e) The subsequent coupling and Nα-Boc deprotection steps were carried 
out as described in steps (c) and (d) respectively using an appropriate Boc-
protected amino acid. 
(f) Isolation of Boc-peptide thioacid form the derivatized resin. After the 
complete synthesis of peptide sequence, the Boc-peptide derivatized resin was 
transferred to a round bottom flask (25 mL) equipped with a magnetic stir bar. A 
solution of piperidine in DMF (20%, 10 mL) was added into the flask and the 
mixture was stirred for 20 min, after which the solid was filtered off and the 
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solution was diluted with EtOAc (20 mL). Then the organic layer was washed 
successively with 0.5 N aq HCl (2 × 10 mL), brine and dried. Evaporation of the 
solvent in a rotovapor afforded the peptide thioacid 171 (48 mg, 95%) as white 
amorphous solid that decomposed prior to melting. 1H NMR (500 MHz, CD3OD) 
δ: 4.56-4.52 (q, J = 7.0 Hz, 1H), 4.46-4.42 (q, J = 7.0 Hz, 1H), 4.28-4.27 (d, J = 
6.0 Hz, 1H), 2.57-2.51(m, 2H), 2.19-2.15 (q, J = 6.5 Hz, 1H), 2.09 (s, 3H), 2.06-
2.00 (m, 1H), 1.90-1.84 (m, 1H), 1.45 (s, 9H) 1.41-1.40 (d, J = 7.5 Hz, 3H), 1.37-
1.36 (d, J = 7.0 Hz, 3H), 1.01-1.00 (d, J = 6.5 Hz, 3H), 0.98-0.96 (d, J = 7.0 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ: 201.3, 172.9, 172.3, 171.7, 156.1, 80.5, 58.5, 
56.3, 53.7, 49.4, 32.1, 31.0, 30.2, 28.4, 19.4, 18.0, 17.5, 15.4; ESI-HRMS Calcd 
for C21H37N4O6S2 [M - H]- : 505.2155. Found: 505.2136. 
Synthesis of Boc-L-Met-L-Ala-L-Val-L-Ala-SH (171) employing HBTU 
and iPr2NEt activation method: 
  (a) Derivatization of aminomethyl polystyrene resin with N-[9-
(tritylthiomethyl)-9H-fluoren-2-yl]succinamic acid (147). In a 10 mL glass reaction 
vessel, aminomethyl polystyrene resin (244 mg, 0.1 mmol) was swelled in DMF 
(2 mL) for 30 min, after which the solvent was removed by filtration. To a stirred 
solution of 147 (114 mg, 0.2 mmol) and HBTU (75 mg, 0.2 mmol) in DMF (1 mL) 
was added DIPEA (50 µL, 0.3 mmol) at room temperature.  The reaction mixture 
was stirred for 20 min before the activated HOBt ester of 147 was added to the 
reaction vessel with an additional DMF (1 mL) which was then shaken for 2 h 
before the resin was washed thoroughly using DMF (3 × 2 mL) and DCM (3 × 2 
mL). 
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(b) Deprotection of trityl group from derivatized aminomethyl polystyrene 
resin. To the reaction vessel containing the derivatized resin was added 
DCM/TFA [v/v 1:1, 1.5 mL, with Et3SiH (65 µL, 0.4 mmol)].  After shaking for 1 h 
the thiol derivatized resin was washed thoroughly using DCM (3 × 2 mL) and a 
5% solution of DIPEA in DCM (2 × 2 mL).  
(c) Coupling reaction. A stirred solution of Boc-Ala-OH (75 mg, 0.4 mmol) 
and HBTU (150 mg, 0.4 mmol) in DMF (1 mL) was treated with DIPEA (100 µL, 
0.6 mmol) and then stirred for 20 min before it was added to the thiol derivatized 
resin with additional DMF (1 mL) and the resulting mixture shaken for 3 h, after 
which the derivatized resin was washed with DMF (3 × 2 mL) and DCM (3 × 2 
mL). 
(d) TFA deprotection of Nα-Boc group. The derivatized resin was treated 
with TFA in DCM (25%, 1.5 mL), and shaken for 30 min. The deprotection step 
was repeated with fresh TFA in DCM (25%, 1.5 mL) for additional 30 min, after 
which the derivatized resin was washed thoroughly using DCM (3 × 2 mL) and 
5% solution of DIPEA in DCM (2 × 2 mL).  
(e) The subsequent coupling and Nα-Boc deprotection steps were carried 
out as described in steps (c) and (d) respectively using an appropriate Boc-
protected amino acid. 
(f) Isolation of Boc-peptide thioacid form the derivatized resin. After the 
complete synthesis of peptide sequence, the Boc-peptide derivatized resin was 
transferred to a round bottom flask (25 mL) equipped with a magnetic stir bar. A 
solution of piperidine in DMF (20%, 10 mL) was added into the flask and the 
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mixture was stirred for 20 min, after which the solid was filtered off and the 
solution was diluted with EtOAc (20 mL). Then the organic layer was washed 
successively with 0.5 N aq HCl (2 × 10 mL), brine and dried. Evaporation of the 
solvent in a rotovapor afforded the peptide thioacid 171 (45 mg, 88%). 
Alloc-His-Ala-Glu(OAll)-Gly-Thr-Phe-Thr-Ser-Asp(OAll)-Val-SH (172): 
Following the same procedure as for the synthesis of Boc-Met-Ala-Val-Ala-SH 
(171), Alloc-peptide derivatized resin (substitution level of Alloc-peptide 
derivatized resin = 0.2161 mmol/g ) was synthesized.  After the complete 
synthesis of peptide sequence, the Boc-peptide derivatized resin (150 mg, 
0.0324 mmol) was transferred to a round bottom flask (10 mL) equipped with a 
magnetic stir bar. A solution of piperidine in DMF (20%, 3 mL) was added into the 
flask and the reaction mixture was stirred for 20 min, after which the solid was 
filtered off and the solvent was removed at room temperature under vacuum. The 
residue was washed with dichloromethane (2 × 2 mL) to removed the N-[(9H-
fluoren-9-yl)methyl]piperidine by-product from the crude peptide thioacid, which 
was subsequently dissolved in acetonitrile/water (v/v 1:1, 3 mL) and subjected to 
RP-HPLC purification (20 - 50% A in B with a flow rate of  8 mL/min over 60 min 
and 215 nm UV detection, retention time = 17 min) to afford the peptide thioacid 
172 (37 mg, 80%) as white amorphous solid that decomposed prior to melting. 
Boc-Ser-Ser-Tyr-Leu-Glu(OAll)-Gly-Gln-Ala-Ala-Lys(Alloc)-SH (173): 
Following the same procedure as for the synthesis of Boc-Met-Ala-Val-Ala-SH 
(171), Boc-peptide derivatized resin (substitution level of Boc-peptide derivatized 
resin = 0.2137 mmol/g ) was synthesized.  Following the same procedure as for 
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the isolation of 172, and RP-HPLC purification of crude mixture (20- 50% A in B 
with a flow rate of 8 mL/min over 60 min and 215 nm UV detection, retention time 
= 18 min) of Boc-peptide derivatized resin (150 mg, 0.0321 mmol) provided the 
peptide thioacid 173 (32 mg, 78%) as white amorphous solid that decomposed 
prior to melting. 
Boc-Ala-Ala-Thr-Cys-Phe-Ala-Arg-Asn-SH   (174) and 
 Following the same procedure as 
for the synthesis of Boc-Met-Ala-Val-Ala-SH (171), a Boc-peptide derivatized 
resin (substitution level of Boc-peptide derivatized resin = 0.2208 mmol/g) was 
synthesized with the following modification of Nα-Boc deprotection step.  After the 
cysteine was attached in the sequence, Et3SiH (0.5%) was added to the solution 
of 25% TFA in dichloromethane during all Nα-Boc deprotection steps.  After the 
complete synthesis of peptide sequence, the Boc-peptide derivatized resin (50 
mg, 0.011 mmol) was transferred to a round bottom flask (10 mL) equipped with 
a magnetic stir bar. A solution of piperidine in acetonitrile (50%, 0.5 mL) was 
added into the flask and the reaction mixture was stirred for 30 min, after which 
the solid was filtered off. RP-HPLC purification of the filtrate (0- 50% A in B with a 
flow rate of 8 mL/min over 72 min and 215 nm UV detection, retention time = 38 
min and 41 min) provided the Boc-peptide thioacid 174 (6 mg, 57%) as a white 
amorphous solid that decomposed prior to melting and the disulfide Boc-peptide 
thioacid 175 (1 mg, 15%) also as a white amorphous solid that decomposed prior 
to melting, respectively. 
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Boc-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val8-Leu-Thr-
Lys-Ala-Lys-Ser-Gln-SH (176): Following the same procedure as for the 
synthesis of Boc-Met-Ala-Val-Ala-SH (171), a Boc-peptide derivatized resin 
(substitution level of Boc-peptide derivatized resin = 0.141 mmol/g) was 
synthesized with the following modification on Nα-Boc deprotection and in 
coupling steps.  After Nα-Boc deprotection from 8th aminoacid in the sequence, 
neutralization of TFA from solid was done with a 5% solution of DIPEA in NMP 
solvent and also NMP was used as coupling solvent. These modifications were 
followed till up to end of synthesis.  After the complete synthesis of peptide 
sequence, the Boc-peptide derivatized resin (50 mg, 0.0071 mmol) was 
transferred to a round bottom flask (10 mL) equipped with a magnetic stir bar. A 
solution of piperidine in acetonitrile (50%, 0.5 mL) was added into the flask and 
the reaction mixture was stirred for 30 min. Then water (1 mL) was added in to 
the reaction mixture, which was subsequently stirred for 1 h before the solids 
which included the insoluble by-product N-[(9H-fluoren-9-yl)methyl]piperidine and 
the resin were filtered off. RP-HPLC purification of the filtrate (0- 50% A in B with 
a flow rate of 8 mL/min over 60 min and 215 nm UV detection, retention time = 
20 min) provided the Boc-peptide thioacid 176 (9 mg, 55%) as white amorphous 
solid that decomposed prior to melting. 
Alloc-His-Ala-Glu(OAll)-Gly-Thr-Phe-Thr-Ser-Asp(OAll)-Val-SBn (179): 
To a stirred solution of 172 (12 mg, 0.0097 mmol) in DMF (50 µL) were added 
successively a solution of 2,4,6-collidine/DMF (v/v 15:85, 10 µL, 0.012 mmol) and 
benzyl bromide (6 µL, 0.048 mmol) at room temperature. The reaction mixture 
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was stirred for 30 min, after which the solvent was removed at room temperature 
under vacuum. The crude solid was washed with dichloromethane (2 × 2 mL). 
The crude peptide thioester was dissolved in acetonitrile/water (v/v 1:1, 1 mL) 
and RP-HPLC purification (0- 50% A in B with a flow rate of 8 mL/min over 60 
min and 215 nm UV detection, retention time = 29 min) provided the peptide 
thioester 179 (12 mg, 92%) as a white amorphous solid that decomposed prior to 
melting. 
Boc-Ser-Ser-Tyr-Leu-Glu(OAll)-Gly-Gln-Ala-Ala-Lys(Allo)-SBn (180): 
Following the same procedure as for the synthesis of 179, using Boc-peptide 
thioacid 173 and RP-HPLC purification of crude mixture (0- 50% A in B with a 
flow rate of 8 mL/min over 60 min and 215 nm UV detection, retention time = 34 
min) provided the peptide thioester 180 in 86% yield. 
Alloc-His-Ala-Glu(OAll)-Gly-Thr-Phe-Thr-Ser-Asp(OAll)-Val-NHSO2-
C6H4-NHAc (181): To a stirred solution of 172 (12 mg, 0.0097 mmol) in a mixture 
of DMF/MeOH (v/v 4:1, 125 µL) was added a solution of 2,4,6-collidine/DMF (v/v 
15:85, 10 µL, 0.0116 mmol) followed by stirring for 5 min. 4-
Acetamidobenzenesulfonyl azide (4 mg, 0.015 mmol) then was added at room 
temperature and the reaction mixture stirred for 1 h, after which the solvent was 
removed at room temperature under vacuum. The crude residue was washed 
with dichloromethane (2 × 2 mL), then crude peptide thioester was dissolved in 
acetonitrile/water (v/v 1:1, 1 mL) and RP-HPLC purification of crude mixture (0- 
50% A in B with a flow rate of 8 mL/min over 60 min and 215 nm UV detection, 
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retention time = 26 min) provided 181 (11 mg, 80%) as white amorphous solid 
that decomposed prior to melting. 
3-Methylthietan-2-one (185), 3-benzylthietan-2-one (199) and thietan-
2-one (200) were prepared according to the literature protocols and had spectra 
data consistent with that given in the literature.241  
Methyl 1-iodomethylcyclohexane carboxylate (202): Prepared 
according to the literature procedure,248 from methyl cyclohexane carboxylate in 
65% yield. Light brown liquid; 1H NMR (500 MHz) δ: 3.72 (s, 3H), 3.32 (s, 2H), 
2.14-2.11 (m, 2H), 1.60-1.28 (m, 8H); 13C NMR (125 MHz) δ: 174.7, 52.3, 47.7, 
34.5, 25.8, 23.2, 15.9; ESI-HRMS Calcd for C9H15O2I [M + Na]+ : 305.0015. 
Found: 305.0031. 
Methyl 1-acetylsulfanylmethylcyclohexane carboxylate (203): 
Prepared according to the literature Procedure,248 from methyl 1-
iodomethylcyclohexane carboxylate in 98% yield.  Brown syrup; 1H NMR (500 
MHz) δ: 3.67 (s, 3H), 3.13 (s, 2H), 2.32 (s, 3H), 2.03-1.59 (m, 2H), 1.59-1.57 (m, 
2H), 1.53-1.50 (m, 1H), 1.39-1.28 (m, 5H); 13C NMR (125 MHz) δ: 195.2, 175.8, 
52.1, 47.5, 37.4, 33.4, 30.8, 25.7, 23.0; ESI-HRMS Calcd for C11H18O3S [M + 
Na]+ : 253.0874. Found: 253.0888. 
2-Thiaspiro[3.5]nonan-1-one (204): Methyl 1-
acetylsulfanylmethylcyclohexane carboxylate (3.92 g, 17 mmol) was dissolved in 
22 mL of Claisen’s alkali (6.25 mol/L KOH in a mixture of CH3OH and H2O (v/v: 
3/1)) and heated to reflux for 3 h, and then cooled to 0 °C. The reaction mixture 
was acidified with 1 N HCl to pH = 1, dichloromethane was added and the 
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organic layer was extracted, washed with water, and brine, and dried. 
Evaporation of the solvent, afforded crude 1-(mercaptomethyl) cyclohexane 
carboxylic acid, which was taken forward for cyclization without purification. 
To a stirred solution of the crude 1-(mercaptomethyl) cyclohexane 
carboxylic acid (2.8 g, 16.1 mmol) and triethylamine (2.6 mL, 17.6 mmol) in 
dichloromethane (70 mL) at -10 °C was added dropwise iso-butyl chloroformate 
(2.4 mL, 17.6 mmol). After the addition was complete, the reaction mixture was 
allowed to come 0 °C over a period of 45 min. The resulting mixture was 
neutralized at 0 °C, with 1 N HCl to pH ~ 4 and the organic layer was extracted, 
dried and concentrated. Chromatographic purification using 2% ethyl acetate in 
hexane afforded 204 (1.08 g, 43%). Colorless liquid; IR (CHCl3) 2931, 2854, 
1771, 1745 cm-1; 1H NMR (500 MHz) δ: 2.81 (s, 2H), 1.88-1.79 (m, 4H), 1.74-1.70 
(m, 2H), 1.52-1.50 (m, 1H), 1.41-1.30 (m, 1H); 13C NMR (125 MHz) δ: 199.2, 
77.1, 32.9, 29.5, 25.0, 22.2; EI-HRMS Calcd for C8H12OS.[M.] : 156.0609. Found: 
156.0615. 
(S)-O-(tert-Butyl) N-(2-oxothietan-3-yl) carbamate (205): Following the 
same procedure as for the preparation of 2-thiaspiro[3.5]nonan-1-one, using N-
tert-butoxycarbonyl-L-cysteine as substrate, and eluting with 20% ethyl acetate in 
hexane, 205 was obtained in 38% yield. White solid, crystallized from ethyl 
acetate/hexane, Mp: 140.5-141.5 °C. [α]22D -40.3 (c 1.2); IR (CHCl3) 3352, 2927, 
1747, 1716, 1682 cm-1; 1H NMR (500 MHz) δ: 5.44 (s, 1H), 5.35 (bs, 1H), 3.44-
3.41 (t, J = 7.5 Hz, 1H), 3.34-3.31 (t, J = 7.5 Hz), 1.46 (s, 9H); 13C NMR (125 
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MHz) δ: 193.7, 154.4, 81.4, 72.5, 28.4; ESI-HRMS Calcd for C8H13NO3S [M + 
Na]+ : 226.0514. Found: 226.0502. 
NMR investigation of 205 with a chiral shift reagent: A stock solution of 
DL-O-(tert-butyl) N-(2-oxothietan-3-yl) carbamate (9 mg, 0.044 mmol) in CDCl3 
(150 µL) was prepared. 50 µL of the stock solution was introduced into an NMR 
tube (5 mm i.d.) and diluted with CDCl3 (700 µL), and the 1H NMR spectrum of 
the sample was recorded at 500 MHz. A stock solution of tris[3-
(heptafluoropropylhydroxymethylene)-(+)-camphorato], europium(III) [Eu(hfc)3] 
(26 mg, 0.22 mmol) was prepared in CDCl3 (75 µL). Then a 5 µL (~0.1 equiv) 
increments of the Eu(hfc)3 solution were added to the NMR tube and the 1H NMR 
spectrum recorded after each addition. The same procedure was repeated for 
the L-isomer of the carbamate. 
General procedure 5. Multi-component coupling reactions using 3-
methylthietan-2-one (185), 3-benzylthietan-2-one (199) and thietan-2-one 
(200), and Mukaiyama’s reagent: To a stirred solution of 3-substituted-thietan-
2-one (185, 199 or 200) (1.0 equiv) in DMF (c = 0.15 – 0.2M) were added 
aromatic thiol (1.5 equiv) and Cs2CO3 (1.0 equiv) at room temperature. The 
reaction mixture was allowed to stir for ~2 h, after which time the color of the 
reaction had turned a faint yellow. Then 2-chloro-1-methylpyridinium iodide (1.5 
equiv) was added, followed immediately by 0.9 equiv of amine. Upon addition of 
2-chloro-1-methylpyridinium iodide and amine the reaction became a dark yellow 
color and further deepened in color as the reaction continued. The reaction 
mixture was allowed to stir ~5 h, after which the DMF was removed under high 
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vacuum and the crude mixture was dissolved in EtOAc and washed with water, 
brine and dried.  Evaporation of solvent, followed by column chromatography 
provided the products as described below. 
General procedure 6. Multi-component coupling reactions using 3-
methylthietan-2-one (185), 3-benzylthietan-2-one (199) and thietan-2-one 
(200) and Sanger’s reagent: To a stirred solution of 3-substituted-thietan-2-one 
(185, 199 or 200) (1.0 equiv) in DMF (c = 0.15 – 0.2M) were added thiol (1.5 
equiv) and Cs2CO3 (1.0 equiv) at room temperature. The reaction was allowed to 
stir for ~2 h, after which time the color of the reaction had turned a faint yellow. 
Then 1-fluoro-2,4-dinitrobenzene (1.5 equiv) was added followed immediately by 
0.9 equiv of amines. Upon addition of 2,4-dinitrofluorobenzene and amine the 
reaction became a dark red color and further deepened in color as the reaction 
continued. The reaction mixture was allowed to stir ~2 h, after which the DMF 
was removed under high vacuum and the crude mixture was dissolved in EtOAc 
and washed with water, brine and dried. Evaporation of solvent, followed by 
column chromatography provided the coupled products as described below. 
N-Phenethyl-3-(phenylthio)propanamide (209): Following general 
procedure 5, using thietan-2-one and eluting with 30% ethyl acetate in hexane, 
209 was obtained in 66% yield.  White solid, crystallized from chloroform/hexane, 
Mp: 74.5-75.0 °C. 1H NMR (300 MHz) δ: 7.34-7.16 (m, 10H), 5.63 (s, 1H), 3.54-
3.48 (q, J  = 6.6 Hz, 2H), 3.21-3.16 (t, J = 7.5 Hz, 2H), 2.83-2.78 (t, J = 6.6, 2H), 
2.43-2.39 (t, J = 7.5 Hz, 2H); 13C NMR (75 MHz) δ: 171.0, 139.0, 135.6, 129.8, 
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129.3, 129.0, 128.9, 126.8, 126.6, 40.9, 36.4, 35.8, 29.6; ESI-HRMS Calcd for 
C17H19NOS [M + Na]+ : 308.1085. Found: 308.1078. 
3-(4-Chlorophenylthio)-N-phenethylpropanamide (210): Following 
general procedure 5, using thietan-2-one and eluting with 32% ethyl acetate in 
hexane, 210 was obtained in 67% yield. White solid, crystallized from 
chloroform/hexane, Mp: 78.8-79.5 °C. 1H NMR (300 MHz) δ: 7.33-7.17 (m, 9H), 
5.62 (s, 1H), 3.54-3.48 (q, J  = 6.6 Hz, 2H), 3.18-3.13 (t, J = 7.2 Hz, 2H), 2.83-
2.78 (t, J = 6.6, 2H), 2.41-2.37 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz) δ: 170.9, 
138.9, 134.2, 132.6, 131.1, 129.4, 129.0, 128.9, 126.8, 40.9, 36.2, 35.8, 29.8; 
ESI-HRMS Calcd for C17H18NOSCl [M + Na]+ : 342.0695. Found: 342.0680. 
Methyl 2-(3-oxo-3-(phenethylamino)propylthio)benzoate (211): 
Following general procedure 5, using thietan-2-one and eluting with 40% ethyl 
acetate in hexane, 211 was obtained in 56% yield. Light yellow syrup; 1H NMR 
(300 MHz) δ: 7.95-7.92 (dd, J = 1.8, 8.0 Hz, 1H), 7.47-7.40 (m, 1H), 7.36-7.29 
(m, 4H), 7.26-7.14 (m, 3H), 5.79 (s, 1H), 3.88 (s, 3H), 3.54-3.47 (q, J  = 6.6 Hz, 
2H), 3.24-3.19 (t, J = 7.2 Hz, 2H), 2.82-2.78 (t, J = 6.6, 2H), 2.52-2.47 (t, J = 7.2 
Hz, 2H); 13C NMR (75 MHz) δ: 171.1, 167.2, 140.8, 139.0, 132.7, 131.5, 129.0, 
128.9, 128.2, 126.8, 126.2, 124.5, 52.4, 41.0, 35.8, 35.5, 28.0; ESI-HRMS Calcd 
for C19H21NO3S [M + Na]+ : 366.1140. Found: 366.1145. 
N-3-(4-Chlorophenylthio)propanoyl piperidine (212): Following general 
procedure 5, using thietan-2-one and eluting with 40% ethyl acetate in hexane, 
212 was obtained in 59% yield. Colorless syrup; 1H NMR (500 MHz) δ: 7.30-7.25 
(m, 4H), 3.56-3.54 (t, J  = 5.5 Hz, 2H), 3.34-3.32 (t, J = 5.5 Hz, 2H), 3.24-3.21 (t, 
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J = 7.5 Hz, 2H), 2.64-2.61 (t, J = 7.5 Hz, 2H), 1.67-1.62 (m, 2H), 1.56-1.53 (m, 
4H); 13C NMR (125 MHz) δ: 169.2, 134.9, 132.2, 130.6, 129.3, 46.7, 43.1, 33.1, 
29.5, 26.7, 25.7, 24.7; ESI-HRMS Calcd for C14H18NOSCl [M + Na]+ : 306.0695. 
Found: 306.0694. 
Methyl N-(3-(phenylthio)-propanoyl)-L-phenylalaninate (213): 
Following general procedure 5, using thietan-2-one and eluting with 30% ethyl 
acetate in hexane, 213 was obtained in 61% yield. Colorless syrup; [α]23D +59.2 
(c 0.6); 1H NMR (500 MHz) δ: 7.35-7.20 (m, 8H), 7.11-7.09 (d, J = 6.5 Hz, 2H), 
6.00 (s, 1H), 4.93-4.89 (q, J  = 6.0 Hz, 1H), 3.74 (s, 3H), 3.20-3.15 (m, 3H), 3.13-
3.09 (dd, J = 5.5, 13.8 Hz, 1H), 2.54-2.46 (m, 2H); 13C NMR (125 MHz) δ: 172.1, 
170.6, 135.9, 135.4, 130.1, 129.5, 129.3, 128.8, 127.4, 126.7, 53.3, 52.6, 38.1, 
36.2, 29.5; ESI-HRMS Calcd for C19H21NO3S [M + Na]+ : 366.1140. Found: 
366.1133. 
3-(4-Chlorophenylthio)-2-methyl-N-phenethylpropanamide (214): 
Following general procedure 6, using 3-methylthietan-2-one and eluting with 25% 
ethyl acetate in hexane, 214 was obtained in 67% yield. White solid, crystallized 
from chloroform/hexane, Mp: 93.0-94.0 °C. 1H NMR (500 MHz) δ: 7.33-7.30 (t, J 
= 7.5 Hz, 2H), 7.27-7.19 (m, 7H), 5.47 (s, 1H), 3.58-3.48 (m, 2H), 3.23-3.18 (dd, J 
= 8.0, 13.5 Hz, 1H), 2.92-2.88 (dd, J = 6.5, 13.5 Hz, 1H), 2.84-2.81 (t, J = 6.5 Hz, 
2H), 2.33-2.26 (m, 1H), 1.22-1.20 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ: 
174.4, 139.0, 134.8, 132.4, 130.9, 129.4, 129.1, 128.9, 126.8, 41.5, 40.7, 37.8, 
35.8, 17.9; ESI-HRMS Calcd for C18H20NOSCl [M + Na]+ : 356.0852. Found: 
356.0859. 
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N-3-(4-Chlorophenylthio)-2-methylpropanoyl piperidine (215):  
Following general procedure 6, using 3-methylthietan-2-one and eluting with 25% 
ethyl acetate in hexane, 215 was obtained in 58% yield. White solid, crystallized 
from chloroform/hexane, Mp: 49.3-50.0 °C. 1H NMR (500 MHz) δ: 7.29-7.25 (m, 
4H), 3.61-3.53 (m, 2H), 3.34-3.29 (m, 3H), 2.95-2.91 (m, 2H), 1.66-1.61 (m, 2H), 
1.57-1.50 (m, 4H), 1.23-1.22 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz) δ: 173.0, 
135.3, 132.3, 130.9, 129.3, 46.9, 43.3, 38.2, 35.8, 27.0, 25.9, 24.8, 17.9; ESI-
HRMS Calcd for C15H20NOSCl [M + Na]+ : 320.0852. Found: 320.0839. 
2-Benzyl-N-phenethyl-3-(phenylthio)propanamide (216): Following 
general procedure 5, using 3-benzylthietan-2-one and eluting with 20% ethyl 
acetate in hexane, 216 was obtained in 64% yield. White solid, crystallized from 
chloroform/hexane, Mp: 78.1-78.7 °C. 1H NMR (500 MHz) δ: 7.30-7.16 (m, 11H), 
7.14-7.12 (d, J = 7.5 Hz, 2H), 7.03-7.02 (d, J = 7.0 Hz, 2H), 5.23 (s, 1H), 3.46-
3.34 (m, 2H), 3.25-3.21 (dd, J = 9.0, 13.3 Hz, 1H), 3.08-3.04 (dd, J = 5.0, 13.8 
Hz, 1H), 2.99-2.95 (dd, J = 9.0, 13.3 Hz, 1H), 2.92-2.88 (dd, J = 6.5, 13.5 Hz, 
1H), 2.72-2.67 (m, 1H), 2.60-2.55 (m, 1H), 2.41-2.36 (m, 1H); 13C NMR (125 
MHz) δ: 173.1, 139.2, 139.1, 136.0, 129.3, 129.2, 129.0, 128.8, 128.7, 126.8, 
126.6, 126.4, 50.0, 40.7, 38.8, 35.8, 35.6; ESI-HRMS Calcd for C24H25NOS [M + 
Na]+ : 398.1555. Found: 398.1549. 
2-Benzyl-3-(4-chlorophenylthio)-N-phenethylpropanamide (217):  
Following general procedure 5, using 3-benzylthietan-2-one and eluting with 20% 
ethyl acetate in hexane, 217 was obtained in 68% yield. White solid, crystallized 
from chloroform/hexane, Mp: 119.8-120.4 °C. 1H NMR (500 MHz) δ: 7.31-7.20 
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(m, 8H), 7.13-7.10 (t, J = 8.5 Hz, 4H), 7.03-7.02 (d, J = 7.0 Hz, 2H), 5.22 (s, 1H), 
3.46-3.34 (m, 2H), 3.24-3.19 (dd, J = 9.0, 13.3 Hz, 1H), 3.03-3.00 (dd, J = 5.0, 
13.8 Hz, 1H), 2.98-2.93 (dd, J = 9.0, 13.3 Hz, 1H), 2.89-2.85 (dd, J = 6.5, 13.5 
Hz, 1H), 2.73-2.68 (m, 1H), 2.60-2.55 (m, 1H), 2.38-2.31 (m, 1H); 13C NMR (125 
MHz) δ: 173.0, 139.1, 139.0, 134.5, 132.3, 130.6, 129.4, 129.3, 129.2, 129.0, 
128.8, 126.9, 126.7, 50.0, 40.7, 38.8, 35.8, 35.7; ESI-HRMS Calcd for 
C24H24NOSCl [M + Na]+ : 432.1165. Found: 432.1167. 
N-[2-Benzyl-3-(4-chlorophenylthio)]propanoyl piperidine (218):  
Following general procedure 6, using 3-benzylthietan-2-one and eluting with 20% 
ethyl acetate in hexane, 218 was obtained in 59% yield. White solid, crystallized 
from chloroform/hexane, Mp: 89.0-90.0 °C. 1H NMR (500 MHz) δ: 7.29-7.26 (m, 
2H), 7.23-7.20 (m, 3H), 7.18-7.13 (m, 4H), 3.60-3.56 (m, 1H), 3.39-3.35 (m, 1H), 
3.35-3.31 (dd, J = 8.5, 13.3 Hz, 1H), 3.17-3.12 (m, 1H), 3.07-2.99 (m, 2H), 2.97-
2.92 (m, 2H), 2.89-2.85 (dd, J = 6.5, 13 Hz, 1H), 1.49-1.43 (m, 4H), 1.36-1.26 (m, 
2H); 13C NMR (125 MHz) δ: 171.6, 139.1, 135.0, 132.1, 130.4, 129.3, 129.2, 
128.7, 126.8, 46.9, 43.3, 43.2, 39.5, 36.4, 26.3, 25.8, 24.6; ESI-HRMS Calcd for 
C21H24NOSCl [M + Na]+ : 396.1165. Found: 396.1159. 
N-[2-Benzyl-3-(pyridine-2-ylthio)] propanoyl piperidine (220): 
Following general procedure 6, using 3-benzylthietan-2-one and eluting with 25% 
ethyl acetate in hexane, 220 was obtained in 57% yield.  White solid, crystallized 
from chloroform/hexane, Mp: 73.0-74.0 °C. 1H NMR (500 MHz) δ: 8.41-8.40 (m, 
1H), 7.48-7.45 (m, 1H), 7.27-7.15 (m, 6H), 6.99-6.96 (m, 1H), 3.59-3.55 (m, 1H), 
3.49-3.38 (m, 4H), 3.13-3.08 (m, 1H), 3.07-2.97 (m, 3H), 1.49-1.41 (m, 4H), 1.26-
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1.21 (m, 2H); 13C NMR (125 MHz) δ: 172.3, 159.1, 149.6, 139.8, 136.1, 129.3, 
128.5, 126.5, 122.5, 119.6, 46.9, 43.3, 43.2, 39.3, 33.3, 26.3, 25.9, 24.7; ESI-
HRMS Calcd for C20H24N2OS [M + Na]+ : 363.1507. Found: 363.1497. 
General procedure 7. Multi-component coupling reaction using (S)-O-
(tert-butyl) N-(2-oxothietan-3-yl) carbamate (205): To a stirred solution of 205 
(1.0 equiv) in DMF (c = 0.15 - 0.2M) were added aromatic thiol (1.2 equiv) and 
Cs2CO3 (1.0 equiv) at room temperature. The reaction mixture was allowed to stir 
for ~6 h, after which time the color of the reaction had turned a faint yellow. Then 
2,4-dinitobenbenzene sulfonamide of amine (1.2 equiv) was added to the 
reaction mixture. Upon addition of sulfonamide the reaction became a dark red, 
and further deepened in color as the reaction continued. The reaction mixture 
was allowed to stir ~1 h, after which the DMF was removed under high vacuum 
and the crude mixture was dissolved in EtOAc and washed with water, brine and 
dried. Evaporation of solvent, followed by column chromatography provided the 
coupled products as described below. 
(R)-O-(tert-Butyl) N-(3-(4-chlorophenylthio)-1-
(phenethylaminocarbonyl)propan-2-yl) carbamate (221): Following general 
procedure 7, eluting with 30% ethyl acetate in hexane, 221 was obtained in 70% 
yield. White solid, crystallized from ethyl acetate/hexane, Mp: 116.5-117.5 °C.  
[α]22D -6.0 (c 1.2); 1H NMR (500 MHz) δ: 7.32-7.22 (m, 7H), 7.19-7.17 (d, J = 7.0 
Hz, 2H), 6.25 (s, 1H), 5.25 (s, 1H), 4.20 (bs, 1H), 3.55-3.40 (m, 2H), 3.26-3.21 
(m, 2H), 2.80-2.77 (t, J = 7.0 Hz, 2H), 1.43 (s, 9H); 13C NMR (125 MHz) δ: 170.2, 
155.5, 138.7, 133.5, 133.0, 131.4, 129.5, 129.0, 128.9, 126.9, 80.7, 54.1, 41.0, 
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36.5, 35.7, 28.5;  ESI-HRMS Calcd for C22H27N2O3SCl [M + Na]+ : 457.1329. 
Found: 457.1313. 
2,4-Dinitro-N-phenethylbenzenesulfonamide (222) was prepared 
according to the literature protocols and had spectra data consistent with that 
given in the literature.281  
(R)-O-(tert-Butyl) N-3-(pyridin-2-ylthio)-1-
(phenethylaminocarbonyl)propan-2-yl) carbamate (223): Following general 
procedure 7, eluting with 30% ethyl acetate in hexane, 223 was obtained in 61% 
yield. White solid, crystallized from chloroform/hexane, Mp: 97.0-97.5 °C. [α]22D -
4.7 (c 0.9); 1H NMR (500 MHz) δ: 8.31 (s, 1H), 7.54-7.50 (m, 1H), 7.29-7.19 (m, 
6H), 7.06-7.03 (t, J = 6.0 Hz, 1H), 6.92 (s, 1H), 6.74 (s, 1H), 4.39 (b, 1H), 3.56-
3.52 (m, 4H), 2.83-2.80 (t, J = 7.0 Hz, 2H), 1.40 (s, 9H); 13C NMR (125 MHz) δ: 
171.0, 158.8, 156.7, 149.2, 139.1, 136.7, 129.0, 128.8, 126.7, 123.1, 120.3, 80.0, 
56.5, 40.9, 36.0, 33.2, 28.5; ESI-HRMS Calcd for C21H27N3O3S [M + Na]+ : 
424.1671. Found: 424.1673. 
N-(4-Bromophenyl)-2,4-dinitrobenzenesulfonamide (224): To a 
solution of 4-bromoaniline (500 mg, 2.9 mmol) and 2,4-dinitrophenylsulfonyl 
chloride (930 mg, 3.5 mmol) in methylene chloride (3 mL) was added pyridine 
(350 µL, 4.4 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 
15 min. and 4 h at room temperature. Then the organic layer was washed with 
1M HCl, water, brine, dried and concentrated. Chromatographic purification using 
20% ethyl acetate in hexane as eluent afforded 224 (680 mg, 58%). Brown solid, 
crystallized from ethyl acetate/hexane, mp: 143.7-144.4 °C. 1H NMR (500 MHz) 
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δ: 8.69-8.68 (d, J = 2.0 Hz, 1H), 8.44-8.42 (dd, J = 2.0, 8.8 Hz, 1H), 8.07-8.06 (d, 
J = 8.8 Hz, 1H), 7.45-7.43 (d, J = 8.8 Hz, 2H), 7.29 (s, 1H), 7.12-7.10 (d, J = 9.0 
Hz); 13C NMR (125 MHz) δ:150.4, 148.7, 137.5, 133.8, 133.7, 133.2, 127.2, 
125.3, 121.2, 121.0; ESI-HRMS Calcd for C12H7N3O6SBr [M - H]- : 399.9239. 
Found: 399.9243. 
(R)-O-(tert-Butyl) N-3-(phenylthio)-1-(4-
bromophenylaminocarbonyl)propan-2-yl) carbamate (225): Following general 
procedure 7, eluting with 20% ethyl acetate in hexane, 225 was obtained in 57% 
yield. White solid, crystallized from chloroform/hexane, Mp: 128.0-129.0 °C.  
[α]22D -3.5 (c 0.95); 1H NMR (500 MHz) δ: 8.31 (s, 1H), 7.43-7.41 (m, 4H), 7.36-
7.35 (d, J = 9.0 Hz, 2H), 7.32-7.29 (t, J = 7.5 Hz, 2H), 7.24-7.21 (t, J = 7.5 Hz, 
1H), 5.34-5.33 (d, J = 7.5 Hz, 1H), 4.35-4.33 (d, J = 6.5 Hz, 1H), 3.43-3.33 (m, 
2H), 1.46 (s, 9H); 13C NMR (125 MHz) δ: 168.8, 156.0, 136.6, 134.4, 132.2, 
130.6, 129.5, 127.4, 121.7, 117.4, 81.4, 54.9, 36.0, 28.5; ESI-HRMS Calcd for 
C20H23N2O3SBr [M + Na]+ : 473.0510. Found: 473.0500. 
N-tert-Butoxycarbonyl-(4-chlorophenylsulfanyl)-L-alaninyl-L-
phenylalanine methyl ester (226): Following general procedure 7, eluting with 
25% ethyl acetate in hexane, 226 was obtained in 62% yield. Colorless syrup; 
[α]22D +15.6 (c 1.1); 1H NMR (500 MHz) δ: 7.33-7.25 (m, 7H), 7.10-7.08 (d, J = 7.0 
Hz, 2H), 6.67-6.65 (d, J = 7.5 Hz, 1H), 5.18 (s, 1H), 4.79-4.76 (q, J = 6.0 Hz, 1H), 
4.21 (s, 1H), 3.73 (s, 3H), 3.24 (bs, 2H), 3.16-3.12 (dd, J = 6.0, 13.8 Hz, 1H), 
3.10-3.06 (dd, J = 5.5, 13.5 Hz, 1H), 1.44 (s, 1H); 13C NMR (125 MHz) δ: 171.6, 
169.9, 155.4, 135.8, 133.4, 133.2, 131.8, 129.5, 128.8, 127.4, 80.8, 54.0, 53.6, 
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52.6, 38.1, 36.6, 28.5; ESI-HRMS Calcd for C24H29N2O5SCl [M + Na]+ : 515.1383. 
Found: 515.1371. 
(R)-O-(tert-Butyl) N-3-(4-chlorophenylthio)-1-(4-
acetamidophenylsulfonamido)propan-2-yl) carbamate (227): To a stirred 
solution of 205 (40 mg, 0.2 mmol) in DMF (1 mL) were added 4-chlorothiophenol 
(34 mg, 0.24 mmol) and Cs2CO3 (64 mg, 0.2 mmol) at room temperature. The 
reaction mixture was allowed to stir for ~6 h, after which time the color of the 
reaction had turned a faint yellow. 4-Acetamidobenzenesulfonyl azide (38 mg, 
0.16 mmol) was added to the reaction mixture. The reaction mixture was allowed 
to stir ~1 h, after which the DMF was removed under high vacuum and the crude 
mixture was purified by column chromatography using 5% methanol in 
dichloromethane to give 227 (57 mg, 68%). White solid, crystallized from ethyl 
acetate/hexane, Mp: 169.0-170.0 °C. [α]22D -13.1 (c 0.1, MeOH); 1H NMR (500 
MHz, MeOH – d4) δ: 7.92-7.90 (d, J = 8.5 Hz, 2H), 7.74-7.73 (d, J = 8.0 Hz, 2H), 
7.31-7.26 (m, 4H), 4.15 (bs, 1H), 3.23-3.19 (dd, J = 5.5, 13.5 Hz, 1H), 3.09-3.05 
(dd, J = 7.5, 13.0 Hz, 1H), 2.16 (s, 3H), 1.39 (s, 9H); 13C NMR (125 MHz, MeOH 
– d4) δ: 170.9, 156.1, 143.7, 134.3, 133.9, 132.5, 132.0, 131.5, 129.2, 129.1, 
129.0, 118.8, 79.8, 54.8, 35.5, 27.5, 22.9; ESI-HRMS Calcd for C22H26N3O6S2Cl 
[M + Na]+ : 550.0849. Found: 550.0826. 
1-[(2,4-Dinitrophenylsulfanyl)methyl]-N-phenethylcyclohexane 
carboxamide (228): To a stirred solution of 2-thiaspiro[3.5]nonan-1-one (204) 
(50 mg, 0.32 mmol) in DMF (2 mL) were added 4-chlorothiophenol (70 mg, 0.48 
mmol) and Cs2CO3 (104 mg, 0.32 mmol) at room temperature. The reaction 
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mixture was allowed to stir for 2 h before 2,4-dinitrofluorobenzene (90 mg, 0.48 
mmol) was added, followed immediately by 2-phenethylamine (36 µL, 0.29 
mmol). Upon addition of 2,4-dinitrofluorobenzene and 2-phenethylamine the 
reaction mixture became a dark red color. The reaction mixture was allowed to 
stir ~2 h, after which the DMF was removed under high vacuum and the crude 
mixture was dissolved in EtOAc and washed with water, brine and dried.  
Evaporation of solvent, followed by column chromatographic purification using 
30% ethyl acetate in hexane elutant afforded 228 (102 mg, 80%). Yellow solid, 
crystallized from ethyl acetate/hexane, Mp: 99.0-99.5 °C. 1H NMR (500 MHz) δ: 
9.03-9.02 (d, J = 2.0 Hz, 1H), 8.36-8.34 (dd, J = 2.5, 9.0 Hz, 1H), 7.65-7.63 (d, J 
= 9.0 Hz, 1H), 7.33-7.20 (m, 5H), 5.88 (s, 1H), 3.54-3.51 (q, 7.0 Hz, 2H), 3.23 (s, 
2H), 2.84-2.81 (t, J = 7.0 Hz, 2H), 2.01-1.98 (m, 2H), 1.65-1.58 (m, 6H), 1.37-
1.35 (m, 2H); 13C NMR (125 MHz) δ: 174.0, 146.7, 145.5, 144.1, 138.8, 129.0, 
128.9, 127.9, 127.2, 126.9, 121.7, 46.7, 42.0, 41.1, 35.6, 34.0, 25.7, 22.7; ESI-
HRMS Calcd for C22H25N3O5S [M + Na]+ : 466.1413. Found: 466.1409. 
2-Mercaptomethyl-3-phenylpropanoyl morpholine (229): To a stirred 
solution of 3-benzylthietan-2-one (45 mg, 0.25 mmol) in DMF (2 mL) was added 
morpholine (26 µL, 0.3 mmol) at room temperature. The reaction mixture was 
allowed to stir for ~4 h, after which the DMF was removed under high vacuum 
and the crude mixture was dissolved in EtOAc and washed with water, brine and 
dried. Evaporation of solvent, followed by column chromatographic purification 
using 30% ethyl acetate in hexane elutant afforded 229 (45 mg, 67%). Colorless 
syrup; 1H NMR (300 MHz) δ: 7.30-7.13 (m, 5H), 3.67-3.55 (m, 2H), 3.50-3.12 (m, 
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4H), 3.11-2.96 (m, 3H), 2.94-2.78 (m, 3H), 2.62-2.53 (m, 1H), 1.52-1.47 (t, J = 
8.1 Hz, 1H); 13C NMR (75 MHz) δ: 172.2, 138.9, 129.2, 128.8, 127.0, 67.0, 66.5, 
47.7, 46.3, 42.4, 39.7, 27.4; ESI-HRMS Calcd for C14H19NO2S [M + Na]+ : 
288.1034. Found: 288.1021. 
(2S)-1-Trityloxydecan-2-ol (236): To a stirred solution of (2S)-decane-
1,2-diol (300 mg, 1.7 mmol), trityl chloride (720 mg, 2.6 mmol), and DMAP (20 
mg, 0.17 mmol) in DMF (4 mL) was added Et3N (0.5 mL, 3.4 mmol) at room 
temperature. The reaction mixture was stirred at room temperature for 12 h. 
Then the reaction was quenched with water (5 mL) and extracted with ethyl 
acetate three times. The combined organic phase was washed with brine, dried 
and concentrated. Chromatographic purification using 5% ethyl acetate in 
hexanes afforded 236 (650 mg, 91%) as colorless syrup. [α]23D +5.5 (c 1.5); 1H 
NMR (500 MHz) δ 7.50-7.49 (t, J = 2.0 Hz, 6H), 7.36-7.33 (m, 6H), 7.30-7.26 (m, 
3H), 3.83-3.79 (m, 1H), 3.24-3.22 (dd, J = 3.5, 9.5 Hz, 1H), 3.10-3.06 (dd, J = 
3.5, 9.5 Hz, 1H), 2.39-2.38 (d, J = 3.5 Hz, 1H), 1.55-1.41 (m, 2H), 1.33-1.29 (m, 
12H) 0.94-0.91 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 144.2, 128.9, 128.1, 
127.3, 86.9, 71.3, 68.1, 33.6, 32.1, 29.9, 29.8, 29.5, 25.8, 22.9, 14.4; ESI-HRMS 
Calcd for C29H36O2 [M + Na]+ : 439.2613. Found: 439.2595. 
(2S)-2-Benzyloxy-1-trityloxydecane (237): To an ice-cooled solution of 
236 (213 mg, 0.51 mmol) in DMF (2 mL) was added sodium hydride (60%, 41 
mg, 1.02 mmol) under stirring. After 30 min, benzyl bromide (91 µL, 0.77 mmol) 
was added and stirring was continued at 0 °C for 1 h. The reaction mixture was 
concentrated, dissolved in ethyl acetate, and washed with saturated aqueous 
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NH4Cl. The aqueous phase was extracted with ethyl acetate three times, and the 
combined organic phase was washed with water and brine, dried and 
concentrated. Chromatographic purification using 2% ethyl acetate in hexanes 
afforded 237 (245 mg, 95%) as colorless syrup. [α]23D -27.8 (c 1.0); 1H NMR (500 
MHz) δ 7.52-7.51 (d, J = 7.5 Hz, 6H), 7.40-7.24 (m, 14H), 4.76-4.74 (d, J = 11.5 
Hz, 1H), 4.58-4.56 (d, J = 11.5 Hz, 1H), 3.59-3.56 (m, 1H), 3.27-3.24 (dd, J = 6.0, 
10.0 Hz, 1H), 3.19-3.16 (dd, J = 6.0, 10.0 Hz, 1H), 1.58-1.55 (m, 2H), 1.35-1.26 
(m, 12H) 0.93-0.90 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 144.5, 139.3, 
129.0, 128.5, 128.2, 128.1, 127.7, 127.2, 86.8, 78.8, 72.3, 66.4, 32.4, 32.1, 29.9, 
29.8, 29.5, 25.7, 22.9, 14.4; ESI-HRMS Calcd for C36H42O2 [M + Na]+ : 529.3083. 
Found: 529.3078. 
(2S)-2-Benzyloxydecan-1-ol (238): To a stirred solution of 237 (245 mg, 
0.48 mmol) and Et3SiH (156 µL, 1.0 mmol) in CH2Cl2 (4 mL) at room temperature 
was added TFA (1 mL). The reaction mixture was stirred at same temperature for 
20 min before it was neutralized by saturated aqueous NaHCO3. Then the 
organic layer was washed with water and brine, dried, and concentrated. 
Chromatographic purification using 15% ethyl acetate in hexane afforded 238 
(125 mg, 98%) as colorless syrup. [α]24D +20.6 (c 1.7); 1H NMR (500 MHz) δ 
7.37-7.35 (t, J = 4.5 Hz, 4H), 7.31-7.30 (m, 1H), 4.65-4.63 (d, J = 11.5 Hz, 1H), 
4.57-4.55 (d, J = 11.5 Hz, 1H), 3.72-3.70 (d, J = 8.5 Hz, 1H), 3.57-3.51 (m, 2H), 
1.98 (br s, 1H), 1.67-1.62 (m, 1H), 1.53-1.48 (m, 1H), 1.37-1.28 (m, 12H) 0.91-
0.89 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 138.8, 128.7, 128.1, 128.0, 80.1, 
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71.7, 64.5, 32.1, 31.1, 30.1, 29.7, 29.5, 25.6, 22.9, 14.4; ESI-HRMS Calcd for 
C17H28O2 [M + Na]+ : 287.1987. Found: 287.1999. 
(2R)-1-Trityloxydecan-2-yl 4-nitrobenzoate (239): To a stirred solution 
of 236 (500 mg, 1.2 mmol), p-nitrobenzoic acid (600 mg, 3.6 mmol) and 
triphenylphosphine (945 mg, 3.6 mmol) in THF (12 mL) at 0 °C was added 
dropwise diisopropyl azodicarboxylate (700 µL, 3.6 mmol). After the addition was 
complete, the reaction mixture was stirred at room temperature for 12 h. The 
resulting mixture was concentrated and chromatographic purification of the crude 
using 5% ethyl acetate in hexanes afforded 239 (550 mg, 81%) as light yellow 
syrup. [α]23D +6.5 (c 1.0); 1H NMR (500 MHz) δ 8.34-8.33 (d, J = 9.0 Hz, 2H), 
8.28-8.26 (d, J = 9.0 Hz, 2H), 7.44-7.42 (m, 6H), 7.28-7.23 (m, 9H), 5.41-5.39 (m, 
1H), 3.35-3.32 (dd, J = 3.5, 10.5 Hz, 1H), 3.30-3.27 (dd, J = 3.5, 10.5 Hz), 1.79-
1.77 (m, 2H), 1.30-1.25 (m, 12H), 0.90-0.86 (t, J = 7.0 Hz, 3H); 13C NMR (125 
MHz) δ 164.6, 150.8, 144.0, 136.3, 131.0, 128.9, 128.1, 127.3, 123.8, 86.7, 75.5, 
65.0, 32.1, 31.1, 29.7, 29.6, 29.4, 25.4, 22.9, 14.3; ESI-HRMS Calcd for 
C36H39NO5 [M + Na]+ : 588.2726. Found: 588.2723. 
(2R)-1-Trityloxydecan-2-ol (240): To a solution of 239 (550 mg, 0.97 
mmol) in MeOH: THF (v/v 3:1, 10 mL) was added K2CO3 (70 mg, 0.5 mmol) and 
the mixture was stirred at room temperature for 1 h. The solvent was removed 
and the residue was partitioned between ethyl acetate and H2O. The organic 
layer was washed with brine, dried and concentrated. Chromatographic 
purification using 5% ethyl acetate in hexanes afforded 240 (400 mg, 98%) as 
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colorless syrup. [α]23D -5.9 (c 1.4); 1H and 13C NMR spectra data consistent with 
the enantiomer (2S)-1-trityloxydecan-2-ol (236). 
(2R)-2-Benzyloxy-1-trityloxydecane (241): Following the same 
procedure as for the preparation of 237, using 240 (315 mg, 0.75 mmol) as 
substrate, 241 (345 mg, 90%) was obtained as colorless syrup. [α]23D +27.1 (c 
1.3); 1H and 13C NMR spectra data consistent with the enantiomer (2S)-2-
benzyloxy-1-trityloxydecane (237). 
(2R)-2-Benzyloxydecan-1-ol (242): Following the same procedure as for 
the trityl deprotection of 237, using 241 (345 mg, 0.68 mmol) as substrate, 242 
(170 mg, 96%) was obtained as colorless syrup. [α]23D -19.0 (c 1.1); 1H and 13C 
NMR spectra data consistent with the enantiomer (2S)-2-benzyloxydecan-1-ol 
(238). 
General Procedure 8.  Mannosylation using the BSP/TTBP/Tf2O 
system: To a stirred solution of donor, Phenyl 2,3-di-O-benzyl-4,6-O-
benzylidene-1-deoxy-1-thio-α-D- mannopyranoside (243)257 (1 equiv), BSP (1.2 
equiv), TTBP (1.5 equiv), and 4 Å molecular sieves (~1 weight equiv. of the 
donor) in CH2Cl2 (0.05 M in substrate) at -60 °C was added Tf2O (1.1 equiv). 
After 30 min of stirring at -60 °C, the reaction mixture was cooled to -78 °C and a 
solution of the glycosyl acceptor (0.7 equiv) in CH2Cl2 (0.05 M + 2 × 0.5 mL rinse) 
was slowly added. The reaction mixture was allowed to come -60 °C over a 
period of 3 h, before NEt3 was added to quench the reaction. The reaction 
mixture was allowed to reach room temperature, filtered through a pad of Celite, 
and washed with CH2Cl2, after which the filtrate was concentrated. 
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Chromatographic purification using ethyl acetate in hexanes afforded the 
corresponding coupled products. 
(2S)-2-Benzyloxydecan-1-yl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-
mannopyranoside (244): Following the general procedure 8, using 238 (45 mg, 
0.17 mmol) as acceptor, and eluting with 10% ethyl acetate in hexanes, 244 (90 
mg, 80%) was obtained as colorless syrup. [α]23D -46.5 (c 1.4); 1H NMR (500 
MHz) δ 7.52-7.50 (d, J = 8.0 Hz, 1H), 7.46-7.45 (d, J = 8.0 Hz, 1H), 7.39-7.37 (d, 
J = 9.5 Hz, 2H), 7.32-7.27 (m, 16H), 5.63 (s, 1H), 4.99-4.96 (d, J = 12.5 Hz, 1H), 
4.88-4.86 (d, J = 12.5 Hz, 1H), 4.68-4.65 (d, J = 12.0 Hz, 1H), 4.62-4.61 (d, J = 
2Hz, 2H), 4.58-4.55 (d, J = 12.5 Hz, 1H), 4.50 (s, 1H), 4.33-4.30 (dd, J = 5.0, 
10.5 Hz, 1H), 4.23-4.19 (t, J = 10 Hz, 1H), 4.0-3.97 (dd, J = 3.5 Hz, 10.5 Hz, 1H), 
3.96-3.94 (d, J = 10.5 Hz, 1H), 3.92-3.91 (d, J = 3.0 Hz, 1H), 3.70-3.64 (m, 1H), 
3.57-3.53 (m, 2H), 3.35-3.10 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 1.55-1.52 (m, 1H), 
1.42-1.38 (m, 1H), 1.30-1.28 (m, 12H) 0.91-0.88 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz) δ 139.2, 138.7, 138.6, 137.8, 129.1, 128.9, 128.6, 128.5, 128.4, 
128.3, 127.9, 127.8, 127.7, 126.3, 103.0, 101.7, 79.0, 78.9, 78.2, 77.5, 76.2, 
75.1, 73.8, 72.7, 68.8, 67.8, 32.1, 32.0, 30.0, 29.8, 29.5, 25.6, 22.9, 14.4; ESI-
HRMS Calcd for C44H54O7 [M + Na]+ : 717.3767. Found: 717.3746. 
(2R)-2-Benzyloxydecan-1-yl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-
mannopyranoside (245): Following the general procedure 8, using 242 (45 mg, 
0.17 mmol) as acceptor, and eluting with 10% ethyl acetate in hexanes, 245 (100 
mg, 86%) was obtained as colorless syrup. [α]23D -41.1 (c 1.2); 1H NMR (500 
MHz) δ 7.55-7.53 (d, J = 8.0 Hz, 2H), 7.50-7.49 (d, J = 8.0 Hz, 2H), 7.43-7.28 (m, 
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16H), 5.65 (s, 1H), 5.04-5.01 (d, J = 12.5 Hz, 1H), 4.92-4.89 (d, J = 12.5 Hz, 1H), 
4.72-4.69 (d, J = 12.0 Hz, 1H), 4.67-4.65 (d, J = 12Hz, 1H), 4.63-4.61 (d, J = 11.5 
Hz, 1H), 4.60-4.58 (d, J = 11.5 Hz, 1H), 4.46 (s, 1H), 4.36-4.33 (dd, J = 5.0, 10.5 
Hz, 1H), 4.26-4.22 (t, J = 9.5 Hz, 1H), 4.05-4.02 (dd, J = 3.5 Hz, 10.5 Hz, 1H), 
3.99-3.97 (d, J = 10.0 Hz, 1H), 3.97-3.95 (d, J = 9.5 Hz, 1H), 3.61-3.56 (m, 3H), 
3.35-3.10 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 1.67-1.63 (m, 2H), 1.50-1.45 (m, 1H), 
1.42-1.38 (m, 1H), 1.35-1.32 (m, 10H) 0.94-0.91 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz) δ 139.1, 138.7, 138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 
128.3, 128.0, 127.8, 126.3, 102.8, 101.7, 78.9, 78.2, 78.1, 76.0, 75.0, 72.6, 71.9, 
71.4, 68.9, 68.0, 32.2, 32.1, 30.0, 29.8, 29.6, 25.7, 23.0, 14.4.  
(2S)-2-Hydroxydecan-1-yl β-D-mannopyranoside (231): To a solution of 
244 (50 mg, 0.072 mmol) in MeOH: THF (v/v 3:1, 6 mL) was added AcOH (100 
µL) and 20% Pd(OH)2/C (20 mg). The mixture was purged with H2 three times 
and shaken under H2 (50 psi) for 12 h. Then the reaction mixture was filtered 
through a Celite pad and washed with MeOH (3 × 5 mL) and concentrated to 
afford 231 (22 mg, 92%) as white foam. [α]23D -19.6 (c 1.0 in MeOH); 1H NMR 
(500 MHz, DMSO-d6) δ 4.85 (br s, 1H), 4.73 (br s, 1H), 4.53 (br s, 2H), 4.41 (s, 
1H), 4.38 (br s, 1H), 3.70-3.68 (m, 2H), 3.67-3.64 (dd, J = 4.5, 10.0 Hz, 1H), 
3.58-3.56 (m, 1H), 3.49-3.46 (dd, J = 5.5, 10.5 Hz, 1H), 3.38-3.71 (m, 1H), 3.35-
3.32 (t, J = 10.0 Hz, 1H), 3.29-3.27 (dd, J = 3.0, 9.0 Hz, 1H), 3.05-3.02 (m, 1H), 
1.41-1.39 (m, 2H), 1.31-1.27 (m, 12H) 0.90-0.87 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, DMSO-d6) δ 100.6, 77.5, 73.7, 73.4, 70.5, 69.1, 67.1, 61.3, 33.6, 31.4, 
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29.3, 29.1, 28.7, 25.2, 22.2, 14.0; ESI-HRMS Calcd for C16H32O7 [M + Na]+ : 
359.2046. Found: 359.2056. 
(2R)-2-Hydroxydecan-1-yl β-D-mannopyranoside (232): Following the 
same procedure as for the benzyl deprotection of 244, using 245 (100 mg, 0.144 
mmol) as substrate, 232 (47 mg, 97%) was obtained as white foam. [α]23D -37.4 
(c 0.7 in MeOH); 1H NMR (500 MHz, DMSO-d6) δ 4.75-4.74 (d, J = 4.5 Hz, 1H), 
4.57-4.56 (d, J = 5.5 Hz, 1H), 4.50-4.49 (d, J = 4.0 Hz, 1H), 4.48-4.45 (t, J = 5.5 
Hz, 1H), 4.40 (s, 1H), 4.30-4.29 (d, J = 4.0 Hz, 1H), 3.73-3.68 (m, 2H), 3.65-3.61 
(dd, J = 7.0, 9.0 Hz, 1H), 3.58-3.56 (m, 1H), 3.49-3.44 (m, 1H), 3.39-3.37 (m, 
2H), 3.34-3.31 (dd, J = 4.0, 9.0 Hz, 1H), 3.28-3.26 (m, 1H), 3.06-3.03 (m, 1H), 
1.41-1.39 (m, 2H), 1.31-1.27 (m, 12H) 0.90-0.87 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, DMSO-d6) δ 100.3, 77.5, 73.7, 73.4, 70.6, 68.9, 67.1, 61.4, 33.4, 31.3, 
29.3, 29.1, 28.7, 25.1, 22.1, 14.0.  
N-(4-Methoxybenzyl)-O-benzyl-L-tyrosine methyl ester (246): To a 
solution of O-benzyl-L-tyrosine methyl ester (400 mg, 1.4 mmol) in MeOH (8 mL) 
were added anisaldehyde (255 µL, 2.1 mmol) and acetic acid (80 µL, 1.4 mmol) 
at room temperature. After stirring for 10 min at this temperature, the solution 
was cooled with an ice bath and solid NaBH4 (80 mg, 2.1 mmol) was added. The 
reaction mixture was stirred for 1 h at 0 C, and then the solvent was 
evaporated. The residue was dissolved in ethyl acetate and the organic layer 
was washed with saturated aqueous Na2CO3, water and brine, dried and 
concentrated. Chromatographic purification using 25% ethyl acetate in hexanes 
afforded 246 (560 mg, 98%) as colorless foam. [α]23D +10.4 (c 1.25); 1H NMR 
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(500 MHz) δ 7.47-7.46 (d, J = 7.5 Hz, 2H), 7.43-7.40 (t, J = 7.5 Hz, 2H), 7.37-
7.7.34 (t, J = 7.5 Hz, 1H), 7.20-7.18 (d, J = 8.5 Hz, 2H), 7.12-7.10 (d, J = 8.5 Hz, 
2H), 6.94-6.92 (d, J = 8.5 Hz, 2H), 6.87-6.85 (d, J = 8.5 Hz, 2H), 5.07 (s, 2H), 
3.81 (s, 3H), 3.79-3.377 (d, J = 13.0 Hz, 1H), 3.68 (s, 3H), 3.63-3.60 (d, J = 13.0 
Hz, 1H), 3.55-3.53 (t, J = 7.0 Hz, 1H), 2.95-2.94 (d, J = 6.5 Hz, 2H), 1.94 (b rs, 
1H); 13C NMR (125 MHz) δ 175.4, 159.0, 157.9, 137.4, 132.0, 130.5, 129.9, 
129.6, 128.8, 128.2, 127.7, 115.1, 114.0, 70.2, 62.3, 55.5, 51.9, 51.7, 39.1; ESI-
HRMS Calcd for C25H27NO4 [M + Na]+ : 428.1838. Found: 428.1849. 
(4R)-3-Decanoyl-4-isopropyloxazolidin-2-one (249): To an ice-cooled 
solution of (4R)-4-isopropyloxazolidin-2-one261 (500 mg, 3.87 mmol) in THF (4 
mL) was added sodium hydride (60%, 195 mg, 4.84 mmol) under stirring. After 
30 min, decanoyl chloride (950 µL, 4.65 mmol) was added and stirring was 
continued for 2 h at room temperature. The reaction mixture was concentrated, 
dissolved in ethyl acetate, and washed with saturated aqueous NH4Cl. The 
aqueous phase was extracted with ethyl acetate three times, and the combined 
organic phase was washed with water and brine, dried and concentrated. 
Chromatographic purification using 10% ethyl acetate in hexanes afforded 249 
(1.06 g, 97%) as colorless syrup. [α]23D -54.2 (c 2.05); 1H NMR (500 MHz) δ 4.44-
4.41 (m, 1H), 4.27-4.24 (t, J = 9.0 Hz, 1H), 4.20-4.18 (dd, J = 3.0, 9.0 Hz, 1H), 
3.0-2.94 (m, 1H), 2.87-2.80 (m, 1H), 2.34-2.31 (m, 1H), 1.68-1.60 (m, 2H), 1.38-
1.25 (m, 12H), 0.91-0.90 (d, J = 7.0 Hz, 3H), 0.88-0.85 (t, J = 7.0 Hz, 3H), 0.87-
0.85 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 173.7, 154.3, 63.5, 58.6, 35.7, 
158 
 
32.1, 29.7, 29.6, 29.5, 29.2, 28.6, 24.7, 22.9, 18.1, 14.9, 14.3; ESI-HRMS Calcd 
for C16H29NO3 [M + Na]+ : 306.2045. Found: 306.2038. 
(4S)-3-Decanoyl-4-isopropyloxazolidin-2-one (250): Following the 
same procedure as for the preparation of 249, using (4S)-4-isopropyloxazolidin-
2-one261 (300 mg, 2.32 mmol) as substrate, 250 (590 mg, 90%) was obtained as 
colorless syrup. [α]23D +55.7 (c 2.0); 1H and 13C NMR spectra data consistent with 
the enantiomer (4R)-3-decanoyl-4-isopropyloxazolidin-2-one (249). 
(4R,2’R)-4-Isopropyl-3-(2’-methyldecanoyl)oxazolidin-2-one (251): To 
a solution of 249 (1.06 g, 3.74 mmol) in THF (7.5 mL) was added dropwise 
NaHMDS (2.0 M in THF, 2.2 mL, 4.4 mmol) at -65 °C to give a slightly yellow 
reaction mixture. After being stirred for 30 min at -65 °C, the reaction mixture was 
cooled to -78 °C and MeI (0.6 mL, 9.4 mmol) was slowly added. The reaction 
mixture was then warmed to -20 °C over a period of 2 h and subsequently 
quenched by the addition of saturated aqueous NH4Cl solution. The mixture was 
extracted with CH2Cl2 three times, and the combined organic was washed with 
brine, dried and concentrated (1H NMR of the crude mixture indicate, dr = 9:1). 
Chromatographic purification of the mixture using 5% ethyl acetate in hexanes 
provided 251 (900 mg, 81%) as colorless syrup. [α]23D -85.6 (c 1.0); 1H NMR (500 
MHz) δ 4.46-4.43 (m, 1H), 4.28-4.24 (t, J = 9.0 Hz, 1H), 4.21-4.18 (dd, J = 3.0, 
9.0 Hz, 1H), 3.74-3.70 (q, J = 7.0 Hz, 1H), 2.37-2.33 (m, 1H), 1.73-1.68 (m, 1H), 
1.38-1.34 (m, 1H), 1.30-1.25 (m, 12H), 1.20-1.19 (d, J = 7.0 Hz, 3H) 0.92-0.90 (d, 
J = 7.0 Hz, 3H), 0.89-0.86 (t, J = 7.0 Hz, 3H), 0.88-0.87 (d, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz) δ 177.6, 153.9, 63.4, 58.7, 37.9, 33.3, 32.1, 30.0, 29.7, 29.5, 
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28.7, 27.5, 22.9, 18.2, 18.1, 14.9, 14.3; ESI-HRMS Calcd for C17H31NO3 [M + 
Na]+ : 320.2202. Found: 320.2191. 
(4S,2’S)-4-Isopropyl-3-(2’-methyldecanoyl)oxazolidin-2-one (252): 
Following the same procedure as for the preparation of 251, using 250 (520 mg, 
1.83 mmol) as substrate, a mixture of diastereomers (dr = 9:1) was obtained. 
Chromatographic purification of the mixture using 5% ethyl acetate in hexanes 
afforded 252 (435 mg, 80%) as colorless syrup. [α]23D -83.9 (c 0.9); 1H and 13C 
NMR spectra data consistent with the enantiomer (4R,2’R)-4-isopropyl-3-(2’-
methyldecanoyl)oxazolidin-2-one (251). 
(2R)-2-Methyldecanoic acid (253): To a stirred solution of 251 (690 mg, 
2.32 mmol) and lithium hydroxide (975 mg, 23.2 mmol) in THF: H2O (v/v 2:1, 21 
mL) at 0 °C was added dropwise hydrogen peroxide (30%, 2.6 mL, 23.2 mmol). 
The reaction was stirred at 0 °C for 3 h before it was quenched by aqueous 
sodium sulfite (30%, 10 mL). The reaction mixture was stirred at 0 °C for 15 min 
then acidified to pH 1-2 with aqueous hydrochloric acid (1 M). The mixture was 
extracted with CH2Cl2 three times, and the combined organic was washed with 
brine, dried and concentrated. Chromatographic purification using 10% ethyl 
acetate in hexanes provided 253 (410 mg, 95%) as clear oil and eluting with 10% 
MTB ether in CH2Cl2 provided (4R)-4-isopropyloxazolidin-2-one (275 mg, 92%) 
as white solid. [α]23D -15.7 (c 1.0 in MeOH); 1H NMR (500 MHz) δ 2.48-2.44 (q, J 
= 7.0 Hz, 1H), 1.71-1.65 (m, 1H), 1.46-1.41 (m, 1H), 1.32-1.23 (m, 12H), 1.19-
1.18 (d, J = 7.0 Hz, 3H), 0.90-0.87 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 
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183.8, 39.6, 33.8, 32.1, 29.7, 29.6, 29.5, 27.4, 22.9, 17.0, 14.3; ESI-HRMS Calcd 
for C11H21O2 [M - H]-: 185.1542. Found: 185.1534. 
(2S)-2-Methyldecanoic acid (254): Following the same procedure as for 
the hydrolysis of 251, using 252 (530 mg, 1.78 mmol) as substrate, 254 (300 mg, 
92%) was obtained as clear oil. [α]23D +14.9 (c 1.0 in MeOH); 1H and 13C NMR 
spectra data consistent with the enantiomer (2R)-2-methyldecanoic acid (253). 
3-(tert-Butylthio)-3-oxopropanoic acid:282 To a stirred solution of 
malonic acid (4.0 g, 38.4 mmol) and ethyl polyphosphate (PPE)283 (6.0 g) in 
CH2Cl2: THF (v/v 6:1, 42 mL) at room temperature was added dropwise tert-
butylthiol (1.1 mL, 9.6 mmol). After stirring for 30 h at room temperature, the 
reaction mixture was diluted with MTB ether (50 mL) and washed the organic 
layer with saturated aqueous NaHCO3 (3 × 20 mL). The combined aqueous 
extracts were acidified to pH 1-2 with aqueous hydrochloric acid (1 M) and 
extracted with CH2Cl2 three times. The combined organic was washed with brine, 
dried and concentrated. Chromatographic purification using 5% MeOH in CH2Cl2 
provided (1.66 g, 99%) as white solid. Mp 43-43.5 °C, literature282 mp 44-45 °C  
(4R)-S-tert-Butyl 4-methyl-3-oxothiododecanoate (255): To a solution 
of 3-(tert-butylthio)-3-oxopropanoic acid (1.0 g, 5.65 mmol) in THF (20 mL) was 
added Mg(OEt)2 (325 mg, 2.84 mmol), and the mixture was stirred at room 
temperature for 24 h. Evaporation of solvent afforded the magnesium enolate of 
3-(tert-butylthio)-3-oxopropanoic acid (820 mg, quantitative) as a white 
powder,260 which was stored in a dry desiccator.  
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To a stirred solution of acid 253 (185 mg, 1.0 mmol) in THF (7 mL) was 
added 1,1’-carbonyldiimidazole (325 mg, 2.0 mmol). After 12 h of stirring at room 
temperature, magnesium enolate of 3-(tert-butylthio)-3-oxopropanoic acid (690 
mg, 2.0 mmol) was added. The reaction mixture was stirred for a further 15 h, 
before saturated NH4Cl was added to quench the reaction. The mixture was 
extracted with CH2Cl2 three times, and the combined organic was washed with 
brine, dried and concentrated. Chromatographic purification using 3% ethyl 
acetate in hexanes provided 255 (250 mg, 83%, a 1:1 mixture of keto and enol 
forms) as light orange oil. [α]24D -19.4 (c 1.25); 1H NMR (500 MHz) δ 5.32 (s, 1/2 
H), 3.60 (s, 1H), 2.69-2.65 (q, J = 7.0 Hz, 1/2H), 2.15-2.11 (q, J = 7.0 Hz, 1/2H), 
1.61-1.57 (m, 1H), 1.52 (s, 9/2H), 1.48 (s, 9/2H), 1.36-1.26 (m, 13H), 1.12-1.10 
(d, J = 7.0 Hz, 3/2H), 1.10-1.08 (d, J = 7.0 Hz, 3/2H), 0.90-0.87 (t, J = 7.0 Hz, 
3H); 13C NMR (125 MHz) δ 206.3, 196.5, 192.8, 180.7,  98.6, 57.0, 49.2, 48.3, 
46.8, 39.7, 34.3, 32.8, 32.1, 30.4, 29.8, 29.7, 29.6, 29.5, 29.4, 27.5, 27.3, 22.9, 
18.2, 16.2, 14.3; ESI-HRMS Calcd for C17H32O2S [M + Na]+: 323.2021. Found: 
323.2016. 
(4S)-S-tert-Butyl 4-methyl-3-oxothiododecanoate (256): Following the 
same procedure as for the preparation of 255, using 254 (130 mg, 0.7 mmol) as 
substrate, 256 (175 mg, 84%, a 1:1 mixture of keto and enol forms) was obtained 
as light orange oil. [α]24D +20.3 (c 1.0); 1H and 13C NMR spectra data consistent 
with the enantiomer (4R)-S-tert-butyl 4-methyl-3-oxothiododecanoate (255). 
N-[(4R)-4-Methyl-3-oxododecanoyl]-N-(4-methoxybenzyl)-O-benzyl-L-
tyrosine methyl ester (257): To a stirred solution of 255 (190 mg, 0.62 mmol), 
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246 (240 mg, 0.59 mmol), and 4 Å molecular sieves (~175 mg) in THF (3 mL) 
was added Et3N (430 µL, 3.1 mmol). After 10 min of stirring at room temperature, 
silver trifluoroacetate (165 mg, 0.75 mmol) was added in one portion, and the 
reaction mixture was stirred for further 1 h at same temperature. The mixture was 
then filtered through a pad of Celite, and washed with CH2Cl2, after which the 
filtrate was concentrated. Chromatographic purification using 20% ethyl acetate 
in hexanes afforded 257 (330 mg, 90%, as a mixture of rotomers) as light yellow 
syrup. [α]24D -116.9 (c 1.0); 1H NMR (500 MHz) δ 7.47-7.44 (t, J = 7.0 Hz, 2H), 
7.41-7.40 (t, J = 7.0 Hz, 2H), 7.38-7.35 (d, J = 7.0 Hz, 1H), 7.10-7.04 (m, 4H), 
6.93-6.88 (d, J = 8.5 Hz, 2H), 6.84-6.80 (d, J  = 8.5 Hz), 5.08 (s, 2H), 5.03 (s, 
2H), 4.41-4.38 (d, J = 15.0 Hz, 1H), 3.85-3.82 (d, J = 15.0 Hz, 1H), 3.79 (s, 3H), 
3.66 (s, 3H), 3.39-3.35 (dd, J = 6.0, 14.5 Hz, 1H), 3.09-2.05 (dd, J = 8.0, 14.5 Hz, 
1H), 2.79-2.75 (q, J = 7.0 Hz, 1H), 1.74-1.72 (m, 1H), 1.41-1.37 (m, 1H), 1.31-
1.27 (m, 12H), 1.09-1.08 (d, J = 7.0 Hz, 3H), 0.89-0.87 (t, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz) δ 208.1, 183.4, 173.2, 171.5, 170.8, 167.8, 159.4, 157.8, 137.3, 
131.6, 130.6, 128.8, 128.1, 127.7, 115.2, 114.3, 70.1, 61.0, 55.6, 55.5, 52.1, 
48.0, 46.4, 42.8, 34.7, 33.1, 32.1, 30.0, 29.7, 29.5, 27.4, 22.9, 16.1, 14.3; ESI-
HRMS Calcd for C38H49NO6 [M + Na]+ : 638.3458. Found: 638.3423. 
(5S,2’R)-5-(4-(Benzyloxy)benzyl)-3-(2’-methyldecanoyl)-1-(4”-
methoxybenzyl)pyrrolidine-2,4-dione (258): To a stirred solution of 257 (300 
mg, 0.49 mmol) in tBuOH: THF (v/v 5:1, 7.5 mL) at room temperature was added 
KOtBu (65 mg, 0.58 mmol) in one portion. The reaction mixture was stirred at 
same temperature for 30 min before it was neutralized by saturated aqueous 
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NH4Cl. Then the reaction mixture was concentrated, dissolved in ethyl acetate, 
and washed with saturated aqueous NH4Cl. The aqueous phase was extracted 
with ethyl acetate three times, and the combined organic phase was washed with 
water and brine, dried and concentrated. Chromatographic purification using 20% 
ethyl acetate in hexanes afforded 258 (260 mg, 92%) as colorless syrup. [α]24D -
211.1 (c 1.0); 1H NMR (500 MHz) δ 7.45-7.41 (t, J = 7.0 Hz, 2H), 7.38-7.35 (t, J = 
7.0 Hz, 2H), 7.30-7.27 (d, J = 7.0 Hz, 1H), 7.08-7.04 (d, J = 8.0 Hz, 2H), 7.03-7.0 
(d, J = 8.0 Hz, 2H), 6.88-6.87 (d, J = 8.0 Hz, 2H), 6.86-6.85 (d, J  = 8.0 Hz, 2H), 
5.22-5.19 (d, J = 15.0 Hz, 1H), 5.05 (s, 2H), 3.91-3.88 (d, J = 15.0 Hz, 1H), 3.81 
(s, 3H), 3.63-3.60 (q, J = 7.0 Hz, 1H), 3.08-3.05 (m, 2H), 1.56-1.52 (m, 1H), 1.43-
1.40 (m, 1H), 1.33-1.22 (m, 12H), 1.18-1.16 (d, J = 7.0 Hz, 3H), 0.89-0.87 (t, J = 
7.0 Hz, 3H); 13C NMR (125 MHz) δ 195.3, 191.9, 173.7, 161.8, 160.1, 155.3, 
131.0, 126.7, 115.4, 103.4, 101.5, 90.7, 65.0, 55.9, 55.6, 36.4, 33.9, 33.6, 32.8, 
29.9, 29.7, 27.3, 22.9, 17.1, 14.3; ESI-HRMS Calcd for C37H45NO5 [M + Na]+ : 
606.3195. Found: 606.3190. 
N-(2,4,6-Trimethoxybenzyl)-O-benzyl-L-tyrosine methyl ester (260): A 
suspension of O-benzyl-L-tyrosine methyl ester hydrochloride (1.43 g, 5.0 mmol), 
1,3,5-trimethoxybenzene (1.26 g, 7.5 mmol) and paraformaldehyde (225 mg, 7.5 
mmol) in MeOH (5 mL) was heated to reflux for 5 h. The reaction mixture was 
concentrated, dissolved in CH2Cl2, and washed with saturated aqueous NHCO3. 
The aqueous phase was extracted with CH2Cl2 three times, and the combined 
organic phase was washed with water and brine, dried and concentrated. 
Chromatographic purification using 55% ethyl acetate in hexanes afforded 260 
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(1.95 g, 84%) as colorless foam. [α]25D +27.4 (c 1.0); 1H NMR (500 MHz) δ 7.44-
7.43 (d, J = 7.5 Hz, 2H), 7.40-7.37 (t, J = 7.5 Hz, 2H), 7.34-7.33 (d, J = 7.5 Hz, 
1H), 7.04-7.03 (d, J = 8.5 Hz, 2H), 6.88-6.86 (d, J  = 8.5 Hz, 2H), 6.05 (s, 2H), 
5.04 (s, 2H), 3.80 (s, 3H), 3.77 (s, 2H), 3.67 (s, 6H), 3.60 (s, 3H), 3.45-3.42 (dd, J 
= 6.0, 8.0 Hz, 1H), 2.93-2.89 (dd, J = 6.0, 10.0 Hz, 1H), 2.86-2.82 (dd, J = 6.0, 
10.0 Hz, 1H), 2.09 (br s, 1H); 13C NMR (125 MHz) δ 175.3, 160.6, 159.5, 157.7, 
137.4, 130.3, 130.2, 128.8, 128.2, 127.7, 114.9, 108.4, 90.4, 77.5, 70.2, 62.0, 
55.7, 55.5, 51.7, 39.9, 38.9; ESI-HRMS Calcd for C27H31NO6 [M + Na]+ : 
488.2049. Found: 488.2040. 
N-[(4R)-4-Methyl-3-oxododecanoyl]-N-(2,4,6-trimethoxybenzyl)-O-
benzyl-L-tyrosine methyl ester (261): To a stirred solution of 255 (65 mg, 0.22 
mmol), 260 (100 mg, 0.22 mmol), and 4 Å molecular sieves (~60 mg) in THF (2.2 
mL) was added Hunig’s base (190 µL, 1.1 mmol). After 10 min of stirring at room 
temperature, silver trifluoroacetate (55 mg, 0.26 mmol) was added in one portion, 
and the reaction mixture was stirred for further 1 h at same temperature. The 
mixture was then filtered through a pad of Celite, and washed with CH2Cl2, after 
which the filtrate was concentrated. Chromatographic purification using 35% 
ethyl acetate in hexanes afforded 261 (135 mg, 93%, as a mixture of rotomers) 
as light yellow syrup. [α]24D -77.2 (c 1.0); 1H NMR (500 MHz) δ 7.45-7.44 (d, J = 
7.5 Hz, 2H), 7.41-7.38 (t, J = 7.5 Hz, 2H), 7.34-7.33 (d, J = 7.5 Hz, 1H), 6.95-6.94 
(d, J = 8.5 Hz, 2H), 6.80-6.78 (d, J  = 8.5 Hz), 6.03 (s, 2H), 5.03 (s, 2H), 4.35-
4.33 (d, J = 15.0 Hz, 1H), 4.17-4.14 (d, J = 15.0 Hz, 1H), 3.89 (s, 2H), 3.81 (s, 
3H), 3.70 (s, 6H), 3.61 (s, 3H), 3.39-3.35 (dd, J = 6.0, 14.5 Hz, 1H), 3.02-2.97 
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(dd, J = 8.0, 14.5 Hz, 1H), 2.79-2.75 (q, J = 7.0 Hz, 1H), 1.74-1.72 (m, 1H), 1.41-
1.37 (m, 1H), 1.31-1.27 (m, 12H), 1.16-1.15 (d, J = 7.0 Hz, 3H), 0.89-0.87 (t, J = 
7.0 Hz, 3H); 13C NMR (125 MHz) δ 209.0, 171.7, 167.5, 161.7, 159.9, 157.3, 
137.5, 131.6, 130.6, 128.8, 128.1, 127.7, 114.5, 104.2, 90.5, 70.1, 61.0, 55.6, 
55.5, 52.1, 48.0, 46.4, 42.8, 34.7, 33.1, 32.1, 30.0, 29.7, 29.5, 27.4, 22.9, 16.0, 
14.3; ESI-HRMS Calcd for C40H53NO8 [M + Na]+ : 698.3669. Found: 698.3666. 
N-[(4S)-4-Methyl-3-oxododecanoyl]-N-(2,4,6-trimethoxybenzyl)-O-
benzyl-L-tyrosine methyl ester (262): Following the same procedure as for the 
preparation of 261, using 256 (85 mg, 0.28 mmol) as substrate, 262 (175 mg, 
91%, as a mixture of rotomers) was obtained as light yellow syrup. [α]24D -98.4 (c 
1.0); 1H NMR (500 MHz) δ 7.45-7.44 (d, J = 7.0 Hz, 2H), 7.40-7.37 (t, J = 7.0 Hz, 
2H), 7.34-7.33 (d, J = 7.0 Hz, 1H), 6.96-6.94 (d, J = 8.5 Hz, 2H), 6.80-6.78 (d, J  
= 8.5 Hz), 6.03 (s, 2H), 5.03 (s, 2H), 4.35-4.32 (d, J = 15.0 Hz, 1H), 4.17-4.14 (d, 
J = 15.0 Hz, 1H), 3.90 (s, 2H), 3.81 (s, 3H), 3.72 (s, 6H), 3.59 (s, 3H), 3.39-3.35 
(dd, J = 6.0, 14.5 Hz, 1H), 3.02-2.98 (dd, J = 8.0, 14.5 Hz, 1H), 2.79-2.75 (q, J = 
6.5 Hz, 1H), 1.74-1.72 (m, 1H), 1.33-1.27 (m, 13H), 1.15-1.14 (d, J = 6.5 Hz, 3H), 
0.89-0.87 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 209.0, 171.7, 167.6, 161.7, 
159.9, 157.3, 137.5, 131.6, 130.6, 128.8, 128.1, 127.7, 114.5, 104.3, 90.6, 70.1, 
61.0, 55.6, 52.1, 48.0, 46.4, 42.8, 34.6, 33.1, 32.1, 30.0, 29.8, 29.5, 27.4, 22.9, 
16.1, 14.3.  
(5S,2’R)-5-(4-Hydroxybenzyl)-3-(2’-methyldecanoyl)-1-(2”,4”,6”-
trimethoxybenzyl)pyrrolidine-2,4-dione (263): To a solution of 261 (100 mg, 
0.148 mmol) in MeOH: THF (v/v 3:1, 8 mL) was added AcOH (50 µL) and 20% 
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Pd(OH)2/C (20 mg). The mixture was purged with H2 three times and shaken 
under H2 (50 psi) for 3 h. Then the reaction mixture was filtered through a Celite 
pad and washed with ethyl acetate (3 × 5 mL). Evaporation of the solvent 
afforded the corresponding debenzylated ketoamide, which was taken forward 
for cyclization without purification. 
To a stirred solution of the ketoamide (65 mg, 0.113 mmol) in tBuOH: THF 
(v/v 5:1, 2 mL) at room temperature was added KOtBu (20 mg, 0.17 mmol) in one 
portion. The reaction mixture was stirred at same temperature for 30 min before it 
was neutralized by saturated aqueous NH4Cl. Then the reaction mixture was 
concentrated, dissolved in ethyl acetate, and washed with saturated aqueous 
NH4Cl. The aqueous phase was extracted with ethyl acetate three times, and the 
combined organic phase was washed with water and brine, dried and 
concentrated. Complete evaporation of the solvent afforded 263 (57 mg, 91%) as 
colorless syrup, which required no further purification. [α]24D -182.2 (c 1.0); 1H 
NMR (500 MHz) δ 6.96-6.94 (d, J = 8.0 Hz, 2H), 6.65-6.64 (d, J  = 8.0 Hz), 6.14 
(s, 2H), 5.13-5.10 (d, J = 14.0 Hz, 1H), 4.43-4.40 (d, J = 14.0 Hz, 1H), 3.83 (s, 
3H), 3.81 (s, 6H), 3.65-3.63 (t, J = 4.0 Hz, 1H), 3.51-3.47 (q, J = 7.0 Hz, 1H), 
3.08-3.05 (m, 2H), 1.56-1.52 (m, 1H), 1.33-1.22 (m, 13H), 1.11-1.10 (d, J = 7.0 
Hz, 3H), 0.89-0.87 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 195.3, 191.9, 173.7, 
161.8, 160.1, 155.3, 131.0, 126.7, 115.4, 103.4, 101.5, 90.7, 65.0, 55.9, 55.6, 
36.4, 33.9, 33.6, 32.8, 29.9, 29.7, 27.3, 22.9, 17.1, 14.3; ESI-HRMS Calcd for 
C32H43NO7 [M + Na]+ : 576.2937. Found: 576.2894. 
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(5S,2’S)-5-(4-Hydroxybenzyl)-3-(2’-methyldecanoyl)-1-(2”,4”,6”-
trimethoxybenzyl)pyrrolidine-2,4-dione (264): Following the same reaction 
sequences as for the preparation of 263, using 262 (125 mg, 0.184 mmol) as 
substrate, 264 (92 mg, 90%) was obtained as colorless syrup. [α]24D -243.6 (c 
1.0); 1H NMR (500 MHz) δ 6.95-6.94 (d, J = 8.5 Hz, 2H), 6.66-6.64 (d, J  = 8.5 
Hz), 6.14 (s, 2H), 5.13-5.10 (d, J = 14.0 Hz, 1H), 4.44-4.42 (d, J = 14.0 Hz, 1H), 
3.83 (s, 3H), 3.80 (s, 6H), 3.66-3.64 (t, J = 4.0 Hz, 1H), 3.51-3.47 (q, J = 7.0 Hz, 
1H), 3.08-3.05 (m, 2H), 1.62-1.58 (m, 1H), 1.41-1.37 (m, 1H), 1.28-1.22 (m, 
12H), 1.0-0.99 (d, J = 7.0 Hz, 3H), 0.89-0.85 (t, J = 7.0 Hz, 3H); 13C NMR (125 
MHz) δ 195.4, 192.0, 173.8, 161.8, 160.1, 155.3, 131.1, 126.5, 115.4, 103.5, 
101.5, 90.7, 65.0, 55.9, 55.6, 36.4, 33.6, 33.4, 32.8, 32.1, 29.8, 29.7, 27.5, 22.9, 
17.5, 14.3.  
(5S,2’R)-5-(4-Hydroxybenzyl)-3-(2’-methyldecanoyl)pyrrolidine-2,4-
dione (233): A solution of 263 (50 mg, 0.09 mmol) in CH2Cl2: TFA: anisole (v/v/v 
85:10:5, 1 mL) was stirred at room temperature for 30 min. After which, the 
mixture was diluted with toluene (2 mL) and concentrated. Chromatographic 
purification using 5% MeOH in CH2Cl2 afforded 233 (27 mg, 80%) as light yellow 
foam. [α]24D -170.4 (c 0.75); 1H NMR (500 MHz, DMSO-d6) δ 9.18 (br s, 1H), 8.95 
(br s, 1H), 6.93-6.91 (d, J = 8.0 Hz, 2H), 6.62-6.60 (d, J  = 8.0 Hz), 4.08-4.07 (m, 
1H), 3.48-3.44 (q, J = 7.5 Hz, 1H), 2.92-2.81 (m, 2H), 1.51-1.48 (m, 1H), 1.36-
1.23 (m, 13H), 1.07-1.06 (d, J = 6.0 Hz, 3H), 0.90-0.88 (t, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz, DMSO-d6) δ 194.5, 191.7, 175.4, 155.9, 130.6, 125.4, 114.7, 
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100.4, 62.4, 35.4, 33.0, 31.3, 31.2, 28.8, 28.7, 28.6, 26.4, 22.1, 16.6, 13.9; ESI-
HRMS Calcd for C22H31NO4 [M + Na]+ : 396.2151. Found: 396.2132.  
(5S,2’S)-5-(4-Hydroxybenzyl)-3-(2’-methyldecanoyl)pyrrolidine-2,4-
dione (234): Following the same procedure as for the N-2,4,6-trimethoxybenzyl 
deprotection of 263, using 264 (100 mg, 0.18 mmol) as substrate, 234 (57 mg, 
84%) was obtained as light yellow foam. [α]24D -183.2 (c 1.0); 1H NMR (500 MHz, 
DMSO-d6) δ 9.20 (br s, 1H), 8.93 (br s, 1H), 6.94-6.92 (d, J = 8.0 Hz, 2H), 6.64-
6.62 (d, J  = 8.0 Hz), 4.01-4.09 (m, 1H), 3.45-3.41 (m, 1H), 2.86-2.85 (d, J = 4.5 
Hz, 2H), 1.57-1.55 (m, 1H), 1.38-1.37 (m, 1H), 1.28-1.23 (m, 12H), 1.00-0.99 (d, 
J = 6.5 Hz, 3H), 0.89-0.86 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 
194.6, 192.0, 175.5, 156.0, 130.7, 125.6, 114.8, 100.4, 62.5, 35.8, 32.5, 31.3, 
28.9, 28.8, 28.7, 28.6, 26.7, 22.1, 17.0, 14.0.  
(4R,9’Z)-4-Isopropyl-3-(octadec-9’-enoyl)oxazolidin-2-one (272): 
Following the same procedure as for the preparation of 249, using (4R)-4-
isopropyloxazolidin-2-one (615 mg, 4.77 mmol) and oleoyl chloride (2.3 mL, 7.15 
mmol) as substrate, and eluting with 10% ethyl acetate in hexanes, 272 (1.8 g, 
96%) was obtained as colorless syrup. [α]24D -43.8 (c 1.0); 1H NMR (500 MHz) δ 
5.35-5.33 9 (m, 2H), 4.45-4.42 (m, 1H), 4.28-4.24 (t, J = 9.0 Hz, 1H), 4.21-4.19 
(dd, J = 3.0, 9.0 Hz, 1H), 3.01-2.95 (m, 1H), 2.88-2.82 (m, 1H), 2.39-2.35 (m, 
1H), 2.04-2.01 (m, 4H), 1.68-1.62 (m, 2H), 1.34-1.27 (m, 20H), 0.92-0.91 (d, J = 
7.0 Hz, 3H), 0.88-0.85 (t, J = 7.0 Hz, 3H), 0.87-0.85 (d, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz) δ 173.6, 154.3, 130.2, 130.0, 63.5, 58.6, 35.7, 32.1, 30.0, 29.9, 29.8, 
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29.7, 29.6, 29.5, 29.4, 29.3, 28.6, 27.4, 24.7, 22.9, 18.2, 14.9, 14.3; ESI-HRMS 
Calcd for C24H43NO3 [M + Na]+ : 416.3141. Found: 416.3126.  
(4S,9’Z)-4-Isopropyl-3-(octadec-9’-enoyl)oxazolidin-2-one (273): 
Following the same procedure as for the preparation of 249, using (4R)-4-
isopropyloxazolidin-2-one (700 mg, 5.42 mmol) and oleoyl chloride (2.7 mL, 8.13 
mmol) as substrate, and eluting with 10% ethyl acetate in hexanes, 273 (2.0 g, 
94%) was obtained as colorless syrup. [α]24D +44.2 (c 1.0); 1H and 13C NMR 
spectra data consistent with the enantiomer (4R,9’Z)-4-isopropyl-3-(octadec-9’-
enoyl)oxazolidin-2-one (272). 
(4R,2’R,9’Z)-4-Isopropyl-3-(2’-methyloctadec-9’-enoyl)oxazolidin-2-
one (274): Following the same procedure as for the preparation of 251, using 
272 (1.5 g, 3.8 mmol) as substrate, a mixture of diastereomers (dr = 8.6:1) was 
obtained. Chromatographic purification of the mixture using 8% ethyl acetate in 
hexanes afforded 274 (1.3 g, 84%) as colorless syrup. [α]24D -57.3 (c 1.0); 1H 
NMR (500 MHz) δ 5.35-5.33 (m, 2H), 4.46-4.43 (m, 1H), 4.28-4.24 (t, J = 9.0 Hz, 
1H), 4.21-4.18 (dd, J = 3.0, 9.0 Hz, 1H), 3.74-3.70 (q, J = 7.0 Hz, 1H), 2.37-2.33 
(m, 1H), 2.01-1.98 (m, 4H), 1.72-1.69 (m, 1H), 1.39-1.27 (m, 21H), 1.20-1.19 (d, 
J = 7.0 Hz, 3H), 0.92-0.91 (d, J = 7.0 Hz, 3H), 0.88-0.85 (t, J = 7.0 Hz, 3H), 0.87-
0.85 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 177.5, 153.9, 130.2, 130.0, 63.4, 
58.6, 37.9, 33.3, 32.1, 30.0, 29.9, 29.8, 29.7, 29.5, 29.4, 28.7, 27.5, 27.4, 22.9, 
18.2, 14.9, 14.3; ESI-HRMS Calcd for C25H45NO3 [M + Na]+ : 430.3297. Found: 
430.3298.  
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(4S,2’S,9’Z)-4-Isopropyl-3-(2’-methyloctadec-9’-enoyl)oxazolidin-2-
one (275): Following the same procedure as for the preparation of 251, using 
273 (1.98 g, 5.0 mmol) as substrate, a mixture of diastereomers (dr = 8.0:1) was 
obtained. Chromatographic purification of the mixture using 8% ethyl acetate in 
hexanes afforded 275 (1.74 g, 85%) as colorless syrup. [α]24D +58.0 (c 1.0); 1H 
and 13C NMR spectra data consistent with the enantiomer (4R,2’R,9’Z)-4-
isopropyl-3-(2’-methyloctadec-9’-enoyl)oxazolidin-2-one (274). 
(2R,9Z)-2-Methyloctadec-9-enoic acid (276): Following the same 
procedure as for the hydrolysis of 249, using 274 (1.3 g, 3.2 mmol) as substrate, 
and eluting with 10% ethyl acetate in hexanes, 276 (900 mg, 95%) was obtained 
as clear oil. [α]24D -7.6 (c 1.0); 1H NMR (500 MHz) δ 5.37-5.34 (m, 2H), 2.48-2.44 
(q, J = 7.0 Hz, 1H), 2.06-2.0 (m, 4H), 1.71-1.66 (m, 1H), 1.46-1.42 (m, 1H), 1.34-
1.26 (m, 20H), 1.19-1.18 (d, J = 7.0 Hz, 3H), 0.91-0.88 (t, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz) δ 183.9, 130.2, 130.0, 39.6, 33.7, 32.1, 30.0, 29.9, 29.8, 29.7, 
29.5, 29.4, 27.4, 22.9, 17.0, 14.3; ESI-HRMS Calcd for C19H35O2 [M - H]-: 
295.2637. Found: 295.2640. 
(2S,9Z)-2-Methyloctadec-9-enoic acid (277): Following the same 
procedure as for the hydrolysis of 249, using 275 (1.45 g, 3.6 mmol) as 
substrate, and eluting with 10% ethyl acetate in hexanes, 277 (1.0 g, 95%) was 
obtained as clear oil. [α]24D +7.1 (c 1.0); 1H and 13C NMR spectra data consistent 
with the enantiomer (2R,9Z)-2-methyloctadec-9-enoic acid (276). 
(2R,9Z)-Methyl 2-methyloctadec-9-enoate (278): To a stirred 
suspension of 276 (810 mg, 2.73 mmol) and Cs2CO3 (890 mg, 2.73 mmol) in 
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DMF (3.0 mL) was added MeI (340 µL, 5.5 mmol) and the mixture was stirred at 
room temperature for 2 h. The solvent was removed and the residue was 
partitioned between ethyl acetate and H2O. The organic layer was washed with 
brine, dried and concentrated. Chromatographic purification using 2% ethyl 
acetate in hexanes afforded 278 (840 mg, 98%) as clear oil. [α]24D -10.2 (c 1.0); 
1H NMR (500 MHz) δ 5.35-5.31 (m, 2H), 3.65 (s, 3H), 2.44-2.40 (q, J = 7.0 Hz, 
1H), 2.01-1.97 (m, 4H), 1.71-1.66 (m, 1H), 1.46-1.42 (m, 1H), 1.30-1.26 (m, 
20H), 1.13-1.12 (d, J = 7.0 Hz, 3H), 0.88-0.85 (t, J = 7.0 Hz, 3H); 13C NMR (125 
MHz) δ 177.5, 130.1, 129.9, 51.5, 39.6, 34.0, 32.1, 30.0, 29.9, 29.8, 29.7, 29.5, 
29.3, 27.4, 22.9, 17.2, 14.3; ESI-HRMS Calcd for C20H38O2 [M + Na]+: 333.2770. 
Found: 333.2761. 
(2S,9Z)-Methyl 2-methyloctadec-9-enoate (279): Following the same 
procedure as for the preparation of 278, using 277 (1.0 g, 3.4 mmol) as 
substrate, and eluting with 2% ethyl acetate in hexanes, 279 (1.04 g, 99%) was 
obtained as clear oil. [α]24D +10.6 (c 1.0); 1H and 13C NMR spectra data consistent 
with the enantiomer (2R,9Z)-methyl 2-methyloctadec-9-enoate (278). 
(2R)-Methyl 2-methyl-9-oxononanoate (280): To a solution of 278 (840 
mg, 2.7 mmol) in CH2Cl2 (15 mL) at -78 °C ozone was bubbled until a blue color 
was observed (10 – 15 min). After which the solution was purged with O2 for 5 
min and dropwise dimethylsulfide (1.0 mL) was added. After the addition was 
complete, the reaction mixture was warmed to room temperature and stirred for 
12 h. Excess dimethylsulfide and solvent were then removed. Chromatographic 
purification using 10% ethyl acetate in hexanes afforded 280 (480 mg, 87%) as 
172 
 
colorless liquid. [α]24D -16.9 (c 1); 1H NMR (500 MHz) δ 9.74-9.73 (t, J = 1.5 Hz, 
1H), 3.64 (s, 3H), 2.41-2.38 (m, 3H), 1.61-1.58 (m, 3H), 1.32-1.28 (m, 1H), 1.30-
1.25 (m, 6H), 1.12-1.11 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 203.0, 177.5, 
51.6, 44.0, 39.6, 33.9, 29.4, 29.2, 27.2, 22.1, 17.3; ESI-HRMS Calcd for 
C11H20O3 [M + Na]+: 223.1310. Found: 223.1289. 
(2S)-Methyl 2-methyl-9-oxononanoate (281): Following the same 
procedure as for the ozonolysis of 278, using 279 (1.04 g, 3.3 mmol) as 
substrate, and eluting with 10% ethyl acetate in hexanes, 281 (600 mg, 90%) 
was obtained as colorless liquid. [α]24D +16.1 (c 1.0); 1H and 13C NMR spectra 
data consistent with the enantiomer (2R)-methyl 2-methyl-9-oxononanoate (280). 
(9Z,4’S)-10-(2’,2’-Dimethyl-1’,3’-dioxolan-4’-yl)dec-9-enoic acid (282): 
To a stirred suspension of (8-carboxyoctyl)triphenylphosphonium bromide 
(270)267 (4.8 g, 9.6 mmol) in THF (100 mL) at -78 °C was added dropwise BuLi 
(1.6 M in cyclohexane, 12.6 mL, 20.1 mmol). After 30 min of stirring at -78 °C, a 
solution of (4R)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (269)268 (1.5 g, 11.5 
mmol) in THF (10 mL + 5 mL rinse) was slowly added. After the addition was 
complete, the reaction mixture was warmed to room temperature over a period of 
4 h, before saturated aqueous NH4Cl was added to quench the reaction. The 
resulting mixture was partially concentrated, residue was diluted with CH2Cl2 and 
the organic layer was extracted, dried and concentrated.  Chromatographic 
purification using 25% ethyl acetate in hexanes afforded 282 (1.95 g, 75%) as 
colorless liquid. [α]23D +7.7 (c 1.0); 1H NMR (500 MHz) δ 5.65-5.60 (m, 1H), 5.42-
5.39 (t, J = 10.0 Hz, 1H), 4.87-4.82 (q, J = 8.0 Hz, 1H), 4.08-4.05 (dd, J = 6.5, 8.0 
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Hz, 1H), 3.54-3.50 (t, J = 8.0 Hz, 1H), 2.36-2.33 (t, J = 7.5 Hz, 2H), 2.15-2.04 (m, 
2H), 1.66-1.61 (m, 2H), 1.43 (s, 3H), 1.41 (s, 3H), 1.39-1.32 (m, 8H); 13C NMR 
(125 MHz) δ 179.9, 135.4, 127.3, 109.3, 72.2, 69.7, 34.2, 29.7, 29.3, 29.2, 29.1, 
27.9, 27.0, 26.2, 24.8; ESI-HRMS Calcd for C15H25O4 [M - H]-: 269.1753. Found: 
269.1742. 
(9Z,4’S)-10-(2’,2’-Dimethyl-1’,3’-dioxolan-4’-yl)-1-
(triphenylphosphoranylidene)undec-9-en-2-one (283): To a stirred solution of 
282 (1.0 g, 3.7 mmol) in CH2Cl2 (15 mL) at 0 °C was added dropwise oxalyl 
chloride (480 µL, 5.5 mmol). After 30 min of stirring at 0 °C, the reaction mixture 
was refluxed for 2 h. Evaporation of solvent and excess oxalyl chloride, afforded 
(9Z,4’S)-10-(2’,2’-dimethyl-1’,3’-dioxolan-4’-yl)dec-9-enoyl chloride, which was 
taken forward without purification. 
To a stirred suspension of methyltriphenylphosphonium bromide (1.96 g, 
5.5 mmol) in THF (50 mL) at -78 °C was added dropwise BuLi (1.6 M in 
cyclohexane, 2.8 mL, 4.4 mmol). The mixture was stirred for 30 min at -78 °C, 
whereupon a solution of (9Z,4’S)-10-(2’,2’-dimethyl-1’,3’-dioxolan-4’-yl)dec-9-
enoyl chloride (3.7 mmol) in THF (8 mL + 4 mL rinse) was slowly added, and the 
final mixture mixture was warmed to room temperature over a period of 4 h. After 
evaporation of THF, the resulting oil was dissolved in ethyl acetate (50 mL) and 
the organic layer was washed with aqueous NaOH (2 N, 50 mL), dried, and 
concentrated. Chromatographic purification using 10% iso-propanol in ethyl 
acetate afforded 283 (1.72 g, 88%) as a yellow viscous oil. [α]23D +5.6 (c 1.0); 1H 
NMR (500 MHz) δ 7.69-7.62 (m, 6H), 7.54-7.51 (t, J = 7.0 Hz, 3H), 7.48-7.42 (m, 
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6H), 5.65-5.59 (m, 1H), 5.41-5.37 (t, J = 10.0 Hz, 1H), 4.86-4.82 (q, J = 8.0 Hz, 
1H), 4.06-4.04 (t, J = 7.0 Hz, 1H), 3.72-3.67 (d, J = 24 Hz, 1H), 3.51-3.48 (t, J = 
8.0 Hz, 1H), 2.32-2.29 (t, J = 7.5 Hz, 2H), 2.12-2.04 (m, 2H), 1.69-1.63 (m, 2H), 
1.41 (s, 3H), 1.39 (s, 3H), 1.37-1.31 (m, 8H); 13C NMR (125 MHz) δ 194.3, 135.5, 
133.3, 132.3, 129.0, 128.7-128.0 (d, J = 82.0 Hz), 127.2, 109.2, 72.2, 69.7, 51.6-
50.8 (d, J = 107.0 Hz), 42.0-41.9 (d, J = 15.0 Hz), 29.9, 29.6, 29.4, 28.0, 27.4, 
27.0, 26.2; ESI-HRMS Calcd for C34H42O3P [M + H]+: 529.2872. Found: 
529.2838.  
(2R,9E,19Z,4’S)-Methyl 20-(2’,2’-dimethyl-1’,3’-dioxolan-4’-yl)-2-
methyl-11-oxocos-9,19-dienoate (284): To a stirred solution of 283 (450 mg, 
0.85 mmol) in CH2Cl2 (5 mL) was added a solution of (2R)-methyl 2-methyl-9-
oxononanoate (280) (190 mg, 0.94 mmol) in CH2Cl2 (2 mL) at room temperature. 
After stirring for 30 min at same temperature, the mixture was warmed to 35 °C 
and stirring was continued for 12 h. The resulting mixture was concentrated and 
chromatographic purification of the crude using 15% ethyl acetate in hexanes 
afforded 284 (315 mg, 82%) as colorless syrup. [α]23D -5.2 (c 1.0); 1H NMR (500 
MHz) δ 6.84-6.78 (m, 1H), 6.09-6.06 (d, J = 16.0 Hz, 1H), 5.64-5.59 (m, 1H), 
5.41-5.37 (t, J = 10.0 Hz, 1H), 4.85-4.81 (q, J = 8.0 Hz, 1H), 4.07-4.04 (dd, J = 
6.0, 8.0 Hz, 1H), 3.66 (s, 3H), 3.52-3.49 (t, J = 8.0 Hz, 1H), 2.53-2.50 (t, J = 7.0 
Hz, 2H), 2.45-2.41 (q, J = 7.0 Hz, 1H), 2.21-2.17 (q, J = 7.0 Hz, 2H), 2.13-2.06 
(m, 2H), 1.64-1.58 (m, 4H), 1.42 (s, 3H), 1.39 (s, 3H), 1.38-1.29 (m, 16H), 1.14-
1.13 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 201.1, 177.5, 147.4, 135.3, 
130.5, 127.3, 109.2, 72.2, 69.7, 51.7, 40.3, 39.6, 33.9, 32.6, 29.8, 29.5, 29.4, 
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29.3, 29.2, 28.3, 27.9, 27.3, 27.0, 26.2, 24.5, 17.3; ESI-HRMS Calcd for 
C27H46O5 [M + Na]+: 473.3243. Found: 473.3233. 
(2S,9E,19Z,4’S)-Methyl 20-(2’,2’-dimethyl-1’,3’-dioxolan-4’-yl)-2-
methyl-11-oxocos-9,19-dienoate (285): Following the same procedure as for 
the preparation of 284, using 283 (480 mg, 0.91 mmol) and 281 (200 mg, 1.0 
mmol) as substrates, and eluting with 15% ethyl acetate in hexanes, 285 (350 
mg, 85%) was obtained as colorless syrup. [α]23D +13.6 (c 2.05); 1H NMR (500 
MHz) δ 6.82-6.76 (m, 1H), 6.08-6.04 (d, J = 16.0 Hz, 1H), 5.62-5.57 (m, 1H), 
5.39-5.35 (t, J = 10.0 Hz, 1H), 4.84-4.79 (q, J = 8.0 Hz, 1H), 4.05-4.02 (t, J = 7.0 
Hz, 1H), 3.65 (s, 3H), 3.50-3.42 (t, J = 8.0 Hz, 1H), 2.51-2.48 (t, J = 7.0 Hz, 2H), 
2.44-2.40 (q, J = 7.0 Hz, 1H), 2.19-2.15 (q, J = 7.0 Hz, 2H), 2.13-2.06 (m, 2H), 
1.62-1.56 (m, 3H), 1.40 (s, 3H), 1.37 (s, 3H), 1.36-1.28 (m, 17H), 1.12-1.11 (d, J 
= 7.0 Hz, 3H); 13C NMR (125 MHz) δ 201.1, 177.5, 147.4, 135.3, 130.5, 127.3, 
109.2, 72.2, 69.7, 51.7, 40.3, 39.6, 33.9, 32.6, 29.8, 29.5, 29.4, 29.3, 29.2, 28.2, 
27.9, 27.3, 27.0, 26.2, 24.4, 17.3.  
(2R,21S)-Methyl 21,22-dihydroxy-2-methyl-11-oxodocosanoate (286): 
To a solution of 284 (300 mg, 0.67 mmol) in MeOH: THF (v/v 3:1, 10 mL) was 
added AcOH (100 µL) and 10% Pd/C (45 mg). The mixture was purged with H2 
three times and shaken under H2 (50 psi) for 3 h. Then the reaction mixture was 
filtered through a Celite pad and washed with ethyl acetate (3 × 5 mL). 
Evaporation of the solvent afforded (2R,4’S)-methyl 20-(2’,2’-dimethyl-1’,3’-
dioxolan-4’-yl)-2-methyl-11-oxodocosanoate, which was taken forward without 
purification. 
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To a stirred solution of (2R,4’S)-methyl 20-(2’,2’-dimethyl-1’,3’-dioxolan-4’-
yl)-2-methyl-11-oxodocosanoate (300 mg, 0.67 mmol) in THF (5 mL) was added 
20% aqueous HCl  (5 mL) at room temperature. The reaction mixture was stirred 
at same temperature for 30 min before it was neutralized by saturated aqueous 
NaHCO3. The resulting mixture was partially concentrated, residue was diluted 
with ethyl acetate and the organic layer was extracted, dried and concentrated.  
Chromatographic purification using 55% ethyl acetate in hexanes afforded 286 
(235 mg, 85%) as white solid. [α]23D -9.2 (c 1.0); 1H NMR (500 MHz) δ 3.71-3.69 
(m, 1H), 3.67 (s, 3H), 3.64-3.62 (m, 1H), 3.43-3.41 (dd, J = 8.0, 11.0 Hz, 1H), 
2.45-2.41 (q, J = 7.0 Hz, 1H), 2.39-2.36 (t, J = 7.0 Hz, 4H), 2.33-2.25 (m, 2H), 
1.64-1.62 (m, 1H), 1.54-1.52 (m, 4H), 1.43-1.40 (m, 4H), 1.28-1.25 (m, 21H), 
1.14-1.13 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 212.1, 177.7, 72.5, 67.1, 
51.7, 43.0, 39.7, 34.0, 33.4, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 25.7, 24.0, 
17.3; ESI-HRMS Calcd for C24H46O5 [M + Na]+: 437.3243. Found: 437.3251. 
(2S,21S)-Methyl 21,22-dihydroxy-2-methyl-11-oxodocosanoate (287): 
Following the same reaction sequences as for the preparation of 286, using 285 
(350 mg, 0.77 mmol) as substrate, 287 (280 mg, 89%) was obtained as white 
solid. [α]23D +9.6 (c 1.0); 1H NMR (500 MHz) δ 3.70-3.68 (m, 1H), 3.65 (s, 3H), 
3.63-3.62 (m, 1H), 3.45-3.41 (t, J = 9.5 Hz, 1H), 2.61 (br s, 2H), 2.43-2.39 (q, J = 
7.0 Hz, 1H), 2.38-2.35 (t, J = 7.0 Hz, 4H), 1.63-1.61 (m, 1H), 1.53-1.51 (m, 4H), 
1.41-1.39 (m, 4H), 1.28-1.25 (m, 21H), 1.13-1.12 (d, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz) δ 212.1, 177.7, 72.5, 67.0, 51.7, 43.0, 39.7, 34.0, 33.4, 29.8, 29.6, 
29.5, 29.4, 29.3, 27.4, 25.7, 24.0, 17.2.  
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(2R,21S)-Methyl 22-tert-butyldiphenylsilyloxy-21-hydroxy-2-methyl-
11-oxodocosanoate (288): To a stirred solution of 286 (230 mg, 0.55 mmol) and 
imidazole (55 mg, 0.84 mmol) in DMF (1 mL) at room temperature was added 
TBDPSCl (155 µL, 0.60 mmol) and the stirring was continued at same 
temperature for 12 h. Then the reaction was quenched with water and extracted 
with ethyl acetate three times. The combined organic phase was washed with 
brine, dried and concentrated. Chromatographic purification using 15% ethyl 
acetate in hexanes afforded 288 (350 mg, 95%) as colorless syrup. [α]23D -3.8 (c 
1.0); 1H NMR (500 MHz) δ 7.68-7.66 (d, J = 7.5 Hz, 4H), 7.44-7.38 (m, 6H), 3.71-
3.69 (m, 1H), 3.67 (s, 3H), 3.65-3.63 (m, 1H), 3.51-3.47 (dd, J = 8.0, 11.0 Hz, 
1H), 2.53-2.52 (d, J = 3.0 Hz, 1H), 2.45-2.41 (q, J = 7.0 Hz, 1H), 2.39-2.36 (t, J = 
7.0 Hz, 4H), 1.64-1.62 (m, 1H), 1.57-1.54 (m, 4H), 1.40-1.38 (m, 4H), 1.28-1.25 
(m, 21H), 1.15-1.14 (d, J = 7.0 Hz, 3H), 1.08 (s, 9H); 13C NMR (125 MHz) δ 
211.9, 177.6, 135.8, 133.4, 130.0, 128.0, 72.2, 68.3, 51.7, 43.0, 39.7, 34.0, 33.0, 
29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 27.1, 25.7, 24.1, 24.0, 19.5, 17.3; ESI-
HRMS Calcd for C40H64O5Si [M + Na]+: 675.4421. Found: 675.4418.  
(2S,21S)-Methyl 22-tert-butyldiphenylsilyloxy-21-hydroxy-2-methyl-
11-oxodocosanoate (289): Following the same procedure as for the preparation 
of 288, using 287 (245 mg, 0.59 mmol) as substrate, and eluting with 15% ethyl 
acetate in hexanes, 289 (375 mg, 97%) was obtained as colorless syrup. [α]23D 
+8.0 (c 1.0); 1H NMR (500 MHz) δ 7.68-7.66 (d, J = 7.5 Hz, 4H), 7.46-7.40 (m, 
6H), 3.71-3.69 (m, 1H), 3.67 (s, 3H), 3.65-3.63 (m, 1H), 3.51-3.47 (dd, J = 7.5, 
10.5 Hz, 1H), 2.52 (br s, 1H), 2.44-2.41 (q, J = 7.0 Hz, 1H), 2.40-2.37 (t, J = 7.0 
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Hz, 4H), 1.64-1.62 (m, 1H), 1.57-1.54 (m, 4H), 1.40-1.38 (m, 4H), 1.28-1.25 (m, 
21H), 1.15-1.14 (d, J = 7.0 Hz, 3H), 1.08 (s, 9H); 13C NMR (125 MHz) δ 211.9, 
177.6, 135.8, 133.4, 130.0, 128.0, 72.2, 68.3, 51.7, 43.0, 39.7, 34.0, 33.0, 29.8, 
29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 27.1, 25.7, 24.1, 24.0, 19.5, 17.3.  
(2R,21R)-1-tert-Butyldiphenylsilyloxy-22-methoxy-21-methyl-12,22-
dioxodocosan-2-yl 4’-nitrobenzoate (290): Following the same procedure as 
for the preparation of 239, using 288 (350 mg, 0.54 mmol) as substrate, and 
eluting with 5% ethyl acetate in hexanes, 290 (385 mg, 90%) was obtained as 
light yellow syrup. [α]23D -2.0 (c 1.0); 1H NMR (500 MHz) δ 8.30-8.28 (d, J = 9.0 
Hz, 2H), 8.20-8.18 (d, J = 9.0 Hz, 2H), 7.64-7.61 (t, J = 7.0 Hz, 4H), 7.41-7.39 
(m, 2H), 7.35-7.31 (m, 4H), 5.30-5.28 (m, 1H), 3.85-3.84 (d, J = 4.5 Hz, 2H), 3.67 
(s, 3H), 2.45-2.41 (q, J = 7.0 Hz, 1H), 2.39-2.36 (t, J = 7.0 Hz, 4H), 1.78-1.74 (m, 
2H), 1.66-1.64 (m, 1H), 1.56-1.53 (m, 5H), 1.40-1.34 (m, 2H), 1.28-1.25 (m, 
20H), 1.15-1.14 (d, J = 7.0 Hz, 3H), 1.02 (s, 9H); 13C NMR (125 MHz) δ 211.8, 
177.6, 164.5, 150.7, 136.3, 135.8, 133.4, 130.9, 130.0, 127.9, 123.7, 76.6, 65.2, 
51.7, 43.0, 39.7, 34.0, 30.7, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 27.4, 26.9, 25.5, 
24.1, 24.1, 19.4, 17.3; ESI-HRMS Calcd for C47H67NO8Si [M + Na]+: 824.4534. 
Found: 824.4667.  
(2R,21S)-1-tert-Butyldiphenylsilyloxy-22-methoxy-21-methyl-12,22-
dioxodocosan-2-yl 4’-nitrobenzoate (291): Following the same procedure as 
for the preparation of 239, using 289 (170 mg, 0.26 mmol) as substrate, and 
eluting with 5% ethyl acetate in hexanes, 291 (195 mg, 94%) was obtained as 
light yellow syrup. [α]23D +7.8 (c 1.0); 1H NMR (400 MHz) δ 8.29-8.26 (d, J = 8.8 
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Hz, 2H), 8.18-8.16 (d, J = 8.8 Hz, 2H), 7.64-7.61 (t, J = 6.8 Hz, 4H), 7.40-7.37 
(m, 2H), 7.34-7.30 (m, 4H), 5.30-5.28 (m, 1H), 3.83-3.82 (d, J = 4.8 Hz, 2H), 3.66 
(s, 3H), 2.44-2.40 (q, J = 7.2 Hz, 1H), 2.38-2.34 (t, J = 7.2 Hz, 4H), 1.76-1.74 (m, 
2H), 1.66-1.64 (m, 1H), 1.56-1.53 (m, 5H), 1.40-1.34 (m, 2H), 1.28-1.25 (m, 
20H), 1.14-1.13 (d, J = 7.2 Hz, 3H), 1.0 (s, 9H); 13C NMR (100 MHz) δ 211.8, 
177.6, 164.5, 150.7, 136.3, 135.8, 133.4, 130.9, 130.0, 127.9, 123.7, 76.6, 65.2, 
51.6, 43.0, 39.7, 34.0, 30.6, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 27.4, 26.9, 25.4, 
24.1, 19.4, 17.3.  
(2R,21R)-Methyl 22-tert-butyldiphenylsilyloxy-21-hydroxy-2-methyl-
11-oxodocosanoate (292): Following the same procedure as for the preparation 
of 240, using 290 (380 mg, 0.47 mmol) as substrate, and eluting with 15% ethyl 
acetate in hexanes, 292 (260 mg, 84%) was obtained as colorless syrup. [α]23D -
7.5 (c 1.0); 1H and 13C NMR spectra data consistent with the enantiomer 
(2S,21S)-methyl 22-tert-butyldiphenylsilyloxy-21-hydroxy-2-methyl-11-
oxodocosanoate (289). 
(2S,21R)-Methyl 22-tert-butyldiphenylsilyloxy-21-hydroxy-2-methyl-
11-oxodocosanoate (293): Following the same procedure as for the preparation 
of 240, using 291 (195 mg, 0.24 mmol) as substrate, and eluting with 15% ethyl 
acetate in hexanes, 293 (140 mg, 88%) was obtained as colorless syrup. [α]23D 
+4.8 (c 1.0); 1H and 13C NMR spectra data consistent with the enantiomer 
(2R,21S)-methyl 22-tert-butyldiphenylsilyloxy-21-hydroxy-2-methyl-11-
oxodocosanoate (288). 
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(2R,21S)-Methyl 21-benzyloxy-22-tert-butyldiphenylsilyloxy-2-methyl-
11-oxodocosanoate (294): To a solution of the alcohol 288 (170 mg, 0.26 
mmol) in cyclohexane: CH2Cl2 (v/v 2:1, 2.5 mL) at 0 oC was added dropwise 
benzyl 2,2,2-trichloroacetimidate (95 µL, 0.5 mmol). After 10 min of stirring at 0 
oC, TfOH (7 µL, 0.1 mmol) was added and the resulting light yellow solution was 
stirred at room temperature for 1 h. The reaction was quenched with the addition 
of saturated aqueous NaHCO3 and the mixture was extracted with CH2Cl2 three 
times. The combined organic phase was washed with brine, dried and 
concentrated. Chromatographic purification using 8% ethyl acetate in hexanes 
afforded 294 (175 mg, 91%) as colorless syrup. [α]23D -17.0 (c 1.0); 1H NMR (500 
MHz) δ 7.72-7.70 (m, 4H), 7.44-7.42 (dd, J = 1.5, 7.5 Hz, 2H), 7.40-7.36 (m, 7H), 
7.34-7.33 (d, J = 4.5 Hz, 2H), 4.70-4.68 (d, J = 11.5 Hz, 1H), 4.55-4.52 (d, J = 
11.5 Hz, 1H), 3.78-3.74 (dd, J = 7.0, 10.0 Hz, 1H), 3.68 (s, 3H), 3.67-3.65 (m, 
1H), 3.48-3.44 (m, 1H), 2.47-2.43 (q, J = 7.0 Hz, 1H), 2.41-2.38 (t, J = 7.5 Hz, 
4H), 1.67-1.65 (m, 1H), 1.58-1.53 (m, 5H), 1.40-1.34 (m, 2H), 1.28-1.25 (m, 
22H), 1.17-1.15 (d, J = 7.0 Hz, 3H), 1.09 (s, 9H); 13C NMR (125 MHz) δ 211.9, 
177.6, 139.3, 135.9, 135.1, 133.9, 129.8, 128.5, 128.0, 127.9, 80.1, 72.3, 66.7, 
51.7, 43.2, 39.7, 34.0, 31.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 27.4, 
27.1, 26.8, 25.6, 24.1, 19.5, 17.3. ESI-HRMS Calcd for C47H70O5Si [M + Na]+: 
765.4890. Found: 765.4887.  
(2S,21S)-Methyl 21-benzyloxy-22-tert-butyldiphenylsilyloxy-2-methyl-
11-oxodocosanoate (295): Following the same procedure as for the preparation 
of 294, using 289 (215 mg, 0.33 mmol) as substrate, and eluting with 8% ethyl 
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acetate in hexanes, 295 (200 mg, 82%) was obtained as colorless syrup. [α]23D -
8.7 (c 1.0); 1H NMR (500 MHz) δ 7.72-7.69 (m, 4H), 7.44-7.42 (dd, J = 1.5, 7.5 
Hz, 2H), 7.40-7.36 (m, 7H), 7.34-7.33 (d, J = 4.5 Hz, 2H), 4.70-4.67 (d, J = 11.5 
Hz, 1H), 4.54-4.52 (d, J = 11.5 Hz, 1H), 3.78-3.75 (dd, J = 6.0, 10.0 Hz, 1H), 3.68 
(s, 3H), 3.67-3.64 (m, 1H), 3.47-3.43 (m, 1H), 2.46-2.42 (q, J = 7.0 Hz, 1H), 2.41-
2.38 (t, J = 7.5 Hz, 4H), 1.63-1.60 (m, 1H), 1.58-1.53 (m, 5H), 1.40-1.34 (m, 2H), 
1.28-1.25 (m, 22H), 1.16-1.15 (d, J = 7.5 Hz, 3H), 1.08 (s, 9H); 13C NMR (125 
MHz) δ 211.9, 177.6, 139.3, 135.9, 135.1, 133.9, 129.8, 128.5, 128.0, 127.9, 
80.1, 72.3, 66.6, 51.7, 43.1, 39.7, 34.0, 31.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.5, 
29.4, 29.3, 27.4, 27.1, 26.8, 25.6, 24.1, 19.5, 17.3. 
(2R,21R)-Methyl 21-benzyloxy-22-tert-butyldiphenylsilyloxy-2-methyl-
11-oxodocosanoate (296): Following the same procedure as for the preparation 
of 294, using 292 (230 mg, 0.35 mmol) as substrate, and eluting with 8% ethyl 
acetate in hexanes, 296 (230 mg, 88%) was obtained as colorless syrup. [α]23D 
+8.4 (c 1.0); 1H and 13C NMR spectra data consistent with the enantiomer 
(2S,21S)-methyl 21-benzyloxy-22-tert-butyldiphenylsilyloxy-2-methyl-11-
oxodocosanoate (295). 
(2S,21R)-Methyl 21-benzyloxy-22-tert-butyldiphenylsilyloxy-2-methyl-
11-oxodocosanoate (297): Following the same procedure as for the preparation 
of 294, using 293 (110 mg, 0.17 mmol) as substrate, and eluting with 8% ethyl 
acetate in hexanes, 297 (105 mg, 84%) was obtained as colorless syrup. [α]23D 
+17.9 (c 1.0); 1H and 13C NMR spectra data consistent with the enantiomer 
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(2R,21S)-methyl 21-benzyloxy-22-tert-butyldiphenylsilyloxy-2-methyl-11-
oxodocosanoate (294). 
(2R,21S)-Methyl 21-benzyloxy-22-hydroxy-2-methyl-11-
oxodocosanoate (298): To a solution of 294 (135 mg, 0.18 mmol) in MeOH: 
THF (v/v 3:1, 2 mL) was added PTSA (45 mg, 0.27 mmol) and the mixture was 
stirred at room temperature for 24 h. After which the reaction mixture was 
concentrated and chromatographic purification using 25% ethyl acetate in 
hexanes afforded 298 (88 mg, 96%) as colorless foam. [α]23D +2.6 (c 1.0); 1H 
NMR (500 MHz) δ 7.36-7.35 (m, 4H), 7.32-7.28 (q, J = 5.0 Hz, 1H), 4.64-4.62 (d, 
J = 11.5 Hz, 1H), 4.56-4.54 (d, J = 11.5 Hz, 1H), 3.71-3.68 (m, 1H), 3.67 (s, 3H), 
3.55-3.51 (m, 2H), 2.44-2.41 (q, J = 7.0 Hz, 1H), 2.40-2.37 (t, J = 7.0 Hz, 4H), 
1.99 (br s, 1H), 1.66-1.64 (m, 2H), 1.58-1.53 (m, 5H), 1.40-1.33 (m, 3H), 1.28-
1.26 (m, 20H), 1.15-1.14 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 211.9, 177.6, 
138.8, 128.7, 128.0, 127.9, 80.0, 71.7, 64.5, 51.7, 43.0, 39.7, 34.0, 31.0, 30.0, 
29.8, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 27.4, 25.6, 24.1, 17.3. ESI-HRMS Calcd 
for C31H52O5 [M + Na]+: 527.3712. Found: 527.3725.  
(2S,21S)-Methyl 21-benzyloxy-22-hydroxy-2-methyl-11-
oxodocosanoate (299): Following the same procedure as for the preparation of 
298, using 295 (190 mg, 0.26 mmol) as substrate, and eluting with 25% ethyl 
acetate in hexanes, 299 (120 mg, 93%) was obtained as colorless foam. [α]23D 
+18.1 (c 1.0); 1H NMR (500 MHz) δ 7.36-7.35 (m, 4H), 7.32-7.28 (q, J = 5.0 Hz, 
1H), 4.64-4.62 (d, J = 11.5 Hz, 1H), 4.56-4.54 (d, J = 11.5 Hz, 1H), 3.71-3.369 
(m, 1H), 3.67 (s, 3H), 3.56-3.51 (m, 2H), 2.44-2.40 (q, J = 7.0 Hz, 1H), 2.39-2.36 
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(t, J = 7.0 Hz, 4H), 1.97 (br s, 1H), 1.66-1.64 (m, 2H), 1.58-1.53 (m, 5H), 1.40-
1.33 (m, 3H), 1.28-1.26 (m, 20H), 1.15-1.13 (d, J = 7.0 Hz, 3H); 13C NMR (125 
MHz) δ 211.9, 177.6, 138.8, 128.7, 128.0, 127.9, 80.1, 71.7, 64.5, 51.7, 43.0, 
39.7, 34.0, 31.1, 30.0, 29.8, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 27.4, 25.6, 24.1, 
17.3.  
(2R,21R)-Methyl 21-benzyloxy-22-hydroxy-2-methyl-11-
oxodocosanoate (300): Following the same procedure as for the preparation of 
298, using 296 (225 mg, 0.3 mmol) as substrate, and eluting with 25% ethyl 
acetate in hexanes, 300 (145 mg, 95%) was obtained as colorless foam. [α]23D -
17.4 (c 1.0); 1H and 13C NMR spectra data consistent with the enantiomer 
(2S,21S)-methyl 21-benzyloxy-22-hydroxy-2-methyl-11-oxodocosanoate (299). 
(2S,21R)-Methyl 21-benzyloxy-22-hydroxy-2-methyl-11-
oxodocosanoate (301): Following the same procedure as for the preparation of 
298, using 297 (100 mg, 0.14 mmol) as substrate, and eluting with 25% ethyl 
acetate in hexanes, 301 (65 mg, 95%) was obtained as colorless foam. [α]23D -2.0 
(c 1.0); 1H and 13C NMR spectra data consistent with the enantiomer (2R,21S)-
methyl 21-benzyloxy-22-hydroxy-2-methyl-11-oxodocosanoate (298). 
(2R,21S)-Methyl 21-benzyloxy-22-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-2-methyl-11-oxodocosanoate (302): 
Following the general procedure 8, using 298 (85 mg, 0.17 mmol) as acceptor, a 
mixture of α/β = 1:5.8 was obtained. Chromatographic purification of the mixture 
using 12% ethyl acetate in hexanes afforded 302 (90 mg, 58%) as colorless 
syrup. [α]24D -41.0 (c 1.0); 1H NMR (500 MHz) δ 7.52-7.50 (d, J = 7.0 Hz, 2H), 
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7.46-7.45 (d, J = 6.0 Hz, 2H), 7.39-7.38 (d, J = 7.5 Hz, 2H), 7.32-7.29 (m, 14H), 
5.63 (s, 1H), 5.0-4.97 (d, J = 12.0 Hz, 1H), 4.88-4.86 (d, J = 12.0 Hz, 1H), 4.68-
4.65 (d, J = 12.5 Hz, 1H), 4.65-4.59 (m, 2H), 4.58-4.55 (d, J = 12.5 Hz, 1H), 4.50 
(s, 1H), 4.33-4.30 (dd, J = 5.0, 10.5 Hz, 1H), 4.23-4.19 (t, J = 9.5 Hz, 1H), 4.0-
3.97 (dd, J = 3.5 Hz, 10.5 Hz, 1H), 3.96-3.91 (m, 2H), 3.68 (s, 3H), 3.67-3.65 (m, 
1H), 3.57-3.53 (m, 2H), 3.35-3.31 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 2.47-2.43 (q, J 
= 7.0 Hz, 1H), 2.40-2.37 (t, 7.0 Hz, 4H), 1.65-1.56 (m, 4H), 1.43-1.39 (m, 2H), 
1.30-1.28 (m, 24H) 1.16-1.14 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 211.9, 
177.6, 139.2, 138.7, 138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 
127.8, 127.7, 126.3, 103.0, 101.7, 79.0, 78.9, 78.2, 76.2, 75.1, 73.8, 72.7, 72.6, 
68.8, 67.8, 51.7, 43.0, 30.7, 34.0, 32.0, 30.0, 29.8, 29.7, 29.6, 29.5, 29.4, 27.4, 
25.7, 24.2, 24.1, 17.3; ESI-HRMS Calcd for C58H78O10 [M + Na]+ : 957.5493. 
Found: 957.5488. 
(2S,21S)-Methyl 21-benzyloxy-22-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-2-methyl-11-oxodocosanoate (303): 
Following the general procedure 8, using 299 (90 mg, 0.18 mmol) as acceptor, a 
mixture of α/β = 1:6.2 was obtained. Chromatographic purification of the mixture 
using 12% ethyl acetate in hexanes afforded 303 (100 mg, 60%) as colorless 
syrup. [α]23D -38.1 (c 1.0); 1H NMR (500 MHz) δ 7.53-7.51 (d, J = 8.0 Hz, 2H), 
7.46-7.45 (d, J = 6.0 Hz, 2H), 7.39-7.38 (d, J = 7.5 Hz, 2H), 7.32-7.29 (m, 14H), 
5.63 (s, 1H), 5.0-4.97 (d, J = 12.0 Hz, 1H), 4.88-4.86 (d, J = 12.0 Hz, 1H), 4.68-
4.66 (d, J = 12.0 Hz, 1H), 4.64-4.59 (m, 2H), 4.58-4.56 (d, J = 12.5 Hz, 1H), 4.50 
(s, 1H), 4.34-4.31 (dd, J = 5.0, 10.5 Hz, 1H), 4.24-4.20 (t, J = 9.5 Hz, 1H), 4.0-
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3.97 (dd, J = 3.5 Hz, 10.5 Hz, 1H), 3.97-3.91 (m, 2H), 3.68 (s, 3H), 3.67-3.65 (m, 
1H), 3.57-3.53 (m, 2H), 3.35-3.31 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 2.47-2.43 (q, J 
= 7.0 Hz, 1H), 2.40-2.37 (t, 7.0 Hz, 4H), 1.65-1.56 (m, 4H), 1.43-1.39 (m, 2H), 
1.30-1.28 (m, 24H) 1.16-1.15 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 211.9, 
177.6, 139.2, 138.7, 138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 
127.8, 127.7, 126.3, 103.0, 101.7, 79.0, 78.9, 78.2, 76.2, 75.1, 73.8, 72.7, 72.6, 
68.8, 67.8, 51.7, 43.1, 40.0, 34.0, 32.0, 30.0, 29.8, 29.7, 29.6, 29.5, 29.4, 27.4, 
25.7, 24.2, 24.1, 17.3.   
(2R,21R)-Methyl 21-benzyloxy-22-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-2-methyl-11-oxodocosanoate (304): 
Following the general procedure 8, using 300 (130 mg, 0.28 mmol) as acceptor, 
a mixture of α/β = 1:6.5 was obtained. Chromatographic purification of the 
mixture using 12% ethyl acetate in hexanes afforded 304 (145 mg, 61%) as 
colorless syrup. [α]24D -36.8 (c 1.0); 1H NMR (500 MHz) δ 7.53-7.52 (d, J = 7.0 
Hz, 2H), 7.48-7.47 (d, J = 7.0 Hz, 2H), 7.40-7.38 (d, J = 7.5 Hz, 2H), 7.37-7.27 
(m, 14H), 5.64 (s, 1H), 5.02-4.99 (d, J = 12.0 Hz, 1H), 4.90-4.88 (d, J = 12.0 Hz, 
1H), 4.70-4.68 (d, J = 12.5 Hz, 1H), 4.66-4.64 (d, J = 11.5 Hz, 1H), 4.61-4.59 (d, 
J = 12.0 Hz, 1H), 4.59-4.56 (d, J = 11.5 Hz, 1H), 4.45 (s, 1H), 4.34-4.31 (dd, J = 
5.0, 10.5 Hz, 1H), 4.24-4.21 (t, J = 9.5 Hz, 1H), 4.03-4.0 (dd, J = 3.5 Hz, 10.5 Hz, 
1H), 3.97-3.93 (m, 2H), 3.68 (s, 3H), 3.58-3.55 (m, 3H), 3.34-3.29 (ddd, J = 5.0, 
9.0, 9.8 Hz, 1H), 2.47-2.43 (q, J = 7.0 Hz, 1H), 2.40-2.37 (t, 7.0 Hz, 4H), 1.65-
1.56 (m, 4H), 1.43-1.39 (m, 2H), 1.30-1.28 (m, 24H) 1.16-1.15 (d, J = 7.0 Hz, 
3H); 13C NMR (125 MHz) δ 211.9, 177.6, 139.1, 138.7, 138.6, 137.8, 129.1, 
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128.9, 128.6, 128.5, 128.4, 128.3, 128.0, 127.8, 126.3, 102.8, 101.6, 78.9, 78.2, 
78.1, 76.0, 75.0, 72.6, 71.9, 71.4, 68.8, 67.9, 51.7, 43.0, 40.0, 34.0, 32.2, 30.0, 
29.8, 29.7, 29.6, 29.5, 29.4, 27.4, 25.7, 24.2, 24.0, 17.3.  
(2S,21R)-Methyl 21-benzyloxy-22-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-2-methyl-11-oxodocosanoate (305): 
Following the general procedure 8, using 301 (60 mg, 0.12 mmol) as acceptor, a 
mixture of α/β = 1:5.4 was obtained. Chromatographic purification of the mixture 
using 12% ethyl acetate in hexanes afforded 305 (65 mg, 58%) as colorless 
syrup. [α]23D -33.8 (c 1.0); 1H NMR (500 MHz) δ 7.52-7.51 (d, J = 6.0 Hz, 2H), 
7.47-7.46 (d, J = 6.0 Hz, 2H), 7.40-7.38 (d, J = 7.5 Hz, 2H), 7.35-7.28 (m, 14H), 
5.63 (s, 1H), 5.01-4.99 (d, J = 12.5 Hz, 1H), 4.89-4.87 (d, J = 12.5 Hz, 1H), 4.70-
4.67 (d, J = 13.0 Hz, 1H), 4.65-4.63 (d, J = 12 Hz, 1H), 4.60-4.58 (d, J = 12 Hz, 
1H), 4.58-4.56 (d, J = 11.5 Hz, 1H), 4.45 (s, 1H), 4.33-4.30 (dd, J = 5.0, 10.5 Hz, 
1H), 4.24-4.20 (t, J = 9.5 Hz, 1H), 4.02-3.99 (dd, J = 3.5 Hz, 10.5 Hz, 1H), 3.97-
3.93 (m, 2H), 3.68 (s, 3H), 3.58-3.54 (m, 3H), 3.33-3.28 (ddd, J = 5.0, 9.0, 9.8 
Hz, 1H), 2.46-2.42 (q, J = 7.0 Hz, 1H), 2.40-2.37 (t, 7.0 Hz, 4H), 1.65-1.56 (m, 
4H), 1.43-1.39 (m, 2H), 1.30-1.28 (m, 24H) 1.16-1.15 (d, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz) δ 211.9, 177.6, 139.0, 138.7, 138.6, 137.8, 129.1, 128.8, 128.6, 
128.5, 128.4, 128.3, 127.9, 127.7, 126.3, 102.8, 101.6, 78.8, 78.2, 78.1, 76.0, 
75.0, 72.5, 71.9, 71.4, 68.8, 67.9, 51.7, 43.0, 40.0, 34.0, 32.2, 30.0, 29.8, 29.7, 
29.6, 29.5, 29.4, 27.4, 25.7, 24.1, 24.0, 17.3. 
(4R,23S)-S-tert-Butyl 23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-4-methyl-3,13-
187 
 
dioxothiotetracosanoate (306): To a solution of 302 (80 mg, 0.085 mmol) in 
dioxane (1 mL)  at room temperature was added aqueous LiOH (2.0 M, 1 mL). 
The mixture was warmed to 45 oC and stirred at same temperature for 12 h. After 
which the mixture was cooled to room temperature, stirred with saturated 
aqueous NH4Cl for 30 min, and extracted with ethyl acetate three times. The 
combined organic phase was washed with brine and dried. Evaporation of 
solvent afforded the desired acid (quantitative), which was used directly for the 
next step. 
Following the same procedure as for the preparation of 255, using 
(2R,21S)-21-benzyloxy-22-(2’,3’-di-O-benzyl-4’,6’-O-benzylidene-β-D-
mannopyranosyloxy)-2-methyl-11-oxodocosanoic acid (80 mg, 0.085 mmol) as 
substrate, and eluting with 15% ethyl acetate in hexanes, 306 (70 mg, 85%, a 6:5 
mixture of keto and enol forms) was obtained as light orange syrup. [α]24D -38.5 
(c 1.0); 1H NMR (500 MHz) δ 7.52-7.51 (dd, J = 1.5, 7.5 Hz, 2H), 7.46-7.45 (d, J 
= 7.5 Hz, 2H), 7.39-7.38 (d, J = 7.5 Hz, 2H), 7.32-7.27 (m, 14H), 5.63 (s, 1H), 
5.33 (s, 5/11H), 4.99-4.97 (d, J = 12.5 Hz, 1H), 4.88-4.86 (d, J = 12.5 Hz, 1H), 
4.68-4.66 (d, J = 12.5 Hz, 1H), 4.63-4.62 (m, 2H), 4.58-4.55 (d, J = 12.5 Hz, 1H), 
4.50 (s, 1H), 4.34-4.31 (dd, J = 5.0, 10.5 Hz, 1H), 4.23-4.19 (t, J = 9.5 Hz, 1H), 
3.99-3.96 (dd, J = 3.0, 10.0 Hz, 1H), 3.96-3.92 (m, 2H), 3.68-3.66 (m, 1H), 3.61 
(s, 12/11H), 3.57-3.53 (m, 2H), 3.35-3.30 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 2.69-
2.65 (q, J = 7.0 Hz, 6/11H), 2.40-2.37 (t, J = 7.0 Hz, 4H), 2.14-2.11 (q, J = 7.0 Hz, 
5/11H), 1.66-1.56 (m, 8H), 1.53 (s, 45/11H), 1.49 (s, 54/11H), 1.47-1.44 (m, 1H), 
1.40-1.34 (m, 1H), 1.30-1.28 (m, 20H) 1.13-1.11 (d, J = 7.0 Hz, 15/11H), 1.11-
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1.09 (d, J = 7.0 Hz, 18/11H); 13C NMR (125 MHz) δ 211.9, 206.3, 196.5, 192.8, 
180.6, 139.2, 138.7, 138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 
127.8, 127.7, 127.6, 126.3, 103.0, 101.7, 98.7, 79.0, 78.9, 78.2, 76.2, 75.1, 73.8, 
72.7, 72.6, 68.8, 67.8, 57.1, 49.2, 48.3, 46.8, 43.1, 39.7, 34.3, 32.8, 32.0, 30.4, 
30.0, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 27.5, 27.3, 25.5, 24.1, 18.2, 16.2; ESI-
HRMS Calcd for C63H86O10S [M + Na]+ : 1057.5839. Found: 1057.5872.  
(4S,23S)-S-tert-Butyl 23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-4-methyl-3,13-
dioxothiotetracosanoate (307): Following the same procedure as for the 
preparation of 306, using 303 (70 mg, 0.075 mmol) as substrate, and eluting with 
15% ethyl acetate in hexanes, 307 (63 mg, 81%, a 7:5 mixture of keto  and enol 
forms) was obtained as light orange syrup. [α]23D -27.5 (c 1.0); 1H NMR (500 
MHz) δ 7.52-7.51 (dd, J = 1.5, 7.5 Hz, 2H), 7.46-7.45 (d, J = 7.5 Hz, 2H), 7.39-
7.38 (d, J = 7.5 Hz, 2H), 7.32-7.27 (m, 14H), 5.63 (s, 1H), 5.33 (s, 5/12H), 4.99-
4.97 (d, J = 12.5 Hz, 1H), 4.88-4.86 (d, J = 12.5 Hz, 1H), 4.68-4.66 (d, J = 12.5 
Hz, 1H), 4.64-4.62 (m, 2H), 4.58-4.56 (d, J = 12.5 Hz, 1H), 4.50 (s, 1H), 4.34-
4.32 (dd, J = 5.0, 10.5 Hz, 1H), 4.23-4.19 (t, J = 9.5 Hz, 1H), 4.0-3.96 (dd, J = 
3.0, 10.0 Hz, 1H), 3.97-3.92 (m, 2H), 3.64-3.60 (m, 1H), 3.61 (s, 14/12H), 3.57-
3.53 (m, 2H), 3.35-3.30 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 2.66-2.65 (q, J = 7.0 Hz, 
7/12H), 2.40-2.37 (t, J = 7.0 Hz, 4H), 2.13-2.2.11 (q, J = 7.0 Hz, 5/12H), 1.66-
1.56 (m, 8H), 1.53 (s, 45/12H), 1.49 (s, 63/12H), 1.47-1.44 (m, 1H), 1.40-1.34 (m, 
1H), 1.30-1.28 (m, 20H) 1.13-1.11 (d, J = 7.0 Hz, 15/12H), 1.11-1.09 (d, J = 7.0 
Hz, 21/12H); 13C NMR (125 MHz) δ 211.9, 206.3, 196.5, 192.8, 180.6, 139.2, 
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138.7, 138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 127.8, 127.7, 
127.6, 126.3, 103.0, 101.7, 98.7, 78.9, 78.8, 78.2, 75.1, 73.8, 72.7, 72.6, 68.8, 
67.8, 57.0, 49.2, 48.4, 46.8, 43.1, 39.7, 34.3, 32.8, 32.0, 30.4, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 27.5, 27.3, 25.5, 24.1, 24.0, 18.2, 16.2.    
(4R,23R)-S-tert-Butyl 23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-4-methyl-3,13-
dioxothiotetracosanoate (308): Following the same procedure as for the 
preparation of 306, using 304 (128 mg, 0.14 mmol) as substrate, and eluting with 
15% ethyl acetate in hexanes, 308 (130 mg, 90%, a 8:5 mixture of keto and enol 
forms) was obtained as light orange syrup. [α]24D -36.8 (c 1.0); 1H NMR (500 
MHz) δ 7.53-7.52 (d, J = 6.5 Hz, 2H), 7.48-7.47 (d, J = 6.5 Hz, 2H), 7.40-7.38 (d, 
J = 7.0 Hz, 2H), 7.37-7.31 (m, 14H), 5.64 (s, 1H), 5.34 (s, 5/13H), 5.02-4.99 (d, J 
= 12.5 Hz, 1H), 4.90-4.88 (d, J = 12.5 Hz, 1H), 4.70-4.68 (d, J = 12.5 Hz, 1H), 
4.66-4.64 (d, J = 12.5 Hz, 1H), 4.61-4.59 (d, J = 12.0 Hz, 1H), 4.59-4.57 (d, J = 
11.5 Hz, 1H), 4.45 (s, 1H), 4.34-4.31 (dd, J = 5.0, 10.5 Hz, 1H), 4.25-4.21 (t, J = 
9.5 Hz, 1H), 4.01-3.99 (m, 1H), 4.0-3.94 (m, 2H), 3.61 (s, 16/13H), 3.58-3.55 (m, 
3H), 3.34-3.29 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 2.67-2.66 (q, J = 7.0 Hz, 8/13H), 
2.41-2.38 (t, J = 7.0 Hz, 4H), 2.15-2.2.12 (q, J = 7.0 Hz, 5/13H), 1.66-1.56 (m, 
8H), 1.54 (s, 45/13H), 1.50 (s, 72/13H), 1.47-1.44 (m, 1H), 1.40-1.34 (m, 1H), 
1.30-1.28 (m, 20H) 1.15-1.13 (d, J = 7.0 Hz, 15/13H), 1.11-1.10 (d, J = 7.0 Hz, 
24/13H); 13C NMR (125 MHz) δ 211.8, 206.2, 196.5, 192.8, 180.6, 139.1, 138.7, 
138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 127.9, 127.8, 126.3, 
102.8, 101.6, 98.7, 78.9, 78.2, 78.1, 75.0, 72.6, 71.9, 71.4, 68.8, 67.9, 57.1, 49.2, 
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48.3, 46.8, 43.1, 39.7, 34.3, 32.8, 30.4, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 27.5, 
27.3, 25.7, 24.1, 24.0, 18.2, 16.2.  
(4S,23R)-S-tert-Butyl 23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-
benzylidene-β-D-mannopyranosyloxy)-4-methyl-3,13-
dioxothiotetracosanoate (309): Following the same procedure as for the 
preparation of 306, using 305 (60 mg, 0.065 mmol) as substrate, and eluting with 
15% ethyl acetate in hexanes, 309 (58 mg, 88%, a 5:2 mixture of keto and enol 
forms) was obtained as light orange syrup. [α]24D -24.3 (c 1.0); 1H NMR (500 
MHz) δ 7.52-7.51 (d, J = 6.0 Hz, 2H), 7.47-7.46 (d, J = 6.5 Hz, 2H), 7.40-7.38 (d, 
J = 7.5 Hz, 2H), 7.37-7.28 (m, 14H), 5.63 (s, 1H), 5.33 (s, 2/7H), 5.01-4.99 (d, J = 
12.5 Hz, 1H), 4.90-4.87 (d, J = 12.5 Hz, 1H), 4.70-4.67 (d, J = 12.5 Hz, 1H), 4.65-
4.63 (d, J = 11.5 Hz, 1H), 4.61-4.58 (d, J = 12.0 Hz, 1H), 4.58-4.56 (d, J = 11.5 
Hz, 1H), 4.45 (s, 1H), 4.33-4.30 (dd, J = 5.0, 10.5 Hz, 1H), 4.24-4.20 (t, J = 9.5 
Hz, 1H), 4.02-3.99 (dd, J = 3.0, 8.5 Hz, 1H), 3.97-3.94 (m, 2H), 3.61 (s, 10/7H), 
3.58-3.54 (m, 3H), 3.34-3.29 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 2.69-2.66 (q, J = 7.0 
Hz, 5/7H), 2.40-2.37 (t, J = 7.0 Hz, 4H), 2.15-2.12 (q, J = 7.0 Hz, 2/7H), 1.66-1.56 
(m, 8H), 1.53 (s, 18/7H), 1.49 (s, 45/7H), 1.47-1.44 (m, 1H), 1.40-1.34 (m, 1H), 
1.30-1.28 (m, 20H) 1.13-1.11 (d, J = 7.0 Hz, 6/7H), 1.11-1.09 (d, J = 7.0 Hz, 
15/7H); 13C NMR (125 MHz) δ 211.8, 206.2, 196.5, 192.8, 180.6, 139.0, 138.7, 
138.6, 137.8, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 127.9, 127.8, 126.3, 
102.8, 101.6, 98.7, 78.9, 78.2, 78.1, 76.0, 75.0, 71.9, 71.4, 68.8, 67.9, 57.0, 49.2, 
48.3, 46.8, 43.1, 39.7, 34.3, 32.8, 32.2, 30.4, 30.0, 29.9, 29.8, 29.7, 29.6, 29.5, 
29.4, 27.5, 27.3, 25.7, 24.5, 24.1, 24.0, 18.2, 16.2.  
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(4R,23S)-N-[23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-benzylidene-β-
D-mannopyranosyloxy)-4-methyl-3,13-dioxotetracosanoyl]-N-(2’,4’,6’-
trimethoxybenzyl)-O-benzyl-L-tyrosine methyl ester (310): Following the 
same procedure as for the preparation of 261, using 306 (65 mg, 0.063 mmol) as 
substrate, and eluting with 35% ethyl acetate in hexanes, 310 (59 mg, 67%, a 
mixture of rotomers) was obtained as light yellow foam. [α]23D -49.4 (c 1.0); 1H 
NMR (500 MHz) δ 7.52-7.51 (d, J = 6.0 Hz, 2H), 7.47-7.45 (m, 4H), 7.40-7.28 (m, 
19H), 6.96-6.94 (d, J = 8.0 Hz, 2H), 6.80-6.78 (d, J = 8.0 Hz, 2H), 6.03 (s, 2H), 
5.63 (s, 1H), 5.03 (s, 2H), 4.98-4.96 (d, J = 12.0 Hz, 1H), 4.88-4.86 (d, J = 12.0 
Hz, 1H), 4.68-4.65 (d, J = 12.5 Hz, 1H), 4.63-4.62 (m, 2H), 4.58-4.55 (d, J = 12.0 
Hz, 1H), 4.50 (s, 1H), 4.36-4.31 (m, 2H), 4.23-4.20 (t, J = 9.5 Hz, 1H), 4.17-4.14 
(m, 1H), 4.00-3.97 (dd, J = 3.0, 11.0 Hz, 1H), 3.96-3.89 (m, 4H), 3.81 (s, 3H), 
3.72 (s, 6H), 3.67-3.65 (m, 1H), 3.59 (s, 3H), 3.56-3.53 (m, 2H), 3.39-3.30 (m, 
2H), 3.01-2.97 (dd, J = 5.5, 14.0 Hz, 1H), 2.79-2.75 (q, J = 7.0 Hz, 1H), 2.39-2.37 
(m, 4H), 1.76-1.74 (m, 1H), 1.64-1.58 (m, 9H), 1.34-1.28 (m, 20H) 1.15-1.13 (d, J 
= 7.0 Hz, 3H); 13C NMR (125 MHz) δ 211.9, 209.0, 171.7, 167.5, 161.7, 159.9, 
157.3, 139.2, 138.7, 138.6, 137.8, 137.5, 131.6, 130.6, 129.1, 128.8, 128.6, 
128.5, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 126.3, 114.5, 104.2, 103.0, 
101.6, 90.6, 79.0, 78.9, 78.2, 76.2, 75.1, 73.8, 72.7, 72.6, 70.2, 68.8, 67.8, 61.0, 
55.6, 55.5, 52.1, 48.8, 46.3, 43.0, 42.8, 34.7, 33.0, 32.0, 30.0, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 27.3, 25.5, 24.1, 16.0; ESI-HRMS Calcd for C86H107NO16 [M + 
Na]+ : 1432.7488. Found: 1432.7444.  
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(4S,23S)-N-[23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-benzylidene-β-
D-mannopyranosyloxy)-4-methyl-3,13-dioxotetracosanoyl]-N-(2’,4’,6’-
trimethoxybenzyl)-O-benzyl-L-tyrosine methyl ester (311): Following the 
same procedure as for the preparation of 261, using 307 (57 mg, 0.038 mmol) as 
substrate, and eluting with 35% ethyl acetate in hexanes, 311 (50 mg, 65%, a 
mixture of rotomers) was obtained as light yellow foam. [α]23D -35.8 (c 1.0); 1H 
NMR (500 MHz) δ 7.53-7.52 (d, J = 6.0 Hz, 2H), 7.47-7.45 (m, 4H), 7.40-7.28 (m, 
19H), 6.97-6.96 (d, J = 8.0 Hz, 2H), 6.81-6.80 (d, J = 8.0 Hz, 2H), 6.04 (s, 2H), 
5.64 (s, 1H), 5.04 (s, 2H), 5.00-4.98 (d, J = 12.0 Hz, 1H), 4.89-4.87 (d, J = 12.0 
Hz, 1H), 4.69-4.66 (d, J = 12.5 Hz, 1H), 4.63-4.60 (m, 2H), 4.59-4.56 (d, J = 12.0 
Hz, 1H), 4.50 (s, 1H), 4.37-4.31 (m, 2H), 4.24-4.20 (t, J = 9.5 Hz, 1H), 4.15-4.12 
(m, 1H), 4.01-3.98 (dd, J = 3.0, 11.0 Hz, 1H), 3.97-3.90 (m, 4H), 3.81 (s, 3H), 
3.73 (s, 6H), 3.60 (s, 3H), 3.58-3.54 (m, 2H), 3.40-3.31 (m, 2H), 3.04-3.00 (dd, J 
= 5.5, 14.0 Hz, 1H), 2.78-2.74 (q, J = 7.0 Hz, 1H), 2.40-2.38 (m, 4H), 1.76-1.74 
(m, 1H), 1.64-1.58 (m, 9H), 1.34-1.28 (m, 20H) 1.18-1.16 (d, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz) δ 211.9, 208.9, 171.7, 167.6, 161.7, 159.9, 157.3, 139.2, 138.7, 
138.6, 137.8, 137.5, 131.6, 130.7, 129.1, 128.8, 128.6, 128.5, 128.4, 128.3, 
128.1, 127.9, 127.8, 127.7, 126.3, 114.5, 104.2, 103.0, 101.7, 90.6, 79.0, 78.9, 
78.2, 76.2, 75.1, 73.8, 72.7, 72.6, 70.2, 68.9, 67.8, 61.0, 55.6, 55.5, 52.1, 47.7, 
46.6, 43.1, 42.8, 34.6, 32.8, 32.0, 30.0, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 27.3, 
25.5, 24.1, 16.2. 
(4R,23R)-N-[23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-benzylidene-β-
D-mannopyranosyloxy)-4-methyl-3,13-dioxotetracosanoyl]-N-(2’,4’,6’-
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trimethoxybenzyl)-O-benzyl-L-tyrosine methyl ester (312): Following the 
same procedure as for the preparation of 261, using 308 (130 mg, 0.125 mmol) 
as substrate, and eluting with 35% ethyl acetate in hexanes, 312 (125 mg, 70%, 
a mixture of rotomers) was obtained as light yellow foam. [α]23D -42.8 (c 1.0); 1H 
NMR (500 MHz) δ 7.54-7.53 (d, J = 6.0 Hz, 2H), 7.49-7.47 (m, 4H), 7.40-7.28 (m, 
19H), 6.98-6.96 (d, J = 8.0 Hz, 2H), 6.82-6.80 (d, J = 8.0 Hz, 2H), 6.05 (s, 2H), 
5.65 (s, 1H), 5.05 (s, 2H), 5.03-5.01 (d, J = 12.0 Hz, 1H), 4.92-4.89 (d, J = 12.0 
Hz, 1H), 4.71-4.69 (d, J = 12.5 Hz, 1H), 4.67-4.65 (d, J = 12.5 Hz, 1H), 4.62-4.60 
(d, J = 12.0 Hz, 1H), 4.60-4.58 (d, J = 12.0 Hz, 1H), 4.46 (s, 1H), 4.38-4.32 (m, 
2H), 4.26-4.22 (t, J = 9.5 Hz, 1H), 4.19-4.17 (m, 1H), 4.03-4.02 (m, 1H), 3.98-
3.92 (m, 4H), 3.82 (s, 3H), 3.74 (s, 6H), 3.61 (s, 3H), 3.60-3.56 (m, 2H), 3.41-
3.38 (dd,  J = 5.5, 14.0 Hz, 1H), 3.35-3.30 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 3.05-
3.01 (dd, J = 5.5, 14.0 Hz, 1H), 2.80-2.77 (q, J = 7.0 Hz, 1H), 2.41-2.38 (m, 4H), 
1.76-1.74 (m, 1H), 1.64-1.58 (m, 8H), 1.47-1.44 (m, 1H), 1.34-1.28 (m, 20H) 
1.17-1.16 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 211.9, 209.0, 171.7, 167.5, 
161.7, 159.9, 157.4, 139.1, 138.7, 138.6, 137.9, 137.5, 131.6, 130.7, 129.1, 
128.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 126.3, 114.5, 
104.2, 102.8, 101.7, 90.6, 78.9, 78.2, 76.0, 75.0, 72.6, 71.9, 71.5, 70.2, 68.9, 
67.9, 61.1, 55.6, 55.5, 52.1, 48.0, 46.4, 43.1, 42.8, 34.7, 33.1, 32.2, 30.0, 29.9, 
29.8, 29.7, 29.6, 29.5, 29.4, 27.4, 25.7, 24.1, 16.1.  
(4S,23R)-N-[23-benzyloxy-24-(2’,3’-di-O-benzyl-4’,6’-O-benzylidene-β-
D-mannopyranosyloxy)-4-methyl-3,13-dioxotetracosanoyl]-N-(2’,4’,6’-
trimethoxybenzyl)-O-benzyl-L-tyrosine methyl ester (313): Following the 
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same procedure as for the preparation of 261, using 309 (50 mg, 0.048 mmol) as 
substrate, and eluting with 35% ethyl acetate in hexanes, 313 (42 mg, 66%, a 
mixture of rotomers) was obtained as light yellow foam. [α]23D -32.0 (c 1.0); 1H 
NMR (500 MHz) δ 7.53-7.51 (d, J = 6.0 Hz, 2H), 7.48-7.46 (m, 4H), 7.40-7.28 (m, 
19H), 6.97-6.95 (d, J = 8.0 Hz, 2H), 6.81-6.79 (d, J = 8.0 Hz, 2H), 6.03 (s, 2H), 
5.63 (s, 1H), 5.04 (s, 2H), 5.01-4.99 (d, J = 12.0 Hz, 1H), 4.90-4.87 (d, J = 12.0 
Hz, 1H), 4.70-4.67 (d, J = 12.5 Hz, 1H), 4.65-4.63 (d, J = 12.5 Hz, 1H), 4.61-4.58 
(d, J = 12.0 Hz, 1H), 4.58-4.56 (d, J = 12.0 Hz, 1H), 4.45 (s, 1H), 4.37-4.31 (m, 
2H), 4.24-4.20 (t, J = 9.5 Hz, 1H), 4.15-4.12 (m, 1H), 4.02-4.01 (m, 1H), 3.97-
3.92 (m, 4H), 3.81 (s, 3H), 3.73 (s, 6H), 3.59 (s, 3H), 3.58-3.55 (m, 2H), 3.39-
3.35 (dd,  J = 5.5, 14.0 Hz, 1H), 3.33-3.28 (ddd, J = 5.0, 9.0, 9.8 Hz, 1H), 3.03-
2.99 (dd, J = 5.5, 14.0 Hz, 1H), 2.78-2.76 (q, J = 7.0 Hz, 1H), 2.40-2.38 (m, 4H), 
1.76-1.74 (m, 1H), 1.64-1.58 (m, 8H), 1.47-1.44 (m, 1H), 1.34-1.28 (m, 20H) 
1.18-1.16 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz) δ 211.9, 208.9, 171.7, 167.6, 
161.7, 159.9, 157.3, 139.0, 138.7, 138.6, 137.8, 137.5, 131.6, 130.7, 129.1, 
128.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 126.3, 114.5, 
104.2, 102.8, 101.6, 90.6, 78.9, 78.1, 76.0, 75.0, 72.6, 71.9, 71.4, 70.2, 68.8, 
67.9, 61.0, 55.6, 55.5, 52.1, 47.7, 46.6, 43.1, 42.8, 34.6, 32.8, 32.2, 30.0, 29.9, 
29.8, 29.7, 29.6, 29.5, 29.4, 27.4, 25.7, 24.1, 16.2. 
(5S,2’R,21’S)-5-(4’’-Hydroxybenzyl)-3-(21’-hydroxy-22’-β-D-
mannopyranosyloxy-2’-methyl-11’-oxodocosanoyl)pyrrolidin-2,4-dione 
(314): To a solution of 310 (40 mg, 0.028 mmol) in MeOH: THF (v/v 3:1, 6 mL) 
was added AcOH (20 µL) and 20% Pd(OH)2/C (20 mg). The mixture was purged 
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with H2 three times and shaken under H2 (50 psi). The progress of the 
deprotection was carefully monitored in every 1 h by ESI-TOF mass 
spectrometry and shaking was continued until no starting material or partially 
benzyl deprotected compounds were observed (3 - 4 h; longer time shaking 
under H2 deprotect the TMB group). After which the reaction mixture was filtered 
through a Celite pad and washed with MeOH (3 × 5 mL). Evaporation of the 
solvent afforded the corresponding debenzylated ketoamide, which was taken 
forward for cyclization without purification. 
To a stirred solution of the ketoamide (27 mg, 0.028 mmol) in MeOH (2 
mL) at room temperature was added KOtBu (12 mg, 0.112 mmol) in one portion. 
The reaction mixture was stirred at same temperature for 30 min before it was 
neutralized to pH 5-6 by Amberlyst-15 ion exchange resin. The solid was filtered 
off, and evaporation of the filtrate afforded (5S,2’R,21’S)-5-(4’’-hydroxybenzyl)-3-
(21’-hydroxy-22’-β-D-mannopyranosyloxy-2’-methyl-11’-oxodocosanoyl)-1-
(2’’,4’’,6’’-trimethoxybenzyl)pyrrolidin-2,4-dione, which was taken forward for TMB 
deprotection without purification.  
A solution of (5S,2’R,21’S)-5-(4’’-hydroxybenzyl)-3-(21’-hydroxy-22’-β-D-
mannopyranosyloxy-2’-methyl-11’-oxodocosanoyl)-1-(2’’,4’’,6’’-
trimethoxybenzyl)pyrrolidin-2,4-dione (25 mg, 0.027 mmol) in CH2Cl2: TFA: 
anisole (v/v/v 90:5:5, 1 mL) was stirred at room temperature for 1 h. After which, 
the mixture was diluted with toluene: MeOH (v/v 1:1, 2 mL) and the mixture was 
concentrated to dryness. The resulting residue was washed with CHCl3 (2 × 2 
mL) and the solvent was decanted. Subsequently, the residue was again 
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dissolved in MeOH (2 mL) and the mixture was concentrated to dryness followed 
by washing with CHCl3 (2 × 2 mL) afforded 314 (19 mg, 90% over three steps) as 
light orange foam. [α]24D -54.0 (c 0.3 in MeOH); 1H NMR (500 MHz, DMSO-d6) δ 
9.20 (br s, 1H), 8.97 (br s, 1H), 6.92-6.90 (d, J = 8.0 Hz, 2H), 6.61-6.59 (d, J = 
8.0 Hz, 2H), 4.40 (s, 1H), 4.09-4.08 (m, 1H), 3.71-3.68 (m, 2H), 3.67-3.64 (dd, J 
= 4.5, 10.0 Hz, 1H), 3.57-3.55 (m, 1H), 3.48-3.45 (dd, J = 6.5, 11.5 Hz, 1H), 3.34-
3.29 (m, 2H), 3.27-3.25 (dd,  J = 3.0, 9.5 Hz, 1H), 3.05-3.01 (m, 1H), 2.89-2.82 
(m, 2H), 2.41-2.39 (m, 4H), 1.47-1.40 (m, 8H), 1.28-1.24 (m, 22H) 1.06-1.05 (d, J 
= 2.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 210.7, 194.6, 191.6, 175.4, 
155.9, 130.6, 125.5, 114.7, 100.6, 100.4, 77.5, 76.0, 73.6, 73.4, 70.5, 69.1, 67.1, 
62.4, 61.4, 41.8, 35.5, 33.6, 33.1, 29.2, 29.1, 29.0, 28.9, 28.8, 28.7, 28.6, 28.5, 
28.4, 26.4, 25.1, 23.3, 16.6; ESI-HRMS Calcd for C49H58NO7 [M + Na]+ : 
772.4213. Found: 772.4199.  
(5S,2’S,21’S)-5-(4’’-Hydroxybenzyl)-3-(21’-hydroxy-22’-β-D-
mannopyranosyloxy-2’-methyl-11’-oxodocosanoyl)pyrrolidin-2,4-dione 
(315): Following the same procedure as for the preparation of 314, using 311 (50 
mg, 0.035 mmol) as substrate, 315 (24 mg, 92%, over three steps) was obtained 
as light orange foam. [α]24D -71.7 (c 0.3 in MeOH); 1H NMR (500 MHz, DMSO-d6) 
δ 9.22 (br s, 1H), 6.95-6.93 (d, J = 8.0 Hz, 2H), 6.63-6.61 (d, J = 8.0 Hz, 2H), 
4.72-4.67 (br m, 5H), 4.41 (s, 1H), 4.05-4.00 (m, 1H), 3.72-3.69 (m, 2H), 3.67-
3.65 (dd, J = 4.5, 10.0 Hz, 1H), 3.58-3.54 (m, 1H), 3.50-3.46 (dd, J = 6.5, 11.5 
Hz, 1H), 3.46-3.44 (m, 1H), 3.35-3.31 (m, 2H), 3.28-3.26 (dd,  J = 3.0, 9.5 Hz, 
1H), 3.06-3.03 (m, 1H), 2.88-2.82 (m, 2H), 2.41-2.39 (m, 4H), 1.47-1.40 (m, 8H), 
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1.28-1.24 (m, 22H) 0.97-0.96 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) 
δ 210.7, 194.7, 191.6, 175.6, 156.0, 130.6, 125.1, 114.7, 100.6, 100.0, 77.5, 
73.7, 73.5, 70.5, 69.1, 67.1, 62.1, 61.3, 41.8, 36.0, 33.6, 32.6, 29.2, 29.1, 29.0, 
28.9, 28.8, 28.7, 28.6, 28.5, 28.4, 26.8, 25.2, 23.3, 17.1; ESI-HRMS Calcd for 
C49H58NO7 [M + Na]+ : 772.4213. Found: 772.4204.  
(5S,2’R,21’R)-5-(4’’-Hydroxybenzyl)-3-(21’-hydroxy-22’-β-D-
mannopyranosyloxy-2’-methyl-11’-oxodocosanoyl)pyrrolidin-2,4-dione 
(316): Following the same procedure as for the preparation of 314, using 312 (28 
mg, 0.02 mmol) as substrate, 316 (13 mg, 91%, over three steps) was obtained 
as light orange foam. [α]24D -47.3 (c 0.3 in MeOH); 1H NMR (500 MHz, DMSO-d6) 
δ 9.24 (br s, 1H), 6.96-6.94 (d, J = 8.0 Hz, 2H), 6.63-6.61 (d, J = 8.0 Hz, 2H), 
4.42 (s, 1H), 3.82-3.81 (m, 1H), 3.72-3.69 (m, 2H), 3.64-3.60 (m, 2H), 3.58-3.54 
(m, 1H), 3.51-3.47 (dd, J = 6.5, 11.5 Hz, 1H), 3.40-3.37 (dd, J = 3.0, 10.0 Hz, 
1H), 3.33-3.28 (m, 2H), 3.06-3.03 (m, 1H), 2.87-2.84 (m, 1H), 2.67-2.64 (m, 1H), 
2.41-2.39 (m, 4H), 1.47-1.40 (m, 8H), 1.28-1.24 (m, 22H) 0.96-0.94 (d, J = 2.0 
Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 210.7, 194.6, 175.8, 155.7, 130.4, 
114.7, 100.2, 77.4, 73.6, 73.4, 70.5, 68.8, 67.0, 61.2, 41.8, 36.7, 33.4, 29.2, 29.1, 
29.0, 28.9, 28.8, 28.7, 28.6, 28.5, 28.4, 26.8, 25.1, 17.2; ESI-HRMS Calcd for 
C49H58NO7 [M + Na]+ : 772.4213. Found: 772.4201.  
(5S,2’S,21’R)-5-(4’’-Hydroxybenzyl)-3-(21’-hydroxy-22’-β-D-
mannopyranosyloxy-2’-methyl-11’-oxodocosanoyl)pyrrolidin-2,4-dione 
(317): Following the same procedure as for the preparation of 314, using 313 (31 
mg, 0.022 mmol) as substrate, 317 (14.5 mg, 88%, over three steps) was 
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obtained as light orange foam. [α]24D -63.4 (c 0.3 in MeOH); 1H NMR (500 MHz, 
DMSO-d6) δ 9.20 (br s, 1H), 8.35 (s, 1H), 6.95-6.94 (d, J = 8.0 Hz, 2H), 6.63-6.62 
(d, J = 8.0 Hz, 2H), 4.41 (s, 1H), 3.72-3.70 (m, 1H), 3.69-3.67 (m, 2H), 3.64-3.58 
(m, 2H), 3.50-3.46 (dd, J = 6.5, 11.5 Hz, 1H), 3.40-3.30 (m, 3H), 3.29-3.26 (dd,  J 
= 3.0, 9.5 Hz, 1H), 3.06-3.03 (m, 1H), 2.88-2.84 (m, 1H), 2.75-2.73 (m, 1H), 2.41-
2.39 (m, 4H), 1.47-1.40 (m, 8H), 1.28-1.24 (m, 22H) 0.94-0.93 (d, J = 2.5 Hz, 
3H); 13C NMR (125 MHz, DMSO-d6) δ 210.6, 194.6, 175.4, 155.8, 130.5, 125.1, 
114.7, 100.3, 77.4, 73.6, 73.4, 70.5, 68.8, 67.1, 62.9, 61.4, 41.8, 36.0, 33.3, 32.8, 
29.2, 29.1, 29.0, 28.9, 28.8, 28.7, 28.6, 28.5, 28.4, 26.8, 25.1, 23.3, 17.4; ESI-
HRMS Calcd for C49H58NO7 [M + Na]+ : 772.4213. Found: 772.4197.  
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ABSTRACT 
DEVELOPMENT AND APPLICATIONS OF THIOACIDS IN PEPTIDE 
CHEMISTRY AND EXPLORATION OF METHODS TOWARD THE 
STEREOCHEMICAL ELUCIDATION AND SYNTHESIS OF VIRGINEONE 
 
by 
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Advisor:  David Crich 
Major: Chemistry 
Degree: Doctor of Philosophy 
This dissertation describes investigations toward the development of 
methods for the synthesis of peptidyl thioacids and thioesters, with particular 
emphasis on applications in peptide chemistry, and the exploration of methods 
toward the assignment of the relative and absolute configuration of virgineone 
and its total synthesis.   
The first part of chapter one introduces the general characteristics and 
reactivity of thioacids, and describes their potential for application to the chemical 
synthesis of peptides and proteins. The second part of chapter one overviews the 
solution and solid-phase synthesis of peptidyl thioacids and thioesters. The last 
section of chapter one reviews the importance of tetramic acid containing natural 
products, and the various methods for their formation, and continues with an 
overview of stereoselective methods for β-mannosylation, such as are required 
for the total synthesis of virgineone, a novel glycosylated tetramic acid containing 
natural product.  
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The second chapter describes studies focused on the development of a 
methodology for the synthesis of amino and peptidyl thioacids based on the 
cleavage of the 9-fluorenylmethyl (Fm) group from 9-fluorenlylmethyl thioesters. 
Subsequently, the formation of native amide bonds in the reaction between C-
terminal peptidyl thioacids and electron deficient N-terminal 2,4-
dinitrobenzenesulfonamides is presented.   
In chapter three, building on the method for the solution-phase synthesis 
of amino and peptidyl thioacids described in chapter two, the development of a 9-
fluorenlylmethyl thioester based linker, N-[9-(tritylthiomethyl)-9H-fluoren-2-
yl]succinamic acid is described. The use of this linker for the synthesis of peptidyl 
thioacids on solid support employing Boc-SPPS is then demonstrated.  
In chapter four, continuing the theme of the development of the chemistry 
of thioacids, a method for the in situ generation of thioacids by the regioselective 
ring opening of β-thiolactones is set out. To further explore this concept, 
investigations were conducted on the ring-opening of various β-thiolactones with 
soft aromatic thiolates to form thiocarboxylates, with subsequent trapping in-situ 
by Mukaiyama’s reagent or Sanger’s reagent in presence of an amine to form 
amide bonds.   
In chapter five, studies toward the assignment of configuration and the 
total synthesis of vigineone are described. A practical synthetic route to various 
stereoisomers of virgineone is elaborated. 
224 
 
In chapter six, overall conclusions of the dissertation are presentated, 
while in chapter seven, the experimental procedures and characterization data 
for the synthesized compounds are documented. 
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